



ICC Birmingham • 19-21 June 2023

## Conference Programme

[www.baus.org.uk](http://www.baus.org.uk)

@BAUSurology

# Contents

ANNUAL  
MEETING  
19-21 June



<b>Sponsors</b>	<b>3</b>	<b>Programme</b>	
<b>Welcome from the President</b>	<b>5</b>	Section of Andrology and Genito-Urethral Surgery Annual Meeting	28
<b>Introduction by the Honorary Secretary</b>	<b>8</b>	Section of Female, Neurological and Urodynamic Urology Annual Meeting	29
<b>General Information</b>	<b>11</b>	Section of Endourology	32
Abstract Book	11	Section of Oncology	33
Accommodation	11	Section of Trainees	34
Badge Scanning	11	Main Programme	
BAUS 2023 Hybrid Format	11	Monday 19 June	37
Certificates of Attendance	11	Tuesday 20 June	47
Clean Air Zone	11	Wednesday 21 June	59
Cloakroom	11		
Conference Catering	11	<b>Medal Winner Biographies</b>	<b>71</b>
Continuing Medical Education	12		
Creche	12	<b>Guest Speaker Biographies</b>	<b>78</b>
Delegate Badges	12		
ePoster Sessions	12	<b>ePosters</b>	<b>83</b>
Exhibition - Location and Opening Hours	12	ePosters 1: Stones, Imaging and Upper Tract Disorders 1	83
Media Check-in	12	ePosters 2: Andrology, Genitourethral Reconstruction, Infertility & Male Genital Cancers	85
Photography	12	ePosters 3: Female Urology and Bladder Dysfunction	87
Prayer Room	13	ePosters 4: Renal Cancer / Testis Cancer / Sarcoma	89
Press Attendance	13	ePosters 5: Management/Governance/Education/Quality Improvement	91
Poster from Every Unit	13	ePosters 6: Inequalities in Urological Healthcare Provision and Training	93
Programme	13	ePosters 7: History of Urology	96
Registration Desk	13	ePosters 8: Prostate Cancer	97
Satellite Symposia	13	ePosters 9: Stones / Imaging / Upper Tract Disorders 2	99
Scientific Session Access	13	ePosters 10: General Urology	101
Sustainability	13	ePosters 11: General Urology 2	103
Teaching & Skills Courses	13	ePosters 12: TUF-BAUS Best of the Regions	106
Travel and Parking	13	ePosters 13: Bladder Cancer: Muscle Invasive	109
Twitter & Social Media	13		
Venue	14	<b>Posters from Every Unit</b>	<b>112</b>
Virtual Interaction	14		
Watch it Again	14	<b>BAUS ACADEMY</b>	<b>119</b>
WiFi	14	Introduction	119
<b>Registration Fees</b>	<b>16</b>	Courses at a Glance	122
<b>Registration Information</b>	<b>20</b>	On-Site Courses	126
Badge Scanning	20		
Cancellations	20	<b>Emergency Procedures</b>	<b>134</b>
Exhibition-Only Registration	20		
Letters of Invitation	20		
<b>Social Programme</b>	<b>21</b>		
Welcome Reception	21		
Networking Reception	21		
<b>Satellite Symposia</b>	<b>23</b>		

## Diamond Sponsor

**Boston  
Scientific**

Advancing science for life™

## Platinum Sponsor

**STORZ**  
KARL STORZ — ENDOSKOPE

## Gold Sponsor

 **Coloplast**

## Silver Sponsors

**bk medical**   
a GE Healthcare company

**janssen**  **Oncology**  
PHARMACEUTICAL COMPANIES OF *Johnson-Johnson*

**medac**  
**PHARMA**

## Bronze Sponsors

  
Advanced  
Accelerator  
Applications  
**A Novartis Company**

**B  
A  
Y  
E  
R**



JOINT MEETING OF BAUS  
ENDO & BSUR 2023

14-15 SEPTEMBER 2023  
HARROGATE CONVENTION CENTRE

# Welcome from the President Jo Cresswell

ANNUAL  
MEETING  
19-21 June



## Welcome to BAUS 2023...

BAUS June 2022 was certainly noteworthy for me personally, as Tim O'Brien passed on the baton of Presidency. It was also a very special meeting for everyone who participated. The event felt so refreshing after 2 years of COVID and the virtual world, and also quite different as BAUS the organisation entered a new and exciting phase. We could see all the behind-the-scenes work on widening participation come to fruition with a real sense of community and belonging for everyone.

BAUS 2023 promises to be even more exciting and innovative. We have learned so much about the value of face-to face events and the types of sessions that flourish when we get together. The program put together by Ian Pearce, Joe Philip and our excellent events team of Harry Heald and Athene Madden, is incredibly varied and informative. Widening Participation continues to be central to all that we do, and our first session considers how we use language and the impact it has, closely followed by the intriguing topic of unexplained urological symptoms. Each morning the first hour showcases one plenary session where we can all share important topics before moving to multiple rooms for more in depth topics.

Part of widening participation is regional engagement. It has been my pleasure to join so many of the regional meetings over the last 6 months and to see the very high standards of presentations. Thank you for making me so welcome. Delighted that we can showcase the best papers from every region in our TUF-BAUS Best Regional Paper session. Thank you to TUF for sponsoring and providing a prize for the overall champion. Great to see the "Poster from every unit" back again.

BAUS is a community for UK Urology, however, we are also a very outward-looking organisation with partnerships and collaborations around The Globe. I am delighted to welcome so many leaders of Urology from around the world. Our international guests will contribute to many sessions with their subspecialist expertise and a lively look at the politics of urology. The theme of global urology runs through the whole meeting. Our BAUS community is compact enough for everyone to meet, interact with and debate the nuances of urology with all our key opinion leaders. Come and be part of the conversation.

All of our specialty sections are delivering cutting edge science and debate addressing the controversies and myths which are currently topical. BSoT and BURST are once again delivering some exciting and novel sessions that are likely to attract many of us, trainee or not. Our SAS@BAUS group will welcome myself and Neil Mortenson, President of the RCS England, to their session discussing the way ahead.

Throughout the last 2 years, one colleague has never ceased to inspire me. Mo Belal is an incredible example to us all in how to face adversity, and I am delighted that he will give this year's BAUS lecture – this is one of those sessions you will talk about for years.

The BAUS medals are being awarded to an amazing group of people. Its always a tough ask to select from such a high calibre field – I am sure you will agree that all are very well-deserved. It is my honour to bestow the medals to such an outstanding group of colleagues. Congratulations to James N'Dow, Rajeev TP, Abhay Rane, Grant Stewart, Suzanne Biers, Charles Reynolds. Join us at the Library of Birmingham to celebrate their achievements as you meet up with old and new friends.

I am enormously grateful to all those who have worked hard to deliver another incredible meeting. Once again, our sponsors are hugely supportive to BAUS. We are very lucky to have such warm and collaborative relationships. The provision of lunch in the Exhibition Hall gives us plenty of opportunity to talk to our industry partners. I reserve a particular mention to Ian Pearce who has worked tirelessly for BAUS as our Honorary Secretary over the last 2 years. It's not goodbye to Ian, however, as he continues as BAUS Vice-President.

A final message to you all, is that we really do welcome suggestions for sessions at our Annual Scientific Meeting for 2024. Please do talk with us early if you have ideas, as the program is often fairly well developed by September for the following June.

Looking forward to seeing you all in Birmingham.

Best wishes

**Jo Cresswell**

President

HAVE A QUESTION FOR  
YOUR PRESIDENT?

PRESIDENT'S ADDRESS  
AND Q&A

21 June, 09.30-10.00 Hall 1



# Welcome from the Honorary Secretary Ian Pearce

ANNUAL  
MEETING  
19-21 June



Following on from the huge success of BAUS 2022 in Birmingham, I am absolutely delighted to be able to welcome you back for what will surely be a great example of the sequel eclipsing the original!!

Of course, I write this and welcome you to BAUS 2023 on behalf not only of Joe Philip, and the incredibly capable events team that is Harry Heald and Athene Madden, but also on behalf of the wider group of amazing friends and colleagues who have given up so much of their time, energy and passion to generate and deliver this meeting.

I'm sure many of you will remember with great pleasure and fondness, our last meeting here in June 2022 which marked a post pandemic return to face to face meetings. In 2023 the format remains the same with every subspecialty featured on every day allowing all of us the luxury of greater choice, variety and content.

We are proud to offer almost 40 hours of specialty content, 13 ePoster sessions, multiple guest lectures and of course daily plenaries and sub-plenaries. Our starter sessions return for Tuesday and Wednesday, some revisiting, some new to the fray. These cover a vast spectrum from art and the history of urology through curriculum changes, andrology tips and trick and onto "Outside the Clinical Box". All set for an 8 'o'clock start, I am sure these will more than compensate for that lost hour in bed!

With over 20 guest speakers from across the globe, representatives from all the world's major national urological associations, and an anticipated 1,500 delegates, this meeting comes with endless potential and opportunities to network, make new acquaintances and forge lasting friendships and collaborations.

Once again, we will be opening the meeting with a social event on the Sunday evening at the renowned and celebrated Library of Birmingham literally just next door to the ICC. Those of us who were lucky enough to make it to the same event last year will appreciate what a fantastic evening this promises to be. Canapes, drinks, chat and laughter will be in abundance, and this really is the perfect opportunity to catch up with friends and colleagues from afar.

The scientific meeting and exhibition hall will open bright and early at 09.00 on the Monday and we kick off with "The Language of Urology" widening participation plenary session. This movement within BAUS has brought extra-ordinary change within the organization and a change that each and every member of BAUS should be deservedly proud. Never before has BAUS been so inclusive of all its members and this vein has been central to BAUS 2023 from beginning to end, just as it was in 2022. Please join us in Hall 1 for what will be an amazing and thought-provoking session without doubt.



Please do make a special effort to attend the BAUS AGM at 12.00 to 12.30 in Hall 1 on Tuesday 20th June – BAUS is very much a member organization, and this is everyone’s opportunity to gain a greater understanding of the inner machinations of your specialty association.

Come to Hall 1 at 09.30 on Wednesday for the Presidential address followed by Q and A – always a lively engaging and informative session. Perhaps you have a burning question or comment to make? We would love to hear from you. This runs seamlessly into the St Paul’s and St Peter’s medal ceremony and then at 10.30 Mo Belal will deliver the BAUS Guest Lecture. If there is one thing not to miss at BAUS 2023, it is this session. I absolutely guarantee that this 30 minutes will have a lifelong lasting impression on you.

Closing the meeting in Hall 1 on Wednesday afternoon will be a pan-specialty guideline update, a 90-minute tour de force very much in keeping with the theme of “everything for everyone” and probably one of the most time efficient educational sessions you will find. This then leads to the poster from every unit session, a chance to learn from each and every unit from around the UK and depart Birmingham awash with practice innovating ideas.

Throughout the meeting, please do visit the exhibition hall and the plethora of trade stands, our industry partners and sponsors have once again provided immense support for BAUS throughout the year as they have in all previous years. Our satellite sessions as always will prove to be cutting edge events delivered by key opinion leaders and the exhibition hall will again generate and enjoy the BAUS Buzz!

This meeting marks the end of my tenure as BAUS Honorary Secretary, a role I have enjoyed immensely, primarily because of the people I have been fortunate enough to have worked with and come into contact with throughout. I am deeply grateful to all my friends and colleagues who have contributed to this and previous meetings, far too numerous to mention individually but I appreciate you will all know who you are.

To the BAUS Section Secretaries, Council, Trustees and the Exec Team, thank you for your endless patience, ideas and feedback. Again, this meeting could not take place without you. Special thanks also to Harry and Athene – their unique blend of patience, effectiveness, charm and energy has made my job an absolute joy.


My final word is to thank Joe Philip for his outstanding friendship, support and contribution, and of course to welcome him in as Honorary Secretary. I know he will do a perfect job and wish him all the very best.

Look forward to seeing you all in Birmingham.

Best wishes

**Ian Pearce**

Honorary Secretary



BAUS ANNUAL MEETING  
2024

ICC BIRMINGHAM  
24-26 JUNE

## Abstract Book

Abstracts will be available online in the Conference Edition of the JCU from 7am on Monday 19 June.

## Accommodation

BAUS is pleased to offer delegates an accommodation booking service provided by Reservation Highway, the official accommodation providers for BAUS 2023. Please book early to secure your preferred hotel - availability in June 2023 is likely to be extremely busy due to sporting events taking place in Birmingham.

[Click here](#) to book your accommodation.

Reservation Highway can assist with any bookings, particularly larger groups.

Tel : +44 (0) 1423 525577

Email: [admin@reservation-highway.co.uk](mailto:admin@reservation-highway.co.uk)

## Badge Scanning

We will be using badge scanning as lead retrieval. Exhibitors can hire scanners and scan delegate badge barcodes to download the following information:

- **Name, Job Title, Place of Work**  
(as you specify on your online registration form)
- **Work Email address**  
(as you specify on your online registration form)

You will receive 1 CME point for attending a Satellite Symposium and getting your badge scanned, badge scanning by exhibitors is not compulsory. If you DO NOT wish to disclose this information to exhibitors, then do not allow your badge to be scanned. Please Note: BAUS Staff will scan you on the entrance into all sessions; this is purely for a count of attendance at the sessions.

## BAUS 2023 Hybrid Format

We are pleased to be returning to a face-to-face format for BAUS 2023 at the ICC Birmingham. Virtual attendance will be available, and content will be streamed live from the ICC Birmingham and available to watch via the BAUS 2023 Platform.

## Certificate of Attendance

Certificates will be emailed to delegates from Wednesday 28th June. Certificates for onsite Teaching & Skills courses will only be issued to those whose attendance is registered by a member of staff.

## Clean Air Zone

Birmingham operates a clean air zone. No vehicle is banned from the zone, but vehicles of specified classes that do not meet emissions standards will be required to pay a daily charge if travelling within the area. You can check if your car is eligible to drive within the Clean Air Zone without charge by visiting [www.brumbreathes.co.uk](http://www.brumbreathes.co.uk). The daily charges apply to the following vehicles: cars, taxis, LGVs, HGVs, coaches and buses and range from £8 for a private car to £50 for HGVs. The criteria for not incurring a charge differs across diesel, petrol, gas, electric and hybrid vehicles. For further information, please [click here](#). For further information, please [click here](#).

## Cloakroom

The complimentary Cloakroom is located along the main concourse and will be open at the following times:

<b>Monday 19 June</b>	<b>0730-1930</b>
<b>Tuesday 20 June</b>	<b>0700-1900</b>
<b>Wednesday 21 June</b>	<b>0700-1700</b>

## Conference Catering

Delegate registrations will include complimentary lunch each day. Street-Food lunch will be served on Monday 19 June & Tuesday 20 June from 12.30-14.00 and Deli Bistro lunch will be served on Wednesday 21 June from 13.00-14.00. Lunch will be available from Exhibition Hall 3.

Dietary requirements will be requested at the time of registration. Please note we endeavour to accommodate all dietary requirements where possible with each venue. However, not all dietary requirements or preferences can be accommodated. If you would like further information, please email [events@baus.org.uk](mailto:events@baus.org.uk)

### Continuing Medical Education

This meeting has been accredited with CME points as follows:

<b>Monday 19 June</b>	<b>6 points</b>
<b>Tuesday 20 June</b>	<b>6 points</b>
<b>Wednesday 21 June</b>	<b>6 points</b>

The Satellite Sessions are each accredited with 1 CME point.

### Creche

There will be a creche facility provided at BAUS 2023. The creche will be run by Nipperbout who will run a daily timetable of activities. The creche will be FREE, however, we require all those who would require use of this facility to indicate during the online registration system; places are extremely limited, so please book early to avoid disappointment. Please note if you book a place and do not turn up you are denying someone a place.

There will also be a dedicated room to parents attending BAUS 2023, for feeding and storage of family equipment.

The creche will be open at the following times:

<b>Monday 19 June</b>	<b>0830 - 1830</b>
<b>Tuesday 20 June</b>	<b>0830 - 1830</b>
<b>Wednesday 21 June</b>	<b>0830 - 1630</b>

The Creche will close each day for an hour over the lunch period (12.30-13.30). This allows creche staff a break. Parents will therefore have to collect their child and feed them. Children can be returned when the creche reopens at 13.30. Nipperbout supply a healthy morning and afternoon snack. Important: Four hours is the maximum time a child can stay in a crèche without being collected for food (Three hours for children aged three years and under).

### Delegate Badges

For security purposes, all delegates and exhibitors must always wear the official BAUS 2023 delegate badge to be admitted to the conference centre and social events. Badges will be issued from the badge kiosks by the Registration Desk.

### ePoster Sessions

Full details of the presenters and ePosters will be available on the BAUS 2023 platform.

### Exhibition - Location and Opening Hours

The exhibition is in Hall 3 of the ICC Birmingham and will be open at the following times:

<b>Monday 19 June</b>	<b>0900 - 1845</b>
<b>Tuesday 20 June</b>	<b>0830 - 1800</b>
<b>Wednesday 21 June</b>	<b>0830 - 1415</b>

**Please Note:** Entry to the conference or exhibition is NOT available to personnel from commercial companies who do not have an exhibition stand.

### Media Check-In

Media Check-In will be located near Hall 1 and a short walk from the Registration Foyer. Media Check-In will be clearly signed, and all speakers & presenters are required to upload slides via Media Check-In. Media Check-In will be open at the following times:

<b>Monday 19 June</b>	<b>0730 - 1800</b>
<b>Tuesday 20 June</b>	<b>0700 - 1800</b>
<b>Wednesday 21 June</b>	<b>0700 - 1415</b>

Full AV information will be sent to all speakers well in advance of the meeting. Any queries prior to the meeting should be directed to BAUS Events ([events@baus.org.uk](mailto:events@baus.org.uk)).

### Photography

BAUS 2023 will have an official photographer and videographer who will be operating onsite. By registering for BAUS 2023, photographs may be taken, and this footage may be used by the organisers for marketing purposes. If you require further information on this, please email BAUS Events ([events@baus.org.uk](mailto:events@baus.org.uk)).

### Poster From Every Unit

Urology units have submitted a piece of work of their choosing for inclusion in the "Poster from Every Unit" initiative. Posters will illustrate any ongoing or completed urological work, research, audit, or QIP or an account of service delivery or expansion.

Posters will be on display for the duration of BAUS 2023 in the Hall 1 Foyer.

### Prayer Room

A room will be available to delegates throughout the conference for private religious observance, please ask the BAUS Registration Desk for further details.

### Press Attendance

We are pleased to welcome members of the press to attend BAUS 2023 and obtain a complimentary Press Pass. If you would like a Press Pass for BAUS 2023, please email BAUS Events ([events@baus.org.uk](mailto:events@baus.org.uk)) and we ask that you send any of the following:

- Media identification, such as an international accredited press pass;
- Business card stating affiliation and position e.g. editor, publisher, writer, reporter etc; or
- Letter on official letterhead from the editor of a publication/website certifying the affiliation, verifying assignment to the meeting and including the editor's contact information

### Programme

We will not have a printed programme for BAUS 2023. Delegates should instead use the BAUS 2023 Platform or save a copy of the Final Programme PDF to a tablet device. Printed 'Programme at a Glance' will be available to collect from the BAUS Registration Desk.

### Registration Desk

The desk will be situated in the Registration Foyer outside the Exhibition Hall 3. It will be open at the following times:

<b>Monday 19 June</b>	<b>0800 - 1800</b>
<b>Tuesday 20 June</b>	<b>0800 - 1800</b>
<b>Wednesday 21 June</b>	<b>0800 - 1415</b>

### Satellite Symposia

Satellite Symposia will be held in Hall 1.

### Scientific Session Access

Scientific sessions are only open to registered delegates. **Please Note:** delegate registration and entry to the conference or exhibition is NOT available to personnel from commercial companies who do not have an exhibition stand.

### Sustainability

For more information of ICC Birmingham's sustainability credentials, please visit: [www.theicc.co.uk/about-us/sustainability/](http://www.theicc.co.uk/about-us/sustainability/)

We will have various water refill points available throughout the venue and encourage delegates to bring their own water bottles and re-usable coffee mugs.

### Teaching & Skills Courses

The Teaching courses: Paediatric Urology, JCU How to Write a Paper and Successful Grant Application, Urogenital Dermatology, Simulated Course for Urology NTN Interviews, Good Urodynamics Practice and Updates in Stone Management and the following Skills courses: Ambulatory Treatment Options for Bladder Outflow Obstruction (Advanced & Basic), Transperineal Biopsy of Prostate & Reading of MRI Scan and Introduction to Robotics will take place at the ICC Birmingham.

Places are strictly limited, and we encourage delegates to book early to avoid disappointment. Certificates for onsite Teaching & Skills courses will only be issued to those whose attendance is registered by a member of staff.

### Travel and Parking

Birmingham is easily reached from Birmingham Airport, with Birmingham New Street a 10-minute train ride from the terminal.

There are three train stations in the city centre, and all just a short walk from the ICC with New Street Station the closest.

Parking is available the Arena Birmingham (B1 2AA) for delegates travelling by car – charges apply. If you would like any further information or assistance, please visit: [www.theicc.co.uk/find-us/](http://www.theicc.co.uk/find-us/)

### Twitter & Social Media

BAUS 2023 is on Twitter:

[@BAUSurology](https://twitter.com/BAUSurology)

#BAUS23

Delegates are reminded of the GMC and BMA guidance in respect to social media.

### Venue

The ICC Birmingham  
8 Centenary Square  
Birmingham  
B1 2EA  
United Kingdom

### Virtual Interaction

Q&A for virtual attendees will be available for all sessions taking place in Hall 1 only. There will be no Q&A for sessions taking place in Halls 4, 8, 9, 10, & 11. Virtual attendees can engage in discussion & debate with other virtual attendees via the chat function.

### Watch it again

Recorded content from the meeting will be uploaded onto the BAUS 2023 platform and available to Watch Again for up to 6 months.


### Wi-Fi

Wi-Fi is available for the duration of the meeting using the following details:

Username: **BAUS2023**

Password: **Birmingham2023**

*All Conference content, speakers and timings are correct at time of publication. The Organisers cannot be held responsible for changes due to circumstances beyond their control, including the withdrawal of speakers from the programme, for any reason.*



# BAUS 2023 Platform

## Web Access

Visit: <https://crowdcomms.com/baus2023>

## Smartphone Access

To download the BAUS 2023 App search 'CrowdComms' on the Apple IOS or Android (Google Play) Store.

Enter the event code: **BAUS2023**. You will be required to enter your email address used to register for BAUS 2023. First time users will be required to set a password

Platform/App launches on 16th June



# Registration Fees (£) - BAUS MEMBERS

ANNUAL  
MEETING  
19-21 June



<b>Early Rate - Up until 23:59 BST 1 May 2023</b>		<b>Standard Rate - From 00:00 BST on 2 May to 09:59 BST on 15 June 2023</b>		<b>Onsite Rate - From 08:30 BST on 19 June</b>
<i>Monday / Tuesday / Wednesday (per day)</i>	<i>Whole Meeting</i>	<i>Monday / Tuesday / Wednesday (per day)</i>	<i>Whole Meeting</i>	<i>Monday / Tuesday / Wednesday (per day)</i>

## BAUS Members

<b>Specialist Register/ Urological Specialist/ International Members</b>	235	575	285	775	305
<b>Virtual attendance</b> Specialist Register/ Urological Specialist/ International Members	n/a	400	n/a	600	n/a
<b>Trainee / Allied Professionals</b>	125	250	285	775	305
<b>Virtual attendance</b> Trainee/ Allied Professionals	n/a	200	n/a	600	n/a
<b>Medical Students and Foundation Year Doctors</b>	40	70	45	75	50
<b>Virtual attendance</b> Medical Students and Foundation Year Doctors	n/a	30	n/a	35	n/a
<b>Retired Members</b>	125	250	125	250	125
<b>Virtual attendance</b> Retired Members	n/a	120	n/a	120	n/a
<b>Honorary Members</b>	No Fee	No Fee	No Fee	No Fee	No Fee
<b>Virtual attendance</b> Honorary Members	No Fee	No Fee	No Fee	No Fee	No Fee

*\*Delegate registrations will include complimentary lunch each day. Street-Food lunch will be served on Monday 19 June & Tuesday 20 June and Deli Bistro lunch will be served on Wednesday 21 June. Lunch will be available from Exhibition Hall 3.*



# Registration Fees (£) - NON-MEMBERS

<b>Early Rate - Up until 23:59 BST 1 May 2023</b>		<b>Standard Rate - From 00:00 BST on 2 May to 09:59 BST on 15 June 2023</b>		<b>Onsite Rate - From 08:30 BST on 19 June</b>
<i>Monday / Tuesday / Wednesday (per day)</i>	<i>Whole Meeting</i>	<i>Monday / Tuesday / Wednesday (per day)</i>	<i>Whole Meeting</i>	<i>Monday / Tuesday / Wednesday (per day)</i>

## Non Members

<b>Urologist / Other (not appearing in categories below)</b>	320	775	350	875	380
<b>Virtual attendance</b> Urologist / Other (not appearing in categories below)	n/a	500	n/a	700	n/a
<b>Urology Trainee</b>	190	435	305	775	355
<b>Virtual attendance</b> Urology Trainee	n/a	345	n/a	645	n/a
<b>Allied Healthcare professionals (Nurses, Administrators, Radiographers, etc)</b>	190	435	305	775	355
<b>Virtual attendance</b> Allied Healthcare Professionals (Nurses, Administrators, Radiographers, etc)	n/a	345	n/a	645	n/a
<b>Scientists</b>	95	195	125	250	155
<b>Virtual attendance</b> Scientist	n/a	150	n/a	250	n/a
<b>Medical Students and Foundation Year Doctors</b>	45	75	n/a	n/a	n/a
<b>Virtual attendance</b> Medical Students and Foundation Year Doctors	n/a	50	n/a	n/a	n/a

*\*Delegate registrations will include complimentary lunch each day. Street-Food lunch will be served on Monday 19 June & Tuesday 20 June and Deli Bistro lunch will be served on Wednesday 21 June. Lunch will be available from Exhibition Hall 3.*



# Conference Catering

Lunch will be available from Exhibition Hall 3. ICC Birmingham have partnered with food waste company Olio to collect and redistribute pre-packed unused food within the local community.

## Monday 19 June

### DRAGON LOTUS BUNS

Duck & Spring Onion Dressing  
Glazed Pork

Shiitake Mushroom & Oyster Dressing (V)

### INDI-GO

Chicken Biryani

Vegetable Biryani (V)

Toppings - Curry Sauce & Onion Scraps

### VEGAN GOBI BOX

Cauliflower Rice Biryani (VG)

Cauliflower Pakora (VG)

**LAYERED BLACKCURRANT MOUSSE  
(VG GF)**

**FONDUE FRUITS - MARSHMALLOWS -  
CHURROS**

## Tuesday 20 June

### FAJITAS

Chicken Fajita

Pulled Pork Fajita

Refried Beans Fajita (V)

Served with Cracking Avacado

### BANG WOK

Chicken & Noddle's

Vegetables & Noddle's

Served with Rice Crackers

### VEGAN STREET

Create your own bowl from a selection of bases & hot toppers

**SWEET WAFFLES & TOPPERS**

**FRUITJACKERS**





## **Wednesday 21 June**

---

### **DELI BISTRO**

Sub Roll of Coronation Chicken Flavoured with Turmeric

Oatmeal Loaf of Tuna & Cucumber

Wrap of Chipotle Houmous (VG)

Moroccan Meze Salad

### **SELECTION OF CRISPS**

#### **CAKES**

Millionaire Shortcake (VG)

Carrot Cake Bar (VG)

Raspberry and Almond Slice (GF)

### **VARIETY OF FRESH FRUIT**

### **BOTTLE WATER OR CANNED SOFT DRINKS**

\*DIETARY REQUIREMENTS REQUESTED AT THE TIME OF REGISTRATION.

WE ENDEAVOUR TO ACCOMMODATE ALL DIETARY REQUIREMENTS WHERE POSSIBLE WITH EACH VENUE.  
HOWEVER, NOT ALL DIETARY REQUIREMENTS OR PREFERENCES CAN BE ACCOMMODATED.

IF YOU WOULD LIKE FURTHER INFORMATION, PLEASE EMAIL [EVENTS@BAUS.ORG.UK](mailto:EVENTS@BAUS.ORG.UK)

---



## Badge Scanning

We will be using badge scanning as lead retrieval. Exhibitors can hire scanners and scan delegate badge barcodes to download the following information:

- **Name, Job Title, Place of Work**  
(as you specify on your online registration form)
- **Work Email address**  
(as you specify on your online registration form)

You will receive 1 CME point for attending a Satellite Symposia and getting your badge scanned, Badge scanning by exhibitors is not compulsory. If you **DO NOT** wish to disclose this information to exhibitors, then do not allow your badge to be scanned. **Please Note:** BAUS Staff will scan you on the entrance into all sessions; this is purely for a count of attendance at the sessions.

## Cancellations

Fees for both the conference and teaching and skills courses, cannot be refunded after 01 May 2023. Cancellations before this date must be confirmed in writing and will be subject to a 10% administration charge.

## Letters of Invitation

Official letters of invitation to help overcome administrative difficulties in some countries can be sent by the BAUS Office. Please email your request in writing before 31 May 2023 to BAUS Events ([events@baus.org.uk](mailto:events@baus.org.uk)). Please note these letters do not commit BAUS to any financial obligation.

## Welcome Reception

**Sunday 18th June 1900-2200**

Join us to kick off BAUS 2023 at the Welcome Reception on Sunday 18th June at the Library of Birmingham and enjoy an evening of drinks and canapes. Tickets to the Welcome Reception cost £20 until 23:59 on 1st May 2023 and £25 from 00:00 on 2nd May 2023. Tickets can be ordered on the online registration system. Exhibitor tickets cost £30 plus VAT and can be purchased via the Exhibitor Social Ticket order site.

Dress Code: **Smart Casual**

### Awards

The following will be awarded at the Welcome Reception:

#### Gold Medal

Presented to: **Abhay Rane OBE**, East Surrey Hospital, Redhill

Citation by: **Sri Sriprasad**, Darent Valley Hospital, Kent

#### Karl Storz Harold Hopkins Golden Telescope Award

Presented to: **Grant Stewart**, University of Cambridge and Addenbrooke's Hospital, Cambridge

Citation by: **Anthony Riddick**, Addenbrooke's Hospital, Cambridge

#### John Anderson Award

Presented to: **Suzanne Biers**, Addenbrooke's Hospital, Cambridge

Citation by: **Nikita Bhatt**, Addenbrookes Hospital, Cambridge

#### Certificate of Distinction

Presented to: **Charles Reynolds**, CJ Medical

Citation by: **Abhay Rane OBE**, East Surrey Hospital, Redhill

#### Keith Yeates Award

Presented to: **Ross Warner**, Leicester General Hospital (May 2022)

**Benjamin Odusanya**, Manchester Royal Infirmary (November 2022)

## Networking Reception

**Monday 19th June 1800-1900**

Enjoy a drinks reception hosted in the ICC Exhibition Hall 3 and network with colleagues & Industry Representatives and browse the Exhibition Hall.

# Welcome Reception

Sunday 18 June 2023

Garden Terrace, Library of Birmingham



**STORZ**  
KARL STORZ — ENDOSKOPE

**Monday 19 June: Karl Storz**  
1315-1400 Hall 1



## Uncertainties in Environmentally Sustainable Surgery

This session will explore the NHS bid to reach NetZero by 2040 and the changes that can be made in the operating theatre to impact on this.

If Surgery is to expand, how do we do it without damaging the wider environment? Education, future proofing and filling knowledge gaps are keypoints. What does modern education also look like in a post covid era?



**Aneel Bhangu, MBChB PhD FRCS**  
NIHR Clinician Scientist in Global Surgery, Honorary Consultant Colorectal, General, and Emergency Surgeon at the University Hospitals of Birmingham

**Monday 19 June: Bayer**  
1530-1600 Hall 1



## The role of the Urologist in the MDT: optimising clinical practice for nonmetastatic castration resistant prostate cancer (nmCRPC) patients

This Bayer-sponsored symposium will provide a practical and collaborative view of how to improve the referral and management of patients with nmCRPC whilst in the urology clinic. Join us for in-depth discussion and expert insight from Professor Noel Clarke and Mr Gianmarco Isgro. This is a Bayer promotional meeting, Bayer products mentioned.

- Recent developments and insights in nmCRPC: from clinical data to realworld evidence – Professor Noel Clarke
- Managing nmCRPC patients in the Urology clinic and alleviating capacity challenges. A Case based discussion - Mr Gianmarco Isgro
- Panel discussion and Q&A



**Noel Clarke**  
Professor of Urological Oncology, The Christie



**Gianmarco Isgro**  
Consultant Urological Surgeon, South Tees Hospital

**Monday 19 June: Coloplast**

1730-1800 Hall 1



## The Place for the Thulium fiber Laser in BPH?



**Michael Straub**  
Munich, Germany

**Tuesday 20 June: Janssen**

0900-0930 Hall 1



## A Multi-Disciplinary Approach to the Primary Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

This promotional Janssen-sponsored symposium will provide a patient-centric overview of a united approach to optimize the treatment of mHSPC. Join us as we review a patient case-study and treatment options, presenting the outcomes of the case which draws on the real-world experience of the expert panel.

- Patient Case Study Presentation
- mHSPC Treatment Options
- Faculty Discussion



**William Cross,**  
Leeds Teaching Hospital



**Mark Prentice,**  
Consultant Clinical Oncologist, Royal Free London

CP-369144 | February 2023



**Tuesday 20 June: Boston Scientific**  
1315-1400 Hall 1

**Boston  
Scientific**  
Advancing science for life™

## Versatility of Holmium Laser technology in stones and BPH treatment

In a post-pandemic healthcare system, not every hospital will be able to afford to purchase multiple lasers. With the advent of the Thulium Fibre Laser, is Holmium laser still the gold standard for Management of Stones and BPH treatment?



**Ben Turney**  
Consultant Urologist,  
Oxford University  
Hospital



**Bhaskar Somani**  
Consultant Urologist,  
Southampton  
Hospital



**Helen Teixeira**  
Consultant Urologist,  
Cornwall Hospital

**Tuesday 20 June: Advanced Accelerator Applications  
(AAA UK)**  
1730-1800 Hall 1



## Advanced Accelerator Applications Symposium

### Speakers:

**Mr William Cross**, Consultant Urologist  
**Professor Amit Bahl**, Consultant Clinical Oncologist  
**Dr Amy Eccles**, Consultant Radionuclide Radiologist

### Other important information:

This promotional meeting has been organised and funded by Advanced Accelerator Applications, a Novartis company, and is for healthcare professionals from GB only.



**William Cross**  
Consultant  
Urologist



**Ahmit Bahl**  
Consultant  
Clinical  
Oncologist



**Amy Eccles**  
Consultant  
Radionuclide  
Radiologist

Wednesday 21 June: BK Medical  
0900-0930 Hall 1

**bk medical**   
a GE Healthcare company

## Prostate MRI for the Urologist

This session will explore the fusion-based prostate cancer management pathway and will cover considerations for implementing a MRI-US fusion service, radiology support, local patient selection, local outcomes and subsequent impact on treatment options.



**John Leveckis**, Doncaster Royal Infirmary

Wednesday 21 June: medac Pharma  
1330-1400 Hall 1

**medac**  
PHARMA

## BCG in NHS Practice - Pragmatic Approaches

Chair: **Param Mariappan**, Edinburgh Bladder Cancer Surgery (EBCS), NHS Lothian

**Current High Risk NMIBC Groups and Patient Selection for BCG**

**Kate Warren**

**Definitions of BCG Failure and Managing this in the NHS**

**Elsie Mensah**

**Options (including clinical trials), in BCG Unresponsive Disease**

**James Catto**



**Param Mariappan**, Edinburgh Bladder Cancer Surgery (EBCS), NHS Lothian



**Kate Warren**, Bristol Urological Institute



**Elsie Mensah**, Guy's and St Thomas' NHS Foundation Trust



**James Catto**, Sheffield Teaching Hospitals NHS Trust



BAUS SECTION OF FNUU  
MEETING

HINXTON HALL  
CONFERENCE CENTRE  
13 DECEMBER 2023

# BAUS Section of Andrology and Genito-Urethral Surgery Annual Meeting

ANNUAL  
MEETING  
19-21 June



Monday 19 June 1100-1230 & 1630-1730  
Tuesday 20 June 1130-1230 & 1530-1630  
Wednesday 21 June 1130-1300 & 1400-1500

## Introduction

**Marc Lucky**, Chair, BAUS Section of Andrology and Genito-Urethral Surgery

**Ayo Kalejaiye**, Secretary, BAUS Section of Andrology and Genito-Urethral Surgery

**Arie Parnham**, Vice Chair, BAUS Section of Andrology and Genito-Urethral Surgery

A very warm welcome to BAUS 2023 in Birmingham. We are delighted that you can join us, and we have an exciting Andrology and Genitourinary Reconstruction program planned which should appeal to all. These three days will provide an exciting opportunity to discuss current issues in andrology and reconstructive surgery as well as provide opportunities to speak to and network with colleagues.

We kick things off on Monday morning at 1100 with an exciting session on Controversies in Andrology which should appeal to the wider audience. Here we will discuss topics such as bilateral testicular fixation in torsion - pros and cons. I will be speaking on managing patients with Chronic Genital Pain, which can be challenging and daunting. With the right approach and support, we can often help this group of patients considerably. We continue in the afternoon with a session on Fertility which is aimed towards the general urologist. There will be some interesting case presentations and MDT style discussions with wider audience participation.

On Tuesday, we are proud to hold the first ever joint AGUS & ESAU Session looking at Andrological Challenges. We have a panel of international experts, and this is a must attend for all! Without question it will provide valuable insights which will come in handy when dealing with complex patients in general clinics. In the afternoon, we have a new video session examining topics such as penile fracture, ejaculatory duct obstruction and the difficult foreskin. A must see for tips and tricks and surgical techniques.

We wrap things up on the Wednesday with a morning session on testicular cancer and management of interesting rare cases. Finally, we close with a session on penile lesions and cancer management followed by talks on urethral disease. The final talk of the day is by Professor Kulkarni on bladder neck stenosis. For those who have not had the pleasure of hearing him speak, it is an opportunity not to be missed.

On behalf of Arie, Ayo, myself and the committee, we look forward to welcoming you to our sessions and meeting you in person.



# BAUS Section of Female, Neurological and Urodynamic Annual Meeting

ANNUAL  
MEETING  
19-21 June



Monday 19 June 1100-1230 & 1630-1730  
Tuesday 20 June 1130-1230, 1400-1500 & 1530-1630  
Wednesday 21 June 1400-1500

## Introduction

**Mo Belal**, Chair, BAUS Section of Female, Neurological and Urodynamic Urology

**Suzanne Biers**, Secretary, BAUS Section of Female, Neurological and Urodynamic Urology



I am delighted to extend a warm welcome to BAUS 2023, on behalf of the BAUS Section of Female, Neurological and Urodynamic Urology. The FNUU subsection Committee; Suzanne Biers (Cambridge, Secretary) Arun Sahai (Vice Chair, London), Ased Ali (Wakefield), Hashim Hashim (Bristol), Magda Kuwaja (Stockport), Mahreen Pakzad (London), Tina Rashid (London), Naz Osman (Sheffield) and Andrew Kozan (BSOT rep) have created a dynamic and educational program for this three-day event.

The program will start on Monday with the Updates session, featuring updates from Chris Harding, Hashim Hashim, and Melissa Davies, the current chair of BAUS Fellowship, on the latest developments in research, clinical trials, publications, and fellowships. We are thrilled to have Chris Chermansky from the United States joining us to discuss the use of stem cells in treating urinary incontinence. Afterwards, we will have a joint session with oncology, with Professor Arnuf Stenzl, Alex Colquhoun, and Suzanne Biers discussing a multidisciplinary approach to premalignant and malignancy seen in functional patients. Sachin Malde and Helena Burden will lead a session on premalignant conditions, while Helena Gresty and Raj Nair will examine malignancy in the neuropathic and reconstructed urinary tract. Nikesh Thiruchelvam will be discussing urinary incontinence and LUTS after cancer surgery.

Tuesday's program includes two sessions. Tamsin Greenwell and Chris Harding will be leading a session on international stress incontinence management, featuring perspectives from Chris Chermansky, Helen O'Connell, and Zaki Almalleh. Later, Claire Taylor and Tom King will be leading a session on paediatric urology transition, with Charlotte Dunford, Andy Baird, and Mark Woodward joining the discussion. This will be followed by a session on managing chronic cystitis, led by Ased Ali and Helen O'Connell, with Mehwash Nadeem, Tom Lewis, and Ruth Doherty discussing bladder pain syndrome, chronic bacterial cystitis, and radiation cystitis.

Wednesday's schedule includes a session on FNUU consensus documents, led by Roland Morley, Tina Rashid, and Alison Downey. Magda Kujawa will provide updates on urethral diverticulum, while I will be discussing ketamine bladder. There will also be an ePoster session on Monday, featuring presentations from various UK functional units.

We also have two excellent teaching courses. Firstly, Neurourology for the General Urologist led by Sheilagh Reid is pre-recorded and available to watch on the BAUS 2023 Platform. The Good Urodynamics Practice led by Chris Harding & Laura Thomas will take place on Wednesday from 1130-1300; places are extremely limited.

I hope you will join us for as many FNUU sessions as possible and look forward to seeing you in person. On behalf of the FNUU subcommittee, I wish you a productive and enjoyable BAUS 2023.



98137053 URO 92 1.0 05/2022/A-E



SCAN ME



<https://go.karlstorz.com/AD-URO-92-en>

# Your Patient. Your Choice.

Because every patient, and every case, is unique  
KARL STORZ Flexible Uretero-Renoscopes

**FLEX-X<sup>2S</sup>** Accessibility

**FLEX-X<sup>C</sup>** Image Quality

**NEW FLEX-X<sup>C1</sup>** Ready When You Are



Monday 19 June 1100-1230 & 1630-1730

Tuesday 20 June 1130-1230

Wednesday 21 June 1130-1230

## Introduction

**Sri Sriprasad**, Chair, BAUS Section of Endourology

**Hari Ratan**, Secretary, BAUS Section of Endourology

BAUS 2023 promises to provide an excellent exposition of ever-increasing urological knowledge and a place for uplifting and relaxing social interaction with colleagues, friends and industry partners.

The section of endourology has put together a versatile and innovative programme to complement the rest of the meeting scheduled across all three days. We are sure that the topics will appeal to both subspecialist endourologists as well as to general urologists.

On Monday 19th June (1100-1230, hall 8), the invited speakers will answer the question "What's new in Endourology?". We look at advances in the follow up the small asymptomatic renal stone, management of stones in diabetics and advances in BPH and ureteroscopy. Our international guest speaker from the USA, Professor Mathew Sorensen will discuss burst wave lithotripsy.

Stents are a 'ticking time bomb' and on Monday afternoon (1630-1730, hall 8) the expert panel will discuss the HSIB report into delayed and forgotten stent removal, medicolegal implications of the 'forgotten stent' and current models in stent tracking. The clinical management of the 'forgotten stent' and the technical nuances of their removal are reviewed.

On Tuesday 20th June (1130- 1230, hall 9), a symposium addresses the management of simple stones in the complex patient, including stones in pregnancy, neuropaths, patients on anticoagulants and frail patients. This symposium is intended as a practical guide to helping manage these patients who we see increasingly frequently.

There are many controversies in endourology and an entire session on Wednesday 21st June (1130-1300, hall 8) features some crossfire debates on hot topics. Is metabolic evaluation useful in stone patients? Can bladder stone removal be combined with a BOO procedure? Is diagnostic ureteroscopy needed for all suspected UTUC? Old versus new lasers? All these topics will be debated by a lively panel!

Apart from this we have the usual favourites including the best ePosters selected from an array of great work that was submitted. The ePosters are innovative, thought provoking and demonstrate best practice for us to take back to our centres. Not to forget the educational courses on many endourological topics!

We are looking forward to seeing you all in Birmingham!





Monday 19 June 1100-1230 & 1630-1730

Tuesday 20 June 1530-1630

Wednesday 21 June 1130-1300

## Introduction

**Jon Aning**, Chair, BAUS Section of Oncology

**Vishwanath Hanchanale**, Secretary, BAUS Section of Oncology

I am super happy to welcome you to BAUS 2023 on behalf of the Section of Oncology Committee. I am particularly grateful to our past secretary Alex Colquhoun who laid foundations and to present secretary Vishwanath Hanchanale who has led the composition of a packed, educational and exciting programme which will be delivered by an all-star faculty.

We will start on the Monday (1100 - 1230, Hall 4) with a focus on kidney cancer, including updates on the role of genomics by Thomas Mitchell, and a summary of developments in advanced disease management and surgical approaches by Sarika Nalagatla, Alex Bex, Aziz Gulamhusein and Naveen Vasudev. Mihir Desai will share his thoughts and experience of pushing the boundaries of robotic surgery in the kidney cancer space and I am delighted that Grant Stewart who will be providing uro-oncological leadership for the inaugural National Kidney Cancer Audit will be joining us for this session to inform us about the audit and share his insights.

On the Tuesday (1530 - 1630, Hall 4) we will switch to discuss upper-tract urothelial carcinoma (UTUC), 'the Cinderella tumour'. During this session Sir John Burn will discuss his research and provide insights into potential future screening approaches and there will be a comprehensive review of present urological and oncological management options for UTUC by Joe Philip, Morgan Roupret, Jose A. Karam and Alison Birtle. UTUC is an area of urology where there is room for improvement across the pathway so we hope that you will find this session stimulating.

On the Wednesday (1130 - 1300, Hall 4) we are providing a Pot-Pourri of Uro-Oncological excitement, including cutting edge updates on topics such as Theranostics in prostate cancer by Sobhan Vinjamuri, Seminoma management by Prabhakar Rajan, and local options for managing low-volume metastatic prostate cancer by Prasanna Sooriakumaran. Morgan Rouprêt will give his insights into the contemporary evidence for pelvic lymph node dissection in prostate cancer. Salah Albuheissi and Vishwanath Hanchanale will be sharing their experience of partial nephrectomy and robotic retroperitoneal lymph node dissection respectively. I am especially pleased that we have been able to include the patients voice in this session too - the preliminary analysis from the BAUS Section of Oncology cystectomy experience audit (C-PAT) will be presented in this session by Preksha Kuppanda.

All that is left to be said is, please check out the Bladder cancer, Renal cancer and Prostate Cancer abstract sessions, outstanding work is being presented across the board. Welcome and thank you to our session chairs and international faculty Mihir Desai (University of Southern California, USA), Morgan Rouprêt (Pitié-Salpêtrière Hospital, France), Jose Karam (MD Anderson, USA) for joining us at BAUS 2023 and sharing your perspectives. Thank you for reading this, we look forward to seeing you at the Section of Oncology sessions and have a great BAUS 2023.



Monday 19 June 1100-1200

Tuesday 20 June 1130-1230

Wednesday 21 June 1130-1315 & 1400-1500

## Introduction

**Nick Boxall**, Chair, BAUS Section of Trainees (BSoT)

**Yinka Gbolahan**, Secretary, BAUS Section of Trainees (BSoT)

It is our pleasure to welcome you to the BAUS Section of Trainees' (BSoT's) programme at BAUS 2023. We continue to be affected by challenges in our training and we hope our 2023 programme focuses on some of these in an engaging and enjoyable way. We give special thanks to the contributions of the rest of the executive committee: Sophie Rintoul-Hoad (Ex-Vice Chair), Sarika Nalagatla (Chair-Elect) and Tony Tien (Vice Chair).

We kick off the programme with our 'Evolving Urological Family' session. Tony Tien will be setting the scene with the results of the BSoT Allied Health Professional Survey. This would be followed by talks from Nick Fletcher (Chair of Association of Surgical Care Practitioners), Chandran Francis (Vice president of Faculty of Physicians Associate RCP) and Khalid Hosney from our BAUS SAS doctors' group. We hope that this session will catalyse understanding on how we can all better work together in the urological community with ongoing workforce difficulties. This session will be chaired by Sarah Wood and Tony Tien.

On Monday afternoon there's BSoT's first e-poster session titled the 'Tackling of inequalities of Urological Healthcare Provision and Training'. This session aims to give a platform into research highlighting the problems of, and solutions to, inequalities faced for patients and colleagues. The session will be chaired by Tim Lane and Yinka Gbolahan.

It's an early rise for us on Tuesday morning as we start the day off right with our running shoes for our now established tradition of the 5km BSoT Fun Run for TUF along the Birmingham Canal with our new Race Director Eoin Dinneen.

Once we've freshened up, we roll into the morning session

'Between a Rock and a Hard Place: The Complex Decision-Making MDT' is our follow-on session on Tuesday afternoon. This session debates some of the tricky clinical decisions we make as urologists. We have a fantastic MDT consisting of not only seasoned pragmatic urologists, but our helpful anaesthetic and medical colleagues to help us through these difficult scenarios. This session will be chaired by Zoe Panayi and Eoin Dinneen.

We finish a packed Tuesday schedule by letting our hair down in the evening at the BSoT social with dinner and drinks kindly sponsored by Storz.

Wrapping up strongly on Wednesday we dive into "Challenging and Championing the Future of Urology" chaired by Nick Boxall and Sarika Nalagatla. This session includes talks from The Pride in Surgery Forum (PRISM), collaboration with industry as trainees and parenting in urology. We will conclude the session with the presentation of the Silver and Bronze Cystoscope Awards.



## BAUS Section of Trainees (BSoT) continued

ANNUAL  
MEETING  
19-21 June



We end on Wednesday afternoon with 'Advanced Urological Procedures in Training'. Join us as we navigate mastering procedures such as HoLEP and urethroplasty, as well as complex sarcoma surgery and renal transplant. This session will be chaired by Katie Brodie and Mark Evans.

The BSoT family look forward to meeting and welcoming you all at BAUS 2023, and please don't forget to visit our stand to meet some of the team during the breaks!



**ON THE MOVE**  
**FOR PATIENTS**



***In a world that doesn't stop,  
you either keep moving or  
get out of the way.***

We're on the move for patients. At Coloplast Interventional Urology, we act with purpose guided by focus, energy sparked by curiosity and speed driven by caring, all to support what patients want and services need.



Coloplast is a proud sponsor of the BAUS  
[coloplast.co.uk](https://coloplast.co.uk)



The Coloplast logo is a registered trademark of Coloplast A/S.  
© 2022-03 All rights reserved. Coloplast A/S, 3050 Humlebaek, Denmark.



Hall 1  
0900-1015

### The Language of Urology: Words Matter

Chairs: **Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough and **Ian Pearce**, Honorary Secretary and Vice-President Elect of BAUS and Manchester Royal Infirmary

- 0900-0905 **BAUS Update on Widening Participation**  
**Susan Willis**, Guy's & St Thomas' Hospital, London
- 0905-0920 **The Butterfly Effect**  
**Tina Rashid**, St George's University Hospital, London
- 0920-0935 **Presenting Complaint: Use of Language that Disempowers Patients**  
**Caitríona Cox**, Academic Clinical Fellow, The Healthcare Improvement Studies (THIS) Institute, University of Cambridge
- 0935-0950 **Hunterian Lecture: The Role of Social Inequalities in the Epidemiology of Urological Cancers: Can This Inform Cancer Screening?**  
**Marcus Cumberbatch**, Hunterian Professor 2023 and Royal Hallamshire Hospital, Sheffield
- 0950-1015 **Q&A and Panel Discussion**

1015-1100

Refreshments, Networking and Exhibition Viewing

Hall 1  
1100-1230

### Unexplained Symptoms in Urology - Exploring Where the Cystoscope Cannot Reach

Chairs: **Helen Simpson**, Victoria Hospital, Kirkcaldy and **Jonathan Glass**, Guy's & St Thomas' Hospital, London

- 1100-1105 **Introduction**  
**Helen Simpson**, Victoria Hospital, Kirkcaldy
- 1105-1120 **Setting the Scene - Patient Stories**  
**Jonathan Glass**, Guy's & St Thomas' Hospital, London
- 1120-1140 **Sexual Abuse and LUTS - What's the Link?**  
**Jalesh Panicker**, Professor of Uro-Neurology, Consultant Neurologist in Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL, London
- 1140-1155 **Sexual Abuse - Its Impact and our Response**  
**Caroline Selai**, Psychologist, Senior Lecturer in Clinical Neuroscience, University College Hospital, London
- 1155-1215 **Physical Symptoms Aren't What They Seem**  
**Alastair Santhouse**, Consultant Neuropsychiatrist at The Maudsley Hospital, London
- 1215-1230 **Audience Voices & Questions**  
**Helen Simpson**, Victoria Hospital, Kirkcaldy

Hall 4  
1100-1230

## What's New in Advanced Kidney Cancer?

Chairs: **Grant Stewart**, University of Cambridge and Addenbrooke's Hospital, Cambridge, **Mihir Desai**, Director of Robotic Surgery, USC Institute of Urology, University of Southern California and **Esther McLarty**, University Hospitals Plymouth

- 1100-1110 **Locally Advanced and Metastatic Kidney Cancer - Diagnosis and Staging**  
**Sarika Nalagatla**, University Hospital Monklands
- 1110-1125 **Cytoreductive Nephrectomy in Contemporary Practice - When?**  
**Axel Bex**, Royal Free Hospital, London
- 1125-1155 **Locally Advanced Tumour with Caval Thrombus**
- 1125-1140 **Old is Gold: Open Surgery?**  
**Aziz Gulamhusein**, The Christie & Manchester University Hospitals NHSFT
- 1140-1155 **Time to Push Robotic Surgery Beyond Caval Boundaries**  
**Mihir Desai**, Director of Robotic Surgery, USC Institute of Urology, University of Southern California
- 1155-1210 **Systemic Treatment Options for Advanced Kidney Cancer**  
**Naveen Vasudev**, Consultant Medical Oncologist, University of Leeds
- 1210-1220 **Role of Genomics in Managing Kidney Cancer?**  
**Thomas Mitchell**, Addenbrooke's Hospital, Cambridge
- 1220-1230 **Development of NICE Guidelines and National Kidney Cancer Audit**  
**Grant Stewart**, University of Cambridge and Addenbrooke's Hospital, Cambridge

Hall 8  
1100-1230

## What's New in Endourology?

Chairs: **Rashmi Singh**, Kingston Hospital, London and **Marco Bolgeri**, St George's Hospital, London

- 1100-1110 **Follow-up of Small Asymptomatic Renal Stones - New EAU Guidelines**  
**Bhaskar Somani**, Southampton General Hospital and Editor, JCU
- 1110-1120 **RIP KUB**  
**Balraj Dhesi**, University Hospitals Birmingham NHS Foundation Trust
- 1120-1130 **Diabetes in Stone Patients**  
**Graham Lipkin**, Consultant Nephrologist, University Hospitals Birmingham NHS Foundation Trust
- 1130-1140 **Burst Wave Lithotripsy - Ready for Prime Time?**  
**Mathew Sorensen**, MD, Urology Clinic at UW Medical Center, Seattle, United States
- 1140-1150 **What's New in PCNL**  
**Sarath Nalagatla**, University Hospital Monklands, Airdrie, Scotland

- 1150-1200 **Advances in Ureteroscopy**  
**Susannah La Touche**, St George's Hospital, London
- 1200-1210 **BPH**  
**Richard Hindley**, Basingstoke and North Hampshire Hospital
- 1210-1230 **Q&A**

Hall 9  
1100-1230

## Controversies in Andrology

Chair: **Duncan Summerton**, Leicester General Hospital and **Sylvia Yan**, St George's Hospital, London

- 1100-1120 **Venous Leak**  
**David Ralph**, University College Hospital, London
- 1120-1140 **Management of Chronic Genital Pain**  
**Marc Lucky**, Aintree University Hospital, Liverpool
- 1140-1210 **Debate: Where is the Harm in Fixing Both Testicles?**
- 1140-1155 **Pro**  
**Peter Grice**, Leicester General Hospital
- 1155-1210 **Against**  
**Judith Dockray**, South Tyneside and Sunderland NHS Foundation Trust
- 1210-1230 **Is the Lue procedure dead?**  
**Christian Seipp**, Wrexham Maelor Hospital

Hall 10  
1100-1230

## FNUU Updates

Chairs: **Mo Belal**, Queen Elizabeth Hospital, Birmingham, **Arjun Nambiar**, Freeman Hospital, Newcastle and **Mahreen Pakzad**, University College Hospital, London

- 1100-1105 **Introduction & Overview**  
**Mo Belal**, Queen Elizabeth Hospital, Birmingham
- 1105-1120 **FNUU Research Update**  
**Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne
- 1120-1140 **FNUU Literature Update**  
**Hashim Hashim**, Southmead Hospital, Bristol
- 1140-1150 **FNUU Fellowship Update**  
**Melissa Davies**, Salisbury NHS Foundation Trust
- 1150-1210 **The Use of Stem Cell Treatment of Urinary Incontinence**  
**Chris Chermansky**, University of Pittsburgh School of Medicine
- 1210-1225 **REJOIN Audit: Preliminary Findings**  
**Arun Sahai**, Guys Hospital, London
- 1225-1230 **Q&A**

Hall 11A  
1100-1200

## The Evolving Urology Family

Chairs: **Tony Tien**, University College London Hospital and **Sarah Wood**, Norfolk & Norwich University Hospital

- 1100-1115     **The BSoT AHP Survey: Setting the Scene**  
**Tony Tien**, University College London Hospital and **Pramit Khetrpal**, Whipps Cross University Hospital
- 1115-1125     **Expanding roles of ANPs/SCPs in Urology**  
**Nicholas Fletcher**, Urology Surgical Care Practitioner, Salford Royal Hospital
- 1125-1130     **Q&A and Discussion**
- 1130-1140     **Physician Associates in Urology**  
**Chandran Louis**, St George's University Hospitals NHS Foundation Trust
- 1140-1145     **Q&A and Discussion**
- 1145-1155     **Championing SAS Doctors**  
**Khaled Hosny**, East Lancashire Hospital NHS Trust
- 1155-1200     **Q&A and Discussion**

1230-1400     Lunch, Networking and Exhibition Viewing

Hall 1  
1315-1400

## Karl Storz Satellite Symposium



See page 23 for details

Hall 1  
1400-1500

## 'Why Global Surgery?'

Chairs: **Abhay Rane OBE**, East Surrey Hospital, Redhill and **Suzie Venn**, University Hospitals Sussex NHS Foundation Trust

- 1400-1420     **Global Surgeons as Advocates and Social Change Agents**  
**John Meara, DMD, MD, MBA**, Kletjian Professor of Global Surgery, Director of the Program in Global Surgery and Social Change, and Professor of Surgery in the Department of Surgery, Harvard Medical School, Boston, United States
- 1420-1430     **Q&A**
- 1430-1450     **Frugal Surgery Works, and is the Need of the Hour**  
**Dhananjaya Sharma**, Head of Department of General Surgery, NSCB Government Medical College, Jalalpur, India
- 1450-1500     **Q&A**



Hall 4  
1400-1500

## Elective Recovery

Chair: **Ian Eardley**, Leeds Teaching Hospital Trust and National Clinical Director Elective Care, NHS England

- 1400-1405 **Introduction**  
**Ian Eardley**, Leeds Teaching Hospital Trust and National Clinical Director Elective Care, NHS England
- 1405-1415 **An Overview of Elective Recovery**  
**Sir James Mackey**, Chief Executive Northumbria Healthcare NHS Trust and National Director of Elective Recovery, NHS England
- 1415-1425 **Dealing with the Outpatient Backlog**  
**Tanya Bleiker**, Consultant Dermatologist, University Hospitals of Derby and Clinical Director for Outpatient Transformation, NHS England
- 1425-1435 **Evidence Based Interventions: Making the Best Use of Resources**  
**Andrew Dickinson**, University Hospitals Plymouth
- 1435-1445 **The Role of Surgical Hubs in Elective Recovery**  
**Ben Ayres**, St George's University Hospitals NHS Trust, London
- 1445-1500 **Q&A and Discussion**

Hall 11B  
1400-1530

## Medical Students Session

Chairs: **Ben Ayres**, St George's University Hospitals NHS Trust and BAUS Education Lead for Medical Students and **Bushra Abdelqader**, St George's University Hospitals NHS Trust

- 1400-1405 **Introduction**  
**Ben Ayres**, St George's University Hospitals NHS Trust
- 1405-1420 **Medical Student Essay Prize Winner Presentation**  
"What steps can be taken in Urology to recover from the COVID pandemic? How do we address health inequalities exposed by the pandemic? How do we promote good Urological health?"  
**Grace Olatunde**, Aston Medical School, Birmingham
- 1420-1435 **Why I Chose Urology?**  
**Susannah La Touche**, St George's Hospital, London  
**Nataniel Tan**, Guy's & St Thomas' Hospital, London  
**Zhi-Yang Low**, Guy's & St Thomas' Hospital, London  
**Bushra Abdelqader**, St George's University Hospitals NHS Trust
- 1435-1455 **Case Based Discussion on Lower Urinary Tract Symptoms**  
**Luis Ribeiro**, Croydon University Hospital, Surrey
- 1455-1515 **Case Based Discussion on Stones**  
**James Akman**, Nottingham City Hospital
- 1515-1530 **The LEARN Study - Lessons Learnt and Next Steps**  
**Alexander Ng**, University College Hospital, London and **Aqua Asif**, University College London, London

Hall 1  
1500-1530

## The Urology Foundation Guest Lecture Survival of the Fittest

We are working in challenging times and now more than ever we look to our leaders. But what exactly is good leadership? How do you develop yourself as a leader and juggle multiple responsibilities? How do you create a successful, high performing, motivated team? We are delighted to welcome Sir Thomas Hughes-Hallett, renowned British barrister, investment banker and philanthropist who will share his experiences and insight into leadership.

**Sir Thomas Hughes-Hallett**, Non-Executive Chair of the Marshall Institute at the London School of Economics and the Chelsea and Westminster Hospital NHS Foundation Trust

Hall 1  
1530-1600

## Bayer Satellite Symposium

See page 23 for details



1530-1630 Refreshments, Networking and Exhibition Viewing

Hall 3 - Stand 230  
1600-1620

## BK Medical Sponsored Silent Symposium

### Fusion-Based Prostate Cancer Management – Diagnosis to Treatment

**John Leveckis**, Doncaster Royal Infirmary



Hall 1  
1630-1730

## Delivering Urological Care – Workstream, and Models of Care, Meet Workforce

Chair: **Steve Payne**, BAUS Workforce Lead

1630-1635 **Introduction & Changes in Urological Working**

**Steve Payne**, BAUS Workforce Lead

1635-1645 **How Urology is Currently Delivered in the UK**

**John McGrath**, Royal Devon and Exeter Hospital

1645-1655 **Are We Keeping Up with the Need, Even Without  
the Pandemic?**

**Ian Eardley**, Leeds Teaching Hospital Trust and National Clinical Director Elective Care, NHS England

1655-1705 **The Urological Workforce and the Future.**

**Justine Royle**, Aberdeen Royal Infirmary and JCST Chair, SAC in Urology

**the Politics/Manpower Conundrum**

**Ian Pearce**, Honorary Secretary and Vice-President Elect of BAUS and Manchester Royal Infirmary

1715-1730 **Q&A**

Hall 4  
1630-1730

**Joint FNUU & Oncology Session: When to Phone a Friend**

Chairs: **Alexandra Colquhoun**, Addenbrooke's Hospital, Cambridge, **Arnulf Stenzl**, University of Tuebingen Department of Urology and **Suzanne Biers**, Addenbrooke's Hospital, Cambridge

1630-1645 **MDT Potential Pre-Malignant Lesions**  
**Sachin Malde**, Guy's and St Thomas' NHS Trust, London  
**Helena Burden**, Southmead Hospital, Bristol

1645-1700 **MDT Malignancy in Neuropathic & Reconstructed Urinary Tract**  
**Helena Gresty**, University College Hospital London  
**Raj Nair**, Guy's and St Thomas' NHS Trust, London

1700-1715 **Urinary Incontinence & LUTS After Cancer Surgery**  
**Nikesh Thiruchelvam**, Addenbrooke's Hospital, Cambridge

1715-1730 **Q&A**

Hall 8  
1630-1730

**Stents – the Ticking Time Bomb**

Chairs: **Susan Willis**, Guy's & St Thomas' Hospital, London and **Sachin Agrawal**, St Peter's Hospital, Chertsey

1630-1640 **Summary of HSIB Report and Recommendations**  
**Hari Ratan**, Nottingham University Hospitals

1640-1650 **Medicolegal Implications of Delayed Stent Removal**  
**John McCabe**, Whiston Hospital, Prescot, Merseyside

1650-1700 **Current Models of Stent Tracking**  
**Huw Garrod**, Arrowe Park Hospital, Wirral

1700-1710 **Forgotten Stents MDT Panel Discussion**

1710-1730 **Q&A**



Hall 9  
1630-1730

## Infertility

Chairs: **Maria Satchi**, Darrent Valley Hospital and **Marc Lucky**, University Hospital Aintree, Merseyside

### 1630-1710 MDT Case Studies & Infertility

#### Case Presentation

**Joachim Jimie**, Aintree University Hospital, Liverpool

#### Panel

**Nikolaos Sofikitis**, University of Ioannina, Greece

**Pippa Sangster**, University College Hospital, London

**Marij Dinkelman-Smit**, Erasmus University Medical Center, Netherlands

**Jonathan Ramsay**, Hammersmith Hospital, London

### 1710-1730 Female Aspects of Fertility: What the Urologist Should Know?

**Richard Russell**, Consultant Gynaecologist & Subspecialist in Reproductive Medicine and Surgery, Hewitt Fertility Centre, Liverpool

Hall 1  
1730-1800

## Coloplast Satellite Symposium



See page 24 for details

Exhibition Hall 3  
1800-1900

## Drinks Reception, Networking and Exhibition Viewing

Hall 8  
1400-1500

## ePoster Session 1: Stones, Imaging and Upper Tract Disorders 1

Chairs: **Mathew Sorensen**, MD, Urology Clinic at UW Medical Center, Seattle, United States and **Sara Ramsey**, Raigmore Hospital, Inverness

Please see page 83 for the ePosters

Hall 9  
1400-1500

## ePoster Session 2: Andrology, Genitourethral Reconstruction, Infertility & Male Genital Cancers

Chairs: **Amerdip Birring**, Russells Hall Hospital, Dudley and **Abi Kanthabalan**, Alexandra Hospital, Redditch

Please see page 85 for the ePosters

Hall 10  
1400-1500

## ePoster Session 3: Female Urology and Bladder Dysfunction

Chairs: **Voula Granitsiotis**, Western General Hospital, Edinburgh and **Jaskarn Rai**, Leicester General Hospital

Please see page 87 for the ePosters

Hall 11A  
1400-1500

## ePoster Session 4: Renal Cancer / Testis Cancer / Sarcoma

Chairs: **James Forster**, Bradford Royal Infirmary and **Faith McMeekin**, Cheltenham General Hospital

Please see page 89 for the ePosters

Hall 10  
1630-1730

## ePoster Session 5: Management/Governance/Education/Quality Improvement

Chairs: **Rickaz Raheem**, Milton Keynes University Hospital and **Theodora Stasinou**, Salford Royal Hospital

Please see page 91 for the ePosters

Hall 11A  
1630-1730

## ePoster Session 6: Inequalities in Urological Healthcare Provision and Training

Chairs: **Tim Lane**, Lister Hospital, Stevenage and **Yinka Gbolahan**, Royal Free Hospital, London

Please see page 93 for the ePosters





Access Prescribing  
Information here >

## REFER EARLY. TREAT EARLY. DELAY DISEASE PROGRESSION. EXTEND LIFE.<sup>1-3</sup>

### Refer early. Treat early

Use ERLEADA® + ADT in patients with mHSPC and high-risk\* nmCRPC to **delay disease progression† and extend life** vs PBO + ADT<sup>‡§\*\*1-3</sup>

### Health Related Quality of Life

**HRQoL was not compromised** by the addition of ERLEADA® to ADT in mHSPC and high-risk\* nmCRPC patients<sup>¶II5-8</sup> PROs were prespecified exploratory endpoints and were assessed using the BPI-SF, BFI, FACT-P and EQ-5D-5L.<sup>2,11</sup>

### PSA response

In a post-hoc exploratory analysis, patients in both TITAN and SPARTAN who had rapid and deep declines in PSA following treatment with ERLEADA® + ADT had **more favourable HRQoL, outcomes and improved patient-reported physical wellbeing** compared to those who didn't achieve such a response<sup>¶4</sup>

### Safety Profile

ERLEADA® + ADT demonstrated a consistent and generally manageable safety profile. For full safety information, please refer to the SmPC<sup>1-3,9,10</sup>

The most common adverse reactions are fatigue (26%), skin rash (26% of any grade and 6% Grade 3 or 4), hypertension (22%), hot flush (18%), arthralgia (17%), diarrhoea (16%), fall (13%), and weight decreased (13%). Other important adverse reactions include fractures (11%) and hypothyroidism (8%).<sup>8,9</sup>

#### ERLEADA® is indicated:<sup>8,9</sup>

- in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk\* of developing metastatic disease
- in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

\*High risk defined as patients with a PSA doubling time of  $\leq 10$  months.<sup>9,10</sup>

Medical castration with GnRH $\alpha$  should be continued during ERLEADA® treatment in patients who have not been surgically castrated.<sup>9,10</sup>

<sup>†</sup>rPFS was a dual primary endpoint of the TITAN study: ERLEADA® + ADT rPFS was 68.2% vs 47.5% for PBO + ADT (median follow-up 22.7 months, HR=0.48; 95% CI, 0.39–0.60; P<0.001). rPFS was defined as the time from randomisation to first imaging based documentation of progressive disease or death, whichever occurred first.<sup>1</sup>

<sup>‡</sup>OS was a dual primary endpoint of the TITAN study: ERLEADA® + ADT median OS was not reached vs 52.2 months with PBO + ADT (median follow-up 44.0 months, HR=0.65; 95% CI, 0.53–0.79; P<0.0001).<sup>2</sup>

<sup>§</sup>MFS was the primary endpoint of the SPARTAN study: ERLEADA® + ADT provided an additional 2 years' MFS vs PBO + ADT (40.5 vs 16.2 months, respectively, HR=0.28; 95% CI, 0.23–0.35; P<0.0001). MFS is defined as time from randomisation to the first detection of distant metastasis on imaging (assessed by blinded independent central review) or death from any cause, whichever occurred first.<sup>11</sup>

<sup>¶</sup>As measured by FACT-P and BPI-SF patient reported outcomes.<sup>4</sup>

<sup>¶</sup>Based on measurements of HRQoL at baseline and throughout treatment. HRQoL total score was a prespecified exploratory endpoint and was assessed using FACT-P and EQ-5D-5L.<sup>8</sup>

<sup>¶</sup>PROs were prespecified exploratory endpoints in TITAN and were assessed using the BPI-SF, BFI, FACT-P, and EQ-5D-5L.<sup>5,6</sup>

<sup>\*\*</sup>Median OS was 73.9 months with ERLEADA® + ADT vs 59.9 months with PBO + ADT; HR=0.78; 95% CI, 0.64–0.96; P=0.016.<sup>3</sup>

ADT, androgen deprivation therapy; BFI, brief fatigue inventory; BPI-SF, brief pain inventory-short form; CI, confidence interval; EQ-5D-5L, EuroQol five-dimension, five-level questionnaire; FACT-P, functional assessment of cancer therapy-prostate; GnRH $\alpha$ , gonadotropin-releasing hormone analogue; HR, hazard ratio; HRQoL, health-related quality of life; MFS, metastasis-free survival; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, non-metastatic castration-resistant prostate cancer; OS, overall survival; PBO, placebo; PROs, patient-reported outcomes; PSA, prostate-specific antigen; rPFS, radiographic progression-free survival; SmPC, summary of product characteristics.

#### References:

1. Chi KN, et al. N Engl J Med. 2019;381(1):13–24.
2. Chi KN, et al. J Clin Oncol. 2021;39(20):2294–2303.
3. Smith MR, et al. Eur Urol. 2021;79(1):150–85.
4. Small EJ, et al. Poster presented at the ASCO Genitourinary Cancers Symposium, 17–19 February 2022.
5. Agarwal N, et al. Lancet Oncol. 2019;20(11):1518–1530.
6. Agarwal N, et al. Poster presented at the ASCO Annual Meeting, 4–8 June 2021. #5068.
7. Agarwal N, et al. Poster presented at the ESMO Congress, 27 September–01 October 2019. #851PD.
8. Oudard S, et al. Poster presented at ESMO Virtual Congress, 19–21 September 2020. #2980.
9. ERLEADA® (apalutamide). Summary of Product Characteristics. Great Britain. Available from: [www.medicines.org.uk/emc/product/9832/smcp](http://www.medicines.org.uk/emc/product/9832/smcp).
10. ERLEADA® (apalutamide). Summary of Product Characteristics. Northern Ireland. Available from: [www.emcmedicines.com/en-gb/northernireland](http://www.emcmedicines.com/en-gb/northernireland).
11. Smith MR, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018;378:1408–1418.

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at [dsafety@its.jnj.com](mailto:dsafety@its.jnj.com).

Janssen Oncology

PHARMACEUTICAL COMPANIES OF

## PROGRAMME

ICC Birmingham, Centenary Square Entrance

0700

### **BSoT Fun Run for TUF -**

#### **Join us to Jog, Chat, Walk - 5K. All Welcome!**

BSoT are organising a very social 5km run to raise money for TUF. Sign up and join the #BSoTfunrunforTUF23 starting at 0700am outside ICC Birmingham Centenary Square Entrance. Bag drop will be available from 0700.

We are asking all runners to kindly pre-register to allow us to compile a list of participants (Health & Safety requirement). To do this please add "BSoT Fun Run" in the additional comments box when you make your donation. Suggested minimum donation is £15 per person - you can make your donation at [Home - The Urology Foundation](#).

Hall 8

0800-0900

### **Starter Session: Managing Emergencies I**

Chairs: **Trevor Dorkin**, Freeman Hospital, Newcastle and **Raveen Sandher**, Guy's & St Thomas's Hospital, London

0800-0815

#### **Penis - Fracture & Priapism**

**Rowland Rees**, Southampton General Hospital

0815-0820

#### **Q&A**

0820-0835

#### **Urethra - Trauma and Iatrogenic Injuries**

**Paul Anderson**, Russells Hall Hospital, Dudley

0835-0840

#### **Q&A**

0840-0855

#### **Urogenital - Fourniers and Foreign Bodies**

**Jonathan Barclay**, The James Cook University Hospital, Middlesbrough

0855-0900

#### **Q&A**

Hall 9

0800-0900

### **Starter Session: Anatomical Drawing**

Chair: **Mary Garthwaite**, Chair of The Urology Foundation

#### **Faculty**

**Lucy Lyons**, Lead tutor for SSC Anatomy and Art, MBBS, UCL Medical School and lecturer in Drawing and in Contextual Studies at The Margate School (ESADHaR).

**Mary Garthwaite**, Chair of The Urology Foundation

**Sophia Cashman**, Addenbrooke's Hospital, Cambridge

Hall 10

0800-0900

### **Starter Session: Outside the Clinical Box**

Chairs: **Shalom Srirangam**, Royal Blackburn Hospital and **Maxine Tran**, Royal Free Hospital, London

0800-0810

#### **Clinical Lead in Urology: Developing an Effective Service**

**Julian Smith**, Southampton General Hospital

0810-0815

#### **Q&A**

0815-0825

#### **How to Achieve Excellence in Surgical Education**

**Justine Royle**, Aberdeen Royal Infirmary and JCST Chair, SAC in Urology

- 0825-0830 **Q&A**
- 0830-0840 **Why Bother with Procurement**  
**Fay Allen**, NHS Supply Chain
- 0840-0845 **Q&A**
- 0845-0855 **Making Networks Work**  
**Ravi Barod**, Royal Free Hospital, London
- 0855-0900 **Q&A**

Hall 11A  
0800-0900

## Starter Session: Museum of Urology ‘Sent to Coventry’

This session will be looking at two people in the history of urology who were, and to some extents still are, looked down on, both have been called quacks by their contemporaries and by subsequent historians. Roundheads and cavaliers all welcome - no one will be sent to Coventry!

- 0800-0820 **Joanna Stephens**  
**Kathryn Ball**, Nottingham City Hospital
- 0820-0840 **Frere Jacque**  
**Jonathan Goddard**, Leicester General Hospital
- 0840-0900 **Thomas Hollier**  
**Priya Kumar**, University Hospital, Coventry

Hall 1  
0900-0930

## Janssen Satellite Symposium

See page 24 for details



Hall 1  
0930-1100

## Learning from the Law

Chair: **Tim O’Brien**, Past-President of BAUS & Guy’s Hospital, London

- 0930-1000 **Debate: Strategic Consent : “Urological Patients should sign consent for surveillance strategies”**  
**Case Presentation**  
**Tim O’Brien**, Past-President of BAUS & Guy’s Hospital, London  
**For the Motion**  
**Vincent J Gnanapragasam**, University of Cambridge  
**Against the Motion**  
**Jonathan Glass**, Guy’s & St Thomas’ Hospital, London
- 1000-1030 **“Montgomery 8 Years On” and Q&A**  
**Lauren Sutherland QC**, Ampersand Advocates, Edinburgh and Byrom Street Chambers, Manchester
- 1030-1050 **“How to be sued” - Reflections on a Career as an Expert Witness**  
**John Reynard**, Churchill Hospital, Oxford
- 1050-1100 **Q&A**



1100-1130 Refreshments, Networking and Exhibition Viewing

Hall 1

1130-1200

**BJU International Guest Lecture:  
Integrated Care Boards - complicated plumbing or the  
route to improved flow systems?**

Chair: **Alan McNeill**, Western General Hospital, Edinburgh, and Chair, BJU International

**Nigel Acheson**, Regional Medical Director, and Higher-Level Responsible Officer for the South Region of NHS England

Hall 4

1130-1230

**Joint AGUS & ESAU Session:  
Andrology Challenges**

Chairs: **Ayo Kalejaiye**, University Hospitals, Birmingham and **Majid Shabbir**, Guy's & St Thomas' Hospital

1130-1140 **Penile Cosmetic Surgery: The Good, the Bad & the Ugly  
(Penile Augmentation Debate)**

**Suks Minhas**, Charing Cross Hospital, London

1140-1145 **Discussion**

1145-1155 **Stuttering Priapism**

**Eduard Ruiz Castañe**, Fundación Puigvert, Barcelona

1155-1200 **Discussion**

1200-1210 **Circumcision in Obesity: To Circ or Not To Circ**

**Carlo Bettocchi**, Ospedali Riuniti University Hospital of Foggia, Italy

1210-1215 **Discussion**

1215-1225 **Management of Peno-Scrotal Hidradenitis Suppurativa**

**Wai Gin (Don) Lee**, University College Hospital, London

1225-1230 **Discussion**

Hall 8

1130-1230

**International Perspective of Urinary Incontinence  
Management**

Chairs: **Tamsin Greenwell**, University College Hospital, London and **Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne

1130-1145 **The American Perspective**

**Chris Chermansky**, University of Pittsburgh School of Medicine

1145-1200 **The Australian Perspective**

**Helen E. O'Connell AO**, President, Urological Society Australia and New Zealand (USANZ)

1200-1215 **The Middle East Perspective**

**Zaki Almalleh**, Cleveland Clinic Abu Dhabi

Hall 9  
1130-1230

## Simple Stones, Complex Patients

Chairs: **Matthew Bultitude**, Guy's & St Thomas' Hospital, London and **Amelia Pietropaolo**, Southampton General Hospital

- 1130-1140     **Stones in Pregnancy**  
**Sri Sriprasad**, Darent Valley Hospital, Kent
- 1140-1150     **Stones in Neuropaths**  
**Stephanie Symons**, Pinderfields Hospital, Wakefield
- 1150-1200     **Stones in Patients on Anticoagulation/Antiplatelet drugs**  
**Sudhakar George**, Consultant Cardiologist, University Hospitals Birmingham NHS Foundation Trust
- 1200-1210     **Stones in Patients with High BMI**  
**Mathew Sorensen**, MD, Urology Clinic at UW Medical Center, Seattle, United States
- 1210-1220     **Assessing Frail Stone Patients**  
**Mark Johnston**, Consultant Geriatrician POPS Lead, Liverpool University Hospitals NHS Foundation Trust
- 1220-1230     **Q&A**

Hall 11A  
1130-1230

## Between a Rock and a Hard Place: Complex Decision-Making MDT

Chairs: **Zoe Panayi**, Royal Preston Hospital and **Eoin Dinneen**, University College Hospital, London

4 MDT Cases with Panel Discussion

### Panel

**Kieran O'Flynn**, Salford Royal Hospital

**Rachel Morrison**, Harrogate District Hospital

**Catherine Meilak**, Perioperative Care of Older People undergoing Surgery (POPS) Consultant, East Kent Hospitals University NHS Foundation Trust

**Joanna Mackie**, Consultant Anaesthetist, Worcestershire Acute Hospitals NHS Trust

Hall 1  
1200-1230

## AGM

Chair: **Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough

The AGM Agenda will be available to Members via the BAUS website.

Hall 3 - Stand 230  
1230-1300

## Janssen Sponsored Silent Symposium



### Integrating Best Practice: How a United Approach Could Optimise the Patient Journey Through Prostate Cancer

Join us at our promotional Janssen-sponsored silent symposium that will feature pre-records from an expert faculty who will share their experiences and perspectives on how to treat and optimise quality of life for patients with metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) and discuss case studies that illustrate referral management from urology to oncology.

#### Quality Care Matters as Much as Quality of Life

**Alison Birtle**, Consultant Clinical Oncologist and Honorary Clinical Professor, Lancashire Teaching Hospital NHS Foundation Trust

#### Optimising Referrals: Examples from Clinical Experience

**Bhavan Rai**, Consultant Urologist and Robotic Surgeon, Freeman Hospital, Newcastle Upon Tyne

1230-1400

Lunch, Networking and Exhibition Viewing

Hall 1  
1315-1400

## Boston Scientific Satellite Symposium



See page 25 for details

Hall 1  
1400-1510

## International British Urology Society: Pay, Pension & Tax

Chairs: **Sandeep Gujral**, Barking, Havering & Redbridge University Hospital and **Elizabeth Osinibi**, University College Hospital, London

1400-1425

### Pension Scheme, Tax and Solution

**Vishal Sharma**, Consultant Cardiologist, Chair BMA Consultants Committee, Chair BMA Pensions Committee

1425-1450

### Pay-Recommendations from the Doctors & Dentists Remuneration Body

**Mike Henley**, Consultant Urologist, BMA Council/Consultants Committee-Pay, T&C's Lead & Committee Deputy Chair.

1450-1500

### Q&A and Summary

1500-1510

### The IBUS PRISM Award

**Ru MacDonagh**, Musgrove Park Hospital, Taunton

Citation by **Jaimin Bhatt**, Queen Elizabeth University Hospital, Glasgow

Presented by **Subu Subramonian**, Queen Elizabeth University Hospital, Glasgow and Past President of IBUS

Hall 8  
1400-1500

## Paediatric Urology Transition Services

Chairs: **Claire Taylor**, Guy's & St Thomas' Hospital, London and **Thomas King**, Queen Elizabeth Hospital, Birmingham

- 1400-1410 **How to Set up a Paediatric Urology Transition Service**  
**Charlotte Dunford**, Norfolk and Norwich University Hospital
- 1410-1430 **Congenital Abnormalities – Pitfalls and Top Tips**  
**Andrew Baird**, Aintree University Hospital, Liverpool
- 1430-1445 **Nocturnal Enuresis in Adolescents**  
**Mark Woodward**, Consultant Paediatric, Bristol Children's Hospital

Hall 11A  
1400-1500

## BURST: Research Updates

Chairs: **Veeru Kasivisvanathan**, University College Hospital, London, **Nikita Bhatt**, Addenbrookes Cambridge University Hospital and **Sinan Khadhour**, Aberdeen Royal Infirmary

- 1400-1415 **Welcome and General BURST Updates**  
**Veeru Kasivisvanathan**, University College Hospital, London, **Nikita Bhatt**, Addenbrookes Cambridge University Hospital and **Sinan Khadhour**, Aberdeen Royal Infirmary
- 1415-1425 **Updates: RESECT**  
**Kevin Gallagher**, Western General Hospital, Edinburgh
- 1425-1450 **Debate: TURBT Should Only Be Done on a Specialist List**  
Chair: **Marcus Cumberbatch**, Royal Hallamshire Hospital, Sheffield
- For**  
**Param Mariappan**, Western General Hospital, Edinburgh
- Against**  
**Helena Burden**, Southmead Hospital, Bristol
- 1450-1500 **Guest Speaker: Leading an NIHR Trial as a Surgical Trainee**  
**Deena Harji**, Consultant Colorectal Surgeon, Manchester University NHS Foundation Trust

Hall 11B  
1400-1615

## Core Trainees in Urology

Chair: **Anna O'Riordan**, Freeman Hospital, Newcastle-Upon-Tyne

- 1400-1410 **Introduction**  
**Anna O'Riordan**, Freeman Hospital, Newcastle-Upon-Tyne
- 1410-1420 **Consent – Important Principles for the Budding Surgeon**  
**Anna O'Riordan**, Freeman Hospital, Newcastle-Upon-Tyne
- 1420-1430 **Chaperone – Best Practice**  
**James Leighton**, Freeman Hospital, Newcastle-Upon-Tyne

1430-1440 **LUTs - Assessment and Identification of the Surgical Candidate Presenting with LUTS**  
**Anna O’Riordan**, Freeman Hospital, Newcastle-Upon-Tyne

### **Surgical Options for Treatment of LUTS - Options:**

1440-1450 **TURP and Prostate Artery Embolisation**  
**Ishtiaqul Rizvi**, James Cook University Hospital

1450-1500 **Holep and Urolift**  
**Ming He**, Freeman Hospital, Newcastle-Upon-Tyne

1500-1510 **Green Light Laser and REzum**  
**Angus Luk**, Freeman Hospital, Newcastle-Upon-Tyne

1510-1525 **Case scenarios / Discussion**

1525-1530 **Audit Competition Introduction**  
**Anna O’Riordan**, Freeman Hospital, Newcastle-Upon-Tyne

1530-1540 **Audit Competition Presentation**

1540-1550 **Audit Competition Presentation**

1550-1610 **National Selection**  
**Bushra Abdelqader**, St George’s University Hospitals NHS Trust

1610-1615 **Closing Remarks**  
**Anna O’Riordan**, Freeman Hospital, Newcastle-Upon-Tyne

1500-1530 Refreshments, Networking and Exhibition Viewing

Hall 11A

1530-1630

## **BURST: Academia for Urology Trainees**

Chairs: **Veeru Kasivisvanathan**, University College Hospital, London, **Nikita Bhatt**, Addenbrookes Cambridge University Hospital and **Sinan Khadhour**, Aberdeen Royal Infirmary

1530-1535 **Introduction to the Academic Session**  
**Sinan Khadhour**, Aberdeen Royal Infirmary

1535-1550 **How to Achieve the Academic Requirement for Urology Registrars (CCT/CESR/ST3), Core Trainees and Medical Students (FY/CT/ACF)**  
**Nikita Bhatt**, Addenbrookes Cambridge University Hospital - CCT/ CESR  
**Kevin Byrnes**, Barking, Havering and Redbridge University Trust - ST3  
**Alexander Ng**, University College Hospital, London - FY/CT/ACF

1550-1625 **Interactive Roundtable: The “How” and “Why” of Research**  
 Chairs: **Meghana Kulkarni**, St George’s NHS Foundation Trust, London, **Arjun Nathan**, Royal Free Hospital, London and **Kevin Byrnes**, Barking, Havering and Redbridge University Trust

**Panel****Maxine Tran**, Royal Free Hospital, London**Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne**Nikesh Thiruchelvam**, Addenbrooke's Hospital, Cambridge**Caroline Moore**, University College Hospital, London**Imran Ahmad**, Queen Elizabeth University Hospital, Glasgow**Sinan Khadhour**, Aberdeen Royal Infirmary**Kevin Gallagher**, Western General Hospital, Edinburgh**Aqua Asif**, University College London, London

1625-1630

**Summary and Closing Remarks****Veeru Kasivisvanathan**, University College Hospital, London, **Nikita****Bhatt**, Addenbrookes Cambridge University Hospital and **Sinan****Khadhour**, Aberdeen Royal Infirmary

Hall 4

1530-1630

**Upper-Tract Urothelial Carcinoma (The Cinderella tumour): Current Status and Future Directions**Chairs: **Bhavan Rai**, Freeman Hospital, Newcastle, **Stephen Bromage**, Stepping Hill Hospital, Stockport and **Tamsin Drake**, Royal Bournemouth General Hospital

1530-1540

**Endoscopic Management of Upper Tract Urothelial Cancer (UTUC)****Joe Philip**, BAUS Honorary Secretary Elect and Southmead Hospital, Bristol

1540-1555

**Management of Lower End During Nephroureterectomy and is There a Role for Nephron-Sparing Surgery?****Morgan Rouprêt**, Pitié-Salpêtrière Hospital, Paris, France

1555-1610

**Lymphadenectomy during Nephroureterectomy- A Luxury or a Necessity?****Jose A. Karam**, MD Anderson Cancer Center, Texas, United States and Assistant Secretary for Europe, Middle East and Africa, American Urological Association (AUA)

1610-1620

**Genetic Screening for UTUC****Sir John Burn**, Newcastle University

1620-1630

**Systemic Options for UTUC: Adjuvant (POUT Trial)/ Neoadjuvant Chemo****Alison Birtle**, Consultant Clinical Oncologist, Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust

Hall 8

1530-1630

**How to Manage Chronic Cystitis**Chairs: **Ased Ali**, Pinderfields Hospital, Wakefield and **Helen E. O'Connell AO**, President, Urological Society Australia and New Zealand (USANZ)

1530-1545

**Bladder Pain Syndrome****Mehwash Nadeem**, James Cook University Hospital, Middlesbrough

- 1545-1600 **Chronic Bacterial Cystitis/National Complex UTI MDT**  
**Tom Lewis**, Consultant Microbiologist, Northern Devon Healthcare NHS Trust
- 1600-1615 **BCG and Radiotherapy Cystitis**  
**Ruth Doherty**, Norfolk and Norwich Hospital
- 1615-1630 **Q&A**

Hall 9  
1530-1630

## Andrology Video Session

Chair: **Asif Muneer**, University College Hospital, London and **Chi-Ying Li**, Whipps Cross Hospital Barts Health, London

- 1530-1537 **How to Manage Recurrent Haemospermia and Ejaculatory Pain**  
**Tet Yap**, Guy's & St Thomas' Hospital, London
- 1537-1542 **Discussion**
- 1542-1556 **How to Manage Ejaculatory Duct Obstruction**  
**David Ralph**, University College Hospital, London
- 1556-1606 **Discussion**
- 1606-1613 **How to Manage the Difficult Foreskin**  
**Peter Malone**, Retired, Royal Berkshire NHS Trust
- 1613-1618 **Discussion**
- 1618-1625 **How to Repair Penile Fractures without Degloving the Penis**  
**Vaibhav Modgil**, Manchester Royal Infirmary
- 1625-1630 **Discussion**

Hall 1  
1630-1730

## Sustainability and Urology in the NHS: Making Healthcare More Environmentally Friendly

Chairs: **Vishwanath Hanchanale**, Liverpool University Hospitals Foundation Trust, **Mahmood Bhutta**, Chair in ENT Surgery and Professor of Sustainable Healthcare, Honorary Consultant ENT Surgeon (UH Sussex) and **Maria Van-Hove**, Greener NHS Fellow, NHS England

- 1630-1635 **Introduction: Ushering in a New Era of Sustainability in Urology**  
**Vishwanath Hanchanale**, Liverpool University Hospitals Foundation
- 1635-1650 **Green NHS: Delivering a Net Zero National Health Service**  
**Maria Van-Hove**, Greener NHS Fellow, NHS England
- 1650-1705 **Towards Greener Scalpels: Revolutionizing Sustainable Practices in Surgery**  
**Mahmood Bhutta**, Chair in ENT Surgery and Professor of Sustainable Healthcare, Honorary Consultant ENT Surgeon (UH Sussex)

- 1705-1720 **Innovating Urology Practice: Pioneering a Sustainable Future**  
**Joseph John**, Royal Devon and Exeter Hospital  
**John McGrath**, Royal Devon and Exeter Hospital
- 1720-1730 **Conclusion and Call to Action / Q&A**  
**Panel Members**

Hall 1  
**1730-1800**

## **Advanced Accelerator Applications (AAA UK) Satellite Symposium**



See page 25 for details



Hall 10  
1130-1230

## ePoster Session 7: History of Urology

Chairs: **Iain Wharton**, University Hospital of Coventry & Warwickshire and **Robyn Webber**, Victoria Hospital, Kirkcaldy

Please see page 96 for the ePosters

Hall 8  
1400-1500

## ePoster Session 8: Prostate Cancer

Chairs: **Taimur Shah**, Imperial Prostate, London and **Meghana Kulkarni**, St George's NHS Foundation Trust, London

Please see page 97 for the ePosters

Hall 9  
1400-1500

## ePoster Session 9: Stones / Imaging / Upper Tract Disorders 2

Chairs: **Hrishikesh Joshi**, University Hospital Cardiff and **Danielle Whiting**, Royal Surrey Hospital

Please see page 99 for the ePosters

Hall 10  
1400-1500

## ePoster Session 10: General Urology 1

Chairs: **Su-Min Lee**, Southmead Hospital, Bristol and **Anna Wright**, Bradford Royal Infirmary

Please see page 101 for the ePosters

Hall 10  
1530-1630

## ePoster Session 11: General Urology 2

Chairs: **Kiki Mistry**, Frimley Park Hospital, Surrey and **Kenneth Hiew**, Belfast City Hospital

Please see page 103 for the ePosters

# TRUSTED IMAGING PARTNERS

**bk**   
medical  
a GE Healthcare company

EMPOWERING UROLOGISTS  
FROM THE CLINIC TO THE OR



Come visit us at **booth #130** and learn more

Hall 10  
0800-0900

## **Starter Session: Curriculum Updates**

- 0800-0815 **Overview of the Curriculum**  
**Dominic Hodgson**, Queen Alexandra Hospital, Portsmouth
- 0815-0830 **Best Practice in MCR**  
**Lisa Lavan**, Queen Alexandra Hospital, Portsmouth
- 0830-0845 **The Curriculum and ARCP**  
**Siobhan Woolsey**, Belfast City Hospital
- 0845-0900 **How to be Successful at CESR Application**  
**Justine Royle**, Aberdeen Royal Infirmary and JCST Chair, SAC in Urology

Hall 9  
0800-0900

## **Starter Session: Managing Emergencies II**

Chairs: **Suzanne Biers**, Addenbrooke's Hospital, Cambridge and **Bhavan Rai**, Freeman Hospital, Newcastle

- 0800-0802 **Introduction**  
**Suzanne Biers**, Addenbrooke's Hospital, Cambridge
- 0802-0819 **The Bleeding Kidney**
- 0802-0811 **Management Algorithm / Tips and Tricks if an Urgent Nephrectomy is Required**  
**John Leveckis**, Doncaster Royal Infirmary
- 0811-0816 **When to Embolise - What Can a Radiologist Do for Me?**  
**Sachin Modi**, Consultant Radiologist, University Hospital Southampton
- 0816-0819 **Q&A**
- 0819-0827 **How to Deal with an Infected Obstructed Kidney in the Absence of Nephrostomy Cover?**  
**Sarath Nalagatla**, University Hospital Monklands, Airdrie, Scotland
- 0827-0830 **Q&A**
- 0830-0838 **How to Manage a Resected Ureter in Theatre?**  
**Voula Granitsiotis**, Western General Hospital, Edinburgh
- 0838-0841 **Q&A**
- 0841-0858 **Intractable Haematuria-Post Radical Pelvic Radiotherapy**
- 0841-0850 **A Urologist's Role**  
**Pradeep Bose**, Morriston Hospital, Swansea
- 0850-0855 **A Radiologist's Role**  
**Sachin Modi**, Consultant Radiologist, University Hospital Southampton
- 0855-0858 **Q&A**
- 0858-0900 **Concluding Remarks**  
**Bhavan Rai**, Freeman Hospital, Newcastle

Hall 8

0800-0900

## Starter Session: Tips and Tricks in Andrology

Chairs: **Vaibhav Modgil**, Manchester Royal Infirmary, and **Judith Dockray**, South Tyneside and Sunderland NHS Foundation Trust

0800-0815 **Peyronie's Disease - How to Keep Out of Trouble**

**Hussain Alnajjar**, University College Hospital, London

0815-0820 **Q&A**

0820-0835 **Grafting in Andrology - Lessons Learned Over the Years**

**Nim Christopher**, University College Hospital, London

0835-0840 **Q&A**

0840-0855 **Medicolegal Cases in Andrology - How to Avoid the Pitfalls**

**Ian Pearce**, Manchester Royal Infirmary

0855-0900 **Q&A**

Hall 11A

0800-0900

## Starter Session: TUF: Research in Focus - Bringing the Urology Community Together to Accelerate Progress

This session is for anyone who is currently active in or has an interest in shaping the future of urological research. The session will include a live survey which will help to shape The Urology Foundation's three-year research strategy.

Come and join us for an interactive session which will examine the role of all stakeholders and communities with an interest in urological research and translational practice. We will discuss the role and experiences of patients and carers, decision makers and influencers in helping to shape the future of urological research. The session will explore the priority areas in urological research, the ways in which The Urology Foundation can help support and accelerate research progress and how we can collectively campaign for and ensure significant investment for the future.

**Rakesh Heer**, Charing Cross Hospital, London and **Imran Ahmad**, Queen Elizabeth University Hospital, Glasgow

Panel: **Mary Garthwaite**, Chair of The Urology Foundation and **Rebecca Porta**, Chief Executive of The Urology Foundation.

Hall 1

0900-0930

## BK Medical Satellite Symposium

See page 26 for details



Hall 1

0930-1000

## President's Address and Q&A

**Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough

Hall 1  
1000-1030

## Presentation of the St Paul's & St Peter's Medal

Chair: **Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough

### 1000-1015 Presentation of the St Paul's Medal

Citation by: **Joe Philip**, BAUS Honorary Secretary Elect and Southmead Hospital, Bristol  
Presented to: **Rajeev TP**, Medicity Guwahati, India

### 1015-1030 Presentation of the St Peter's Medal

Citation by: **Sam McClinton**, NHS Grampian  
Presented to: **James N'Dow**, University of Aberdeen, Scotland

Hall 1  
1030-1100

## BAUS Guest Lecture: The Gift of Adversity: Thriving after Spinal Cord Injury

Chair: **Muhammad Shamim Khan**, Guy's & St Thomas' Hospitals, London

**Mo Belal**, Queen Elizabeth Hospital, Birmingham

1100-1130

Refreshments, Networking and Exhibition Viewing

Hall 1  
1130-1200

## JCU Guest Lecture: 'Regulatory Fairness and Overcoming Discriminatory Treatment: A Personal Story'...

Chair: **Bhaskar Somani**, Southampton General Hospital and Editor-in-chief JCU

**Omer Karim**, The Royal Marsden Hospital and Charing Cross Hospital London

Hall 4  
1130-1300

## A Potpourri of Uro-Oncology Excitement!

Chairs: **Jim Armitage**, Addenbrooke's Hospital, Cambridge, **Morgan Rouprêt**, Pitié-Salpêtrière Hospital, Paris, France and **Beth Hickerton**, Liverpool Foundation Trust

### 1130-1140 Molecular Imaging and Theranostics in Prostate Cancer

**Sobhan Vinjamuri**, Nuclear Medicine Consultant, Royal Liverpool University Hospital

### 1140-1155 Pelvic Lymph Node Dissection for High-Risk Prostate Cancer

**Morgan Rouprêt**, Pitié-Salpêtrière Hospital, Paris, France

### 1155-1205 Local Options in Managing Low-Volume Metastatic Prostate Cancer

**Prasanna Sooriakumaran**, University College Hospital, London

### 1205-1215 Extending Partial Nephrectomy for Large Renal Tumours

**Salah Al-Buheissi**, Southmead Hospital, Bristol

- 1215-1225 **Therapy De-escalation in Stage 2 Seminoma-A UK Perspective**  
**Prabhakar Rajan**, Barts Health NHS Trust, London
- 1225-1245 **Robotic Retroperitoneal Lymph Node Dissection**  
**Vishwanath Hanchanale**, Liverpool University Hospitals Foundation Trust
- 1245-1300 **Patient perspective - Outcome from the BAUS Section of Oncology UK Cystectomy Experience Audit (C-PAT)**  
**Preksha Kuppanda**, Research Associate, North Bristol NHS Trust

Hall 8  
1130-1300

## Controversies in Endourology

Chairs: **Subu Subramonian**, Queen Elizabeth Hospital, Birmingham and **Stephanie Guillaumier**, Victoria Hospital, Kirkcaldy, NHS Fife

- 1130-1150 **Metabolic Evaluation of All Stone Formers - Valuable or Not?**  
**Pro**  
**Oliver Wiseman**, Addenbrooke's Hospital, Cambridge  
**Against**  
**Ben Turney**, Churchill Hospital, Oxford
- 1150-1210 **Bladder Stone - BOO Procedure or Defer?**  
**Pro**  
**Rashmi Singh**, Kingston Hospital, London  
**Against**  
**James Donaldson**, Aberdeen Royal Infirmary and University of Aberdeen
- 1210-1230 **Diagnostic Ureteroscopy is Needed for All Suspected UTUC?**  
**Pro**  
**Daron Smith**, University College Hospital, London  
**Against**  
**Kay Thomas**, Guy's & St Thomas' Hospital, London
- 1230-1250 **Old vs New Lasers - Are They Really Needed?**  
**Pro**  
**Jake Patterson**, Royal Hallamshire Hospital, Sheffield  
**Against**  
**Stephen Miller**, Nottingham City Hospital
- 1250-1300 **Q&A and Discussion**

Hall 9  
1130-1215

## Andrology MythBusters Part 1: Testis Cancer

Chairs: **Salah Al-Buheissi**, Southmead Hospital, Bristol and **Jean McDonald**, North Middlesex University Hospital

- 1130-1140 **Do We Need to Clamp the Cord in Radical Orchiectomy?**  
**Elizabeth Osinibi**, University College Hospital, London
- 1140-1150 **Management of Small Testis Lesions**  
**Hussain Alnajjar**, University College Hospital, London
- 1150-1200 **Management of Inguinoscrotal Sarcoma**  
**Jeremy Oates**, The Christie NHS Foundation Trust, Manchester
- 1200-1210 **Inguinal vs. Scrotal Radical Orchiectomy**  
**Prashant Patel**, University Hospitals Birmingham NHS Foundation Trust
- 1210-1215 **Questions**

Hall 11A  
1130-1300

## Challenging and Championing the Future of Urology

Chairs: **Nick Boxall**, Peterborough City Hospital and **Sarika Nalagatla**, University Hospital Monklands

- 1130-1140 **Update on BSoT's Activities**  
**Nick Boxall**, Peterborough City Hospital
- 1140-1155 **Allyship in Urology**  
**Xander Stephenson-Allen**, Medical Doctor and Equality, Diversity and Inclusion Lead, Pride in Surgery Forum (PRiSM), RCS England
- 1155-1205 **Q&A and Discussion**
- 1205-1220 **How to Collaborate with Industry as a Trainee**  
**Oliver Wiseman**, Addenbrooke's Hospital, Cambridge  
**Charles Reynolds**, CJ Medical
- 1220-1230 **Parents in Urology**  
**Yalini Shanmugabavan**, West Hertfordshire Teaching Hospital NHS Trust
- 1230-1240 **Starting Consultant Life: Are You Ever Ready?**  
**Sophie Rintoul-Hoad**, Epsom and St Helier University Hospitals NHS Trust
- 1240-1245 **Q&A and Discussion**
- 1245-1300 **What Can BSoT Do for You? (Open Discussion)**
- 1300-1315 **Silver & Bronze Cystoscope Awards and Handover of BSoT Chair**
- Silver Cystoscope**  
**Vishwanath Hanchanale**, Liverpool University Hospitals Foundation
- Bronze Cystoscope**  
**David Thurtle**, Addenbrooke's Hospital, Cambridge

Hall 1  
1200-1300

## The Politics of Urology – International Intrigue

**A panel of Urology Leadership from across the globe will share their experiences – the good, the bad and the ugly – of influencing healthcare policy.**

Chairs: **Rajeev TP**, Medicity Guwahati, India and **Joe Philip**, BAUS Honorary Secretary Elect and Southmead Hospital, Bristol

- 1200-1210 **The Politics of Multiple National Interests**  
**Arnulf Stenzl**, University of Tübingen Medical School, Tübingen, Germany and Secretary General of the European Association of Urology (EAU) Executive Office
- 1210-1220 **The Politics of Healthcare Funding – Obama Care and Beyond**  
**Jose A. Karam**, MD Anderson Cancer Center, Texas, United States and Assistant Secretary for Europe, Middle East and Africa, American Urological Association (AUA)
- 1220-1230 **Standardising Access to Urology for a Population of Over 1 billion**  
**Sanjay Kulkarni**, Endosurgery Institute, Pune, India and President, Urological Society of India (USI)
- 1230-1240 **Small Population, Vast Continent – Urology Spread Thin**  
**Helen E. O’Connell AO**, President, Urological Society Australia and New Zealand (USANZ)
- 1240-1250 **A small Ireland – Punching Above its Weight**  
**Barry Jones**, RCSI Hospitals NorthEast, Dublin and President, Irish Society of Urology (ISU)
- 1250-1300 **AUA Leadership Retreat**  
**Nikita Bhatt**, Addenbrookes Cambridge University Hospital

Hall 9  
1215-1300

## Andrology MythBusters Part 2: Penile Cancer

Chairs: **Ben Ayres**, St George’s Hospital, London and **Michelle Christodoulidou**, University College Hospital, London

- 1215-1230 **Do All Penile Lesions Need a Biopsy**  
**Anna Mainwaring**, Morriston Hospital, Swansea
- 1230-1245 **Do All Men with Suspected Penile Cancer Need an MRI and Staging CT and PET CT**  
**Morgan Cleasby**, Consultant Radiologist, University Hospitals Birmingham NHS Foundation Trust
- 1245-1300 **Management of Pre-Malignant Penile Lesions**  
**Kirby Sebro**, NHS Lothian

1300-1400

Lunch, Networking and Exhibition Viewing



Hall 1  
1330-1400

## medac Pharma Satellite Symposium



See page 26 for details

Hall 1  
1400-1500

## SAS/LED/NCH Doctors and the Royal Colleges: The Way Forward

Chairs: **Rickaz Raheem**, Milton Keynes University Hospital and Co-chair ISECSN and **Ravi Banthia**, Western General Hospital, Edinburgh

- 1400-1405 **Introduction**  
**Rickaz Raheem**, Milton Keynes University Hospital and Co-chair ISECSN
- 1405-1415 **BAUS & SAS: Walking the Walk**  
**Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough
- 1415-1435 **Support from the RCS**  
**Neil Mortensen**, Professor of Colorectal Surgery, University of Oxford Medical School and President of Royal College of Surgeons of England
- 1435-1455 **Discussion and Q&A**  
**Rickaz Raheem**, Milton Keynes University Hospital and Co-chair ISECSN and **Ravi Banthia**, Western General Hospital, Edinburgh
- 1455-1500 **Closing Remarks**  
**Ravi Banthia**, Western General Hospital, Edinburgh

Hall 4  
1400-1500

## Urethral Disease

Chairs: **Aditya Manjunath**, Southmead Hospital, Bristol and **Daniela Andrich**, University College Hospital, London

- 1400-1425 **Bladder Neck Stenosis Post TURP and RALP**  
**Sanjay Kulkarni**, Endosurgery Institute, Pune, India and President Elect, Urological Society of India (USI)
- 1425-1440 **New Endoscopic Management of Urethral Stricture**  
**Andrew Chetwood**, Frimley Park Hospital, Surrey
- 1440-1500 **Stricture MDT**  
Chairs: **Ammar Alhasso**, Western General Hospital, Edinburgh and **Tamsin Greenwell**, University College Hospital, London  
**Presenter:**  
**Mark Johnson**, Airedale NHS Foundation Trust  
**Panel**  
**Sanjay Kulkarni**, Endosurgery Institute, Pune, India and President Elect, Urological Society of India (USI)  
**Aditya Manjunath**, Southmead Hospital, Bristol  
**Paul Anderson**, Russell's Hall Hospital, Dudley  
**Andrew Baird**, Aintree University Hospital, Liverpool  
**Katie Moore**, Manchester Royal Infirmary

Hall 8  
1400-1500

## Urolink

Chair: **Chandra Shekhar Biyani**, St James's University Hospital, Leeds and **Michael Ng**, Torbay Hospital, Torquay

- 1400-1415 **The Landscape of Prostate Cancer Diagnostics in Zambia LA TP Prostate Biopsy in Africa - Initial Experience**  
**Nishant Bedi**, St Bartholomew's Hospital, London
- 1415-1420 **Q&A**
- 1420-1435 **Surgical Skills Acquisition in High and LMICs - Is There Any Difference?**  
**Lesley Hunt**, Consultant Colorectal Surgeon, Northern General Hospital, Sheffield
- 1435-1440 **Q&A**
- 1440-1455 **Without Equipment - The Essential Need for Engineering in Global Surgery**  
**Peter Culmer**, Associate Professor School of Mechanical Engineering, University of Leeds
- 1455-1500 **Q&A**

Hall 9  
1400-1500

## FNUU Consensus Documents

Chairs: **Tina Rashid**, St George's University Hospital, London, **Alison Downey**, Pinderfields Hospital, Wakefield and **Roland Morley**, Charing Cross Hospital, London

- 1400-1420 **Urethral Diverticulum**  
**Magda Kujawa**, Stepping Hill Hospital, Stockport
- 1420-1440 **Ketamine Bladder**  
**Mo Belal**, Queen Elizabeth Hospital, Birmingham
- 1440-1500 **Discussion with BAUS Membership**

Hall 11A  
1400-1500

## Advanced Urological Procedures in Training

Chairs: **Katie Brodie**, Western General Hospital, Edinburgh and **Mark Evans**, Belfast City Hospital

- 1400-1430 **How to Master Advanced Procedures as a Trainee**
- 1400-1410 **HoLEP**  
**Sam Folkard**, Maidstone and Tunbridge Wells NHS Trust
- 1410-1415 **Q&A and Discussion**
- 1415-1425 **Urethroplasty**  
**Holly Ni Raghallaigh**, St George's Hospital, London
- 1425-1430 **Q&A and Discussion**

- 1430-1440 **Sarcomas and the Trainee**  
**Aziz Gulamhusein**, The Christie & Manchester University Hospitals  
NHSFT
- 1440-1445 **Q&A and Discussion**
- 1445-1455 **Renal Transplant and the Urology Trainee**  
**Rhana Zakri**, Guy's & St Thomas' Hospitals, London
- 1455-1500 **Q&A and Discussion**

Hall 1

1500-1630

## Guideline Updates

Chairs: **Alan McNeill**, Western General Hospital, Edinburgh and **Sarah Itam**, Frimley Health NHS Foundation Trust

- 1500-1505 **Introduction**  
**Alan McNeill**, Western General Hospital, Edinburgh and **Sarah Itam**,  
Frimley Health NHS Foundation Trust
- 1505-1520 **Andrology & Genito-Urethral Surgery**  
**Varun Sahdev**, Southampton General Hospital
- 1520-1525 **Q&A**
- 1525-1540 **Endourology**  
**Robert Geraghty**, Freeman Hospital, Newcastle
- 1540-1545 **Q&A**
- 1545-1600 **Female Neurological & Urodynamic Urology**  
**Nicholas Faure Walker**, Princess Royal University Hospital,  
Orpington
- 1600-1605 **Q&A**
- 1605-1620 **Oncology**  
**Joseph John**, Royal Devon and Exeter Hospital
- 1620-1625 **Q&A**
- 1625-1630 **Concluding Remarks**  
**Alan McNeill**, Western General Hospital, Edinburgh and **Sarah Itam**,  
Frimley Health NHS Foundation Trust

Hall 1

1630-1700

## Best Poster from Every Unit

Chairs: **Ian Pearce**, Honorary Secretary and Vice-President Elect of BAUS and  
Manchester Royal Infirmary and **Mo Sahu**, Queen Alexandra Hospital, Plymouth

- 1630-1635 **Introduction**  
**Ian Pearce**, Honorary Secretary and Vice-President Elect of BAUS and  
Manchester Royal Infirmary and **Mo Sahu**, Queen Alexandra Hospital,  
Plymouth
- 1635-1640 **Training & Innovation**  
**Ayo Kalejaiye**, University Hospitals, Birmingham

- 1640-1645 **Stone Services**  
**Hari Ratan**, Nottingham University Hospitals
- 1645-1650 **Service Development**  
**Suzanne Biers**, Addenbrooke's Hospital, Cambridge
- 1650-1655 **Cancer & Robotics**  
**Vishwanath Hanchanale**, Liverpool University Hospitals Foundation
- 1655-1700 **General & Diagnostics**  
**Joe Philip**, BAUS Honorary Secretary Elect and Southmead Hospital,  
Bristol

Hall 10  
1130-1305

## ePoster 12: TUF-BAUS Best of the Regions

Chairs: **Mark Lynch**, Croydon University Hospital, Surrey, **Imran Ahmad**, Queen Elizabeth University Hospital, Glasgow and **Caroline Moore**, University College Hospital, London

Please see page 106 for the ePosters

Hall 10  
1400-1500

## ePoster 13: Bladder Cancer: Muscle & Non-Muscle Invasive

Chairs: **Flora Rodger**, Queen Elizabeth University Hospital and **Edward Calleja**, Eastbourne District General Hospital

Please see page 109 for the ePosters

# Introducing medac Academy, an online platform hosting educational content designed for Healthcare Professionals



- | Urology nursing NMIBC eLearning modules
- | 6 interactive modules, plus supporting case studies
- | Content written by Healthcare Professionals



**Sign up now**  
[www.medacacademy.co.uk](http://www.medacacademy.co.uk)

Includes products promoted by medac Pharma

**medac**  
PHARMA

## St Paul's Medal

### Rajeev T P



Professor Rajeev T P holds tenure as the Professor and Head, Department of Urology and Renal Transplantation, Gauhati Medical College, Assam, India.

He undertook his Medical training (MBBS) and Post Graduation in General Surgery (Masters in Surgery) at the same Medical College before specializing in Urology (Master in Chirurgiae-M.Ch) at the premier All-India Institute of Medical Sciences, New Delhi, India. He was the recipient of the Gold Medal for M.Ch ( Urology ) from All-India Institute of Medical Sciences.

Professor Rajeev has undertaken Fellowship in Endourology, Laparoscopic and Robotic Urology at the University of Minnesota, Minneapolis, USA where he is also a Visiting Professor.

He is an Educator and Supervisor for the Higher specialist training in Urology leading to the M.Ch in Urology for the University of Health Sciences, Assam and also to the various M.Ch and DNB (Urology) centers in India. He sits on the panel of Examiners for the M.Ch and DNB Higher specialist training programs in Urology across various Universities in India.

He holds senior positions for the Government of India, Medical Council of India and the National Board of Examinations, with his portfolio including assessing Urology services in various centers and helping bench marking training quality for Urology in India. He is a member of the Sub Speciality Board in Reconstructive Urology of the National Board of Examinations, Govt of India.

He has had a major role in helping develop the framework for the Government of India's Ayushman Bharat Scheme (for Urology), thereby improving access to specialist Urological health care for patients who were considered to be below the poverty line. This program helped bridge the divide between accessibility to healthcare balancing with the availability and provision of healthcare; utilizing the capacity in the private sector but with minimizing cost under this scheme.

He is an enthusiastic innovator believing in using technology and low-cost modifications to help improve health care delivery, reducing morbidity and mortality and developing simulation for training through his Faculty role with Uro medical Technology, Training and Simulation and cadaveric programs of the Indian School of Urology.

Professor Rajeev was instrumental in forming the Youth Wing (YOU) of the Urological Society of India during his tenure as Secretary General. Now this Youth wing is the back bone of the Urological Society of India. Further, he has started an exclusive section for Women Urologists of India during the annual congress of Urological Society of India which has created an overwhelming enthusiasm among the female Urologists.

## Medal Winner Biographies continued

ANNUAL  
MEETING  
19-21 June



Professor Rajeev T P has published over 120 peer reviewed articles and has been an invited Speaker to more than 15 International organizations. He is currently the Scientific Chair, Societe Internationale d'Urologie and also the Treasurer, South Asian Association of Urological Surgeons.

Above all, Professor Rajeev is a well-known cricketer and he has represented the University cricket, State Schools and the Assam state in Ranji Trophy and won lot of accolades.



### St Peter's Medal

## James N'Dow



James N'Dow gained his medical degree in the University of Aberdeen, Scotland, UK; where he is now Professor of Urological Surgery and Director of the Academic Urology Unit. He is appointed to the first Chair of Urological Surgery in Aberdeen's 528-year history as a medical school. Prof N'Dow is also Adjunct Secretary General at the European Association of Urology (EAU) with over 19,000 members globally. In this role, he has responsibility for the European School of Urology, European Urology Scholarship Programme, the EAU Young Urology Office with 2500 young surgeon members, the EAU Patient Office, the European Urology Accredited Continuing Medical Education Programme as well as the European Association of Urology Guidelines Office. He was Chairman of the Clinical Practice Guidelines Office Board of the EAU for 7 years before demitting office in July 2021. Under his leadership, the EAU Guidelines have become the most comprehensive and most trusted urological surgical practice guidelines globally; they are now endorsed by over 75 countries.

He was Co-ordinating Editor within the Cochrane Collaboration from 2008 - 2012; prior to that, he was Editor within the Cochrane Collaboration for a number of years. His research interests are in Global health, evidence-based practice, large observational studies and multicentre randomised clinical trials with a competitive research grant income of over GBP£43 million with publications in high impact journals such as the Lancet and New England Journal of Medicine. He is coordinator of two large European Commission funded projects, PIONEER €12M (38 partners across 9 countries; prostate cancer focus) and OPTIMA €21.3M (38 partners across 13 countries; breast cancer, lung cancer and prostate cancer focus). Further details on OPTIMA can be found here <https://www.optima-oncology.eu/>.

He has returned to The Gambia several times a year since 2001 to provide charitable surgical services in the public government hospitals and maternal health centres in The Gambia, taking along teams of healthcare providers with him. Prof N'Dow soon realised after years of charitable work that this was not the longterm solution to sustainable quality health system strengthening in low resource settings; the poor (especially pregnant mothers) still lacked access to affordable quality healthcare and charitable efforts were not sustained. He therefore founded Horizons (<http://www.horizonstrustuk.org>), an innovative social enterprise model designed to be a catalyst for sustainable systemic and permanent transformation of maternal and infant healthcare in West Africa and beyond, piloting in The Gambia first to learn lessons.

Professor N'Dow is trustee for the University of Aberdeen Development Trust. He is also co-Founder and Managing Director of the Urological CANcer Scottish charity (UCAN; <https://www.ucanaberdeen.com/>). UCAN has now raised over GBP£7 million so far (cash and in-kind) and funded the opening of the first Urological Cancer Care Centre in Scotland co-located with the acute urology services, formally launched by the Health Minister in 2008. He has contributed to the UK National Institute of Clinical Excellence (NICE Guidelines), UK Urology Specialty Advisory Committee, and he was Trustee for British Journal of Urology International from 2009 - 2014. Professor N'Dow has a Urological Surgical practice in the University of Aberdeen Teaching Hospitals/ NHS Grampian, sub-specialising in penile surgery.

In 2022, James was honoured to have been appointed as Deputy Lieutenant of the County of Aberdeenshire.

Gold Medal

## Abhay Rane OBE



Abhay Rane MS FRCSGlasg(Urol) graduated from Poona University in India in 1983, and trained in urology in the United Kingdom and the United States. He was appointed to his current post as Consultant Urological Surgeon at Surrey and Sussex NHS Trust in 1999.

In the College he has served as Vice President (Surgical), Ordinary Councillor, Associate Director (International) and Regional Advisor.

He is Visiting Professor at Canterbury Christchurch University, Kent and Clinical Professor at two prestigious US Universities: Keck School of Medicine at the University of Southern California and the Icahn School of Medicine at Mount Sinai, New York.

He is an advisor to the National Institute of Clinical Excellence (NICE) and has worked as the national urology representative to the NICE Interventional Procedures Advisory Committee. He is elected to the Board of the European Section of Uro - Technology of the European Association of Urology and is a Director of the Endourological Society. A former Council member of the British Association of Urological Surgeons (BAUS), he represents BAUS at the International Member Committee of the American Urological Association.

Abhay was appointed by Her Majesty Queen Elizabeth II as Officer of the Most Excellent Order of the British Empire in the 2014 Honours List for services to laparoscopic surgery.

He has keen interests in surgical education, training and mentoring and the role that College performs nationally and internationally in these contexts.

Karl Storz Golden Telescope

### Grant Stewart



Grant Stewart is Professor of Surgical Oncology at the University of Cambridge, where he has a focus on developing and promoting surgery related clinical trials and translational research. As a urological surgeon, Grant has a specific interest in optimising management of patients with initially localised renal cancer, an area of great need within the disease. He provides all modes of treatment for kidney cancer, from major open surgery to robotic minimally invasive approaches. In 2016 Grant developed the robotic kidney surgery programme in Cambridge and now leads the multi-speciality robotic surgery programme.

Grant's career mission is to optimise management of localised kidney cancer, to that end he recruits ~90% of his patients to practice-changing clinical trials (e.g. RAMPART, WIRE, NAXIVA, ARTIST). Grant's research programme has a clear narrative from kidney cancer screening/early detection to peri-surgical systemic therapy trials. His high impact work includes: surgical/translational lead of the multi-national SORCE and RAMPART adjuvant trials in RCC (JCO 2020), understanding the development/progression/heterogeneity of RCC (Nature 2022, Cell 2018, CCR 2013), completion of the first IVC tumour thrombus neoadjuvant systemic therapy trial (BJC 2022), practice changing RCC follow-up research (EAU guidelines). He leads the World's only trial of RCC screening (Yorkshire Kidney Screening Trial) with plans via NHS England to roll this out nationally, and is the global urology lead for the practice changing COVIDSurg study (Lancet, Lancet Oncology, BJS, Anaesthesia). His research metrics are: £165 million research grant/clinical trial income and over 220 peer reviewed publications.

Grant leads the CRUK Cambridge Centre Clinical Cabinet and the Urological Malignancy and Integrated Cancer Medicine Programmes. He has been a key lead in renewal of the CRUK Cambridge Cancer Centre, the NIHR BRC4, REF (Cambridge ranking 1st for Medicine) and development of the clinical and research elements of the new Cambridge Cancer Research Hospital. He is Chair of the Science and Education Committee and a trustee of TUF, where with BAUS he developed the TUF Clinical Trials Unit. As trustee for Kidney Cancer UK, he has led the Kidney Cancer Accord which has led to approval of a much-needed NICE guideline for kidney cancer. He chairs the Kidney Cancer Pathway for the GIRFT Academy, is Deputy Editor of The Surgeon and Section Editor of the BJU International.

He is passionate about clinical and academic training and Director of the Academic Clinical Fellow Programme in Cambridge, the UK's largest ACF programme.

Grant has received multiple accolades: King James IVth Professorship 2022 (RCSEd), John Fitzpatrick Award 2022 (Kidney Cancer Association), Honorary Professor University of Leeds, elected member of Association of Academic European Urologists and James IV Association of Surgeons Travelling Fellow 2022.

### John Anderson Award

## Suzanne Biers



Suzanne Biers is a consultant at Addenbrookes Hospital in Cambridge subspecialising in female, functional and reconstructive urology. She graduated from St. George's Hospital Medical School, University of London, with the Brackenbury Prize in Surgery, and completed an MD degree in Oxford, receiving the BAUS John Blandy Award for research publications in 2007.

Suzanne's commitment to education is reflected in her roles as co-author and co-editor of 7 textbooks, including the Oxford Handbook of Urology, since the 1st edition in 2002 up to her current work as lead author on the 5th edition. She has been Course Director on 8 different surgical simulation courses, including the Cambridge Emergency Urology Surgical Skills Course which Suzanne is now developing as a national project with BAUS in her role as Lead. She also contributes to functional and reconstructive courses for doctors at all levels working in urology, general surgery and gynaecology.

She has been a Clinical Lead for the 2-year Urology Master's Degree at Anglia Ruskin University from its initiation in 2014, helping to equip early years training doctors with a broad urology knowledge base and experience of research and publication.

Suzanne has been Deputy Training Programme Director in the East of England Deanery since 2018 and was previously the local Clinical Lead for urology trainees. She received the BAUS Silver Cystoscope Regional Award for training in 2021. She has been faculty on a range of BAUS courses including the Core Urology and FRCS Revision Courses since 2011 and has recently been appointed BAUS co-lead for Specialist Trainees. Suzanne continues as Secretary of BAUS FNUU Section and Section Lead for Education. She has published national consensus documents on challenging functional problems and has contributed to national practice through her work on the NICE Urinary Incontinence and Prolapse Guidelines. She is the Eastern Region NIHR Urology Champion for Research and is active as both Principal and Sub-Investigator in national studies.

Suzanne is very grateful for the tremendous opportunities that a career in Urology provides. She is privileged to work with so many inspiring colleagues and trainees and extends her huge gratitude to everyone who has given their time, knowledge and expertise to collaborate with her.

The Urology Foundation Guest Lecture

## Sir Thomas Hughes-Hallett



Sir Thomas Hughes-Hallett's involvement in charities began in the 1990s when he became a trustee, and later Chairman, of the Michael Palin Centre for Stammering Children. In 2000 he was appointed Chief Executive of Marie Curie Cancer Care. Over the next 12 years he led the organisation through a period of significant change, which saw diversification of their activities and the charity becoming a household name.

In 2012 he was knighted in the Queen's Birthday Honour's List for his services to Philanthropy and in 2013 was presented with the prestigious Beacon Fellowship for Philanthropy Advocacy. He is the founder and Chair of Helpforce charity and co-founder of The Marshall Institute within the London School of Economics and Political Science. He is also the former Chair of Chelsea and Westminster Hospital NHS Foundation Trust, a former Trustee of The Esmée Fairbairn Foundation and The King's Fund, and sat on the Board of the Westminster Abbey Foundation. Sir Thomas has served the Department of Health as a Chair or member of a number of advisory boards. He is now Chair of the John Innes Centre, an independent, international centre of excellence in plant science, genetics and microbiology.

BJU International Guest Lecture

## Nigel Acheson



Nigel Acheson is Regional Medical Director and Higher-Level Responsible Officer for the South Region of NHS England. With a population of 13.4 million, the Region stretches from Cornwall to Kent and includes the cities of Bristol, Oxford and Southampton.

Born in Belfast, Nigel trained in Birmingham and was appointed as a consultant gynaecological oncologist in 2002, moving to the Royal Devon and Exeter (RD&E) Hospital in Exeter to help develop the Gynaecological Cancer Centre there and learn to sail.

From his time as a National Advisor and Clinical Lead to the Department of Health's Enhanced Recovery Partnership Programme, Nigel actively promotes the involvement of patients as partners in their care. Whilst Medical Director for the Peninsula Cancer Network in the Southwest of England, Nigel helped to re-establish the patient and public group with the chair and vice-chair becoming members of the network Board.

BAUS Guest Lecture

### Mo Belal



Mr Mo Belal is a Consultant Urological Surgeon; Queen Elizabeth Hospital, Birmingham since 2011 with a specialist interest in Female, Functional, Neuro-urology and Urinary tract reconstruction. He is the current chair of the BAUS Section of FNUU. He is currently working with NHS England representing BAUS as the Mesh lead.

Whilst cycling with a friend, he was struck by a tree resulting in a spinal cord injury and paralysis in February 2021. After multiple operations and 8 months in hospital with over 1000 hours of rehabilitation he has returned to his career as a urological surgeon. He will share his insights from his injury and the journey back to work.



### Journal of Clinical Urology (JCU) Guest Lecture

## Omer Karim



Omer was born in Omdurman in the Sudan of Sudanese and Irish parents. He lived in the Sudan until he was five years old and then went to West Germany where his father was a Cultural Attaché, looking after students all over Europe. In 1968, the family moved to the UK. At King's Macclesfield he became Head Boy, played rugby for Cheshire U19 and then went to Charing Cross Hospital Medical School where he was captain of the First XV.

Following his FRCS he did research at the Brady Institute of Urology, Johns Hopkins Medical Institutions for his MSc. He was an SR at the Royal London and subsequently was appointed a Consultant Urologist in 1995 to East Berkshire. He developed an expertise in nerve sparing radical prostatectomy and converted to robotic assisted surgery in 2004. He has published over 100 peer-reviewed papers and performed over 3,500 robotic assisted operations.

He has been a proctor in robotic assisted surgery since 2008, and regularly teaches surgeons in the UK and Europe. He has taught in South Africa, India and Turkey. He has been elected to Council of the Royal College of Surgeons of England and the British Medical Association. In 2021, he was the first doctor to successfully sue the General Medical Council for racial discrimination, although the GMC has since appealed the ET judgement.

Apart from medicine, he has been involved in business, floating a small medical diagnostic company on AIM in 2000 which was subsequently sold to Laborie. In 2000, he also set up a private diagnostic outpatient facility ([www.bridge-clinic.com](http://www.bridge-clinic.com)) in Maidenhead.

He speaks basic Arabic and German and fluent French. He has Irish, British and Sudanese nationalities. He is married with two children. In his spare time, he cycles, grows cacti and succulents, and is a beekeeper.

WHEN ELIGIBLE PATIENTS PRESENT WITH  
A PSA DOUBLING TIME  $\leq 10$  MONTHS,<sup>1\*</sup>

# THINK HIGH-RISK nmCRPC AND HELP EXTEND WHAT'S IMPORTANT<sup>1-4</sup>

NUBEQA® (darolutamide) is a second-generation AR inhibitor that in combination with ADT can help you extend MFS and OS<sup>†</sup> in high-risk nmCRPC, with low rates of treatment discontinuation due to adverse events (Nubeqa + ADT 8.9% vs placebo + ADT 8.7%) It can help to maintain QoL too.<sup>5</sup>

Nubeqa + ADT significantly prolonged the time to deterioration of FACT-P PCS versus placebo + ADT (HR 0.80, 95% CI 0.70–0.91; P = 0.0005)

Think high-risk nmCRPC. Think referral. Think NUBEQA®<sup>1-4</sup>

#### SAFETY PROFILE:

The most common adverse reactions in nmCRPC patients receiving darolutamide was fatigue/aesthetic conditions (15.8%). The most common serious adverse reactions were ischaemic heart disease (1.9%), urinary retention (1.6%), pneumonia (1.4%), haematuria (1.0%) and heart failure (1.0%).<sup>4</sup>

#### INDICATION:

NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease or with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.<sup>4</sup>

ADT: androgen deprivation therapy; AE: Adverse event; AR: androgen receptor; MFS: metastasis free survival; nmCRPC: non-metastatic castration resistant prostate cancer; PSA: prostate specific antigen; OS: overall survival; QoL: quality of life.

\*nmCRPC is defined as no radiological evidence of metastatic disease, a rising PSA concentration and a PSA doubling time of  $\leq 10$  months.<sup>1\*</sup>

<sup>†</sup>Median MFS for NUBEQA + ADT was 40.4 months (n=955) and 18.4 months for placebo + ADT (n=554) (HR: 0.41; 95% CI: 0.34-0.50; p<0.001).<sup>2</sup> At 3 years, NUBEQA + ADT significantly reduced the risk of death by 31% vs. placebo + ADT (83% vs. 77%; HR: 0.69; 95% CI: 0.53-0.88; p=0.003). A secondary endpoint was overall survival (OS). OS for Nubeqa was 78/955 and 58/554 (HR 0.71 (95% CI 0.50-0.99) p=0.045).<sup>3</sup>

**References:** 1. Payne H et al. Establishing a consensus for the management of non-metastatic castration-resistant prostate cancer in the UK. Available at <https://oncology.bayer.co.uk/prostate/resources> (Accessed April 2023). 2. Fizazi K et al. *N Engl J Med.* 2019;380(13):1235-1246. 3. Fizazi K et al. *N Engl J Med.* 2020;383:1040-1049. 4. NUBEQA (darolutamide) Summary of Product Characteristics. Available at <https://www.medicines.org.uk/emc/product/11324/smpc> (Accessed April 2023). 5. Smith MR et al. *Eur J Cancer.* 2021;154:138-146. 6. Cornford P et al. *Euro Uro.* 2021;79: 263-282.

Be in the know at:  
[oncology.bayer.co.uk](https://oncology.bayer.co.uk)

Or scan the QR code. This links to a  
Bayer promotional website.



**NUBEQA®**  
(darolutamide) 300 mg tablets

#### NUBEQA® (darolutamide) 300 mg film-coated tablets Prescribing Information – Great Britain (Refer to full Summary of Product Characteristics (SmPC) before prescribing)

**Presentation:** Each film-coated tablet contains 300 mg of darolutamide. **Indication(s):** NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease or with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel. **Posology & method of administration:** Treatment should be initiated and supervised by a specialist physician experienced in treatment of prostate cancer. Medical castration with a luteinising hormone-releasing hormone (LHRH) analogue should be continued during treatment of patients not surgically castrated. For oral use. The tablets should be taken whole with food. **Adults:** 600 mg darolutamide (two tablets of 300 mg) taken twice daily, equivalent to a total daily dose of 1200 mg. mHSPC patients should start darolutamide in combination with docetaxel. The first 6 cycles of docetaxel should be administered within 6 weeks after the start of darolutamide treatment. Treatment with darolutamide should be continued until disease progression or unacceptable toxicity even if a cycle of docetaxel is delayed, interrupted, or discontinued. If a patient experiences a  $\geq$  Grade 3 toxicity or an intolerable adverse reaction related to darolutamide, dosing should be withheld or reduced to 300 mg twice daily until symptoms improve. Treatment may then be resumed at a dose of 600 mg twice daily. **Children & adolescents:** There is no relevant use of darolutamide in the paediatric population. **Elderly:** No dose adjustment is necessary. **Renal Impairment:** No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m<sup>2</sup>) not receiving haemodialysis, the recommended starting dose is 300 mg twice daily. **Hepatic Impairment:** No dose adjustment is necessary for patients with mild hepatic impairment. The available data on darolutamide pharmacokinetics in moderate hepatic impairment is limited. Darolutamide has not been studied in patients with severe hepatic impairment. For patients with moderate and severe hepatic impairment (Child-Pugh Classes B and C), the recommended starting dose is 300 mg twice daily. **Contra-indications:** Hypersensitivity to the active substance or to any of the excipients. Women who are or may become pregnant. **Warnings & precautions:** Monitor for signs and symptoms of ischaemic heart disease. Optimise management of cardiovascular risk factors. Discontinue darolutamide for Grade 3-4 ischaemic heart disease. Seizure occurred in patients receiving darolutamide. Advise patients of the risk of developing a seizure while receiving darolutamide. Consider discontinuation of darolutamide in patients who develop a seizure during treatment. Cases of idiosyncratic hepatic reactions with increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to  $\geq 5$  and  $\geq 20 \times$  upper limit of normal (ULN) have been reported in darolutamide clinical trials. Idiosyncratic liver injury has also been reported in the post-marketing setting. The ALT and AST elevations were reversible upon darolutamide discontinuation. In case of hepatic transaminase elevations suggestive of idiosyncratic drug-induced liver injury related to darolutamide, permanently discontinue darolutamide. The available data in patients with severe renal impairment are limited. As exposure might be increased those patients should be closely monitored for adverse reactions. The available data in patients with moderate hepatic impairment are limited, and darolutamide has not been studied in patients with severe hepatic impairment. As exposure might be increased those patients should be closely monitored for adverse reactions. Patients with clinically significant cardiovascular disease in the past 6 months including stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, and symptomatic congestive heart failure were excluded from the clinical studies. Therefore, the safety of darolutamide in these patients has not been established. Use of strong CYP3A4 and P-gp inducers during treatment with darolutamide may decrease the plasma concentration of darolutamide and is not recommended, unless there is no therapeutic alternative. Selection of an alternate concomitant medicinal product with less potential to induce CYP3A4 or P-gp should be considered. Patients should

be monitored for adverse reactions of BCRP, OATP1B1 and OATP1B3 substrates as co-administration with darolutamide may increase the plasma concentrations of these substrates. Co-administration with rosuvastatin should be avoided unless there is no therapeutic alternative. In patients with a history of risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval, physicians should assess the benefit-risk ratio including the potential for Torsade de pointes prior to initiating NUBEQA. NUBEQA 300mg film-coated tablets contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose galactose malabsorption should not take this medicinal product. **Interactions:** For the effect of other medicinal products on the action of darolutamide (e.g. CYP3A4, P-gp inducers and CYP3A4, P-gp and BCRP inhibitors, UGT1A9 inhibitors and docetaxel) and the action of darolutamide on other medicinal products (BCRP, OATP1B1, OATP1B3 substrates, P-gp substrates, docetaxel, CYP3A4 substrates and other medicinal products that prolong the QT interval) refer to the relevant SmPCs. **Pregnancy & lactation:** Darolutamide is not indicated in women of childbearing potential, and it is not to be used in women who are, or may be, pregnant or breast-feeding. Unknown whether darolutamide or its metabolites are present in semen. If the patient is engaged in sexual activity with a woman of childbearing potential, a highly effective contraceptive method (<1% failure rate per year) should be used during and for 1 week after completion of treatment. Unknown whether darolutamide or its metabolites are excreted in human milk. No studies in animals have been conducted to evaluate the excretion of darolutamide or its metabolites into milk. A risk to the breast-fed child cannot be excluded. There are no human data on the effect of darolutamide on fertility. Based on animal studies, darolutamide may impair fertility in males of reproductive potential. **Effects on ability to drive and use machines:** Darolutamide has no or negligible influence on the ability to drive and use machines. **Undesirable effects:** Adverse reactions observed in patients with nmCRPC Very common: fatigue/aesthetic conditions, neutrophil count decreased, bilirubin increased, AST increased. Common: ischaemic heart disease, heart failure, rash, pain in extremity, musculoskeletal pain, fractures. Serious adverse reactions: urinary retention, pneumonia, haematuria, seizure. Adverse reactions observed in patients with mHSPC treated with darolutamide in combination with docetaxel. Very common: hypertension, rash, blood bilirubin increased, ALT increased, AST increased. Serious adverse reactions: fractures, ischaemic heart disease, seizure, febrile neutropenia, neutrophil count decreased, pneumonia. Prescribers should consult the SmPC in relation to other side effects (see section 4.8 of SmPC). **Overdose:** In the event of intake of a higher than recommended dose, treatment with darolutamide can be continued with the next dose as scheduled. There is no specific antidote for darolutamide and symptoms of overdose are not established. **Legal Category:** POM. **Package Quantities & Basic NHS Costs:** Pack of 112 film-coated tablets, £4,040. **MA Number(s):** PLGB 00010/0677. **Further information available from:** Bayer plc, 400 South Oak Way, Reading RG2 6AD, United Kingdom. Telephone: 0118 206 3000. **Date of preparation:** November 2022

NUBEQA® is a trademark of the Bayer Group

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc. Tel: 0118 206 3500, Fax: 0118 206 3703, Email: [pvuk@bayer.com](mailto:pvuk@bayer.com)

This advert was created and funded by Bayer for Great British healthcare professionals.

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Monday 19 June, 1400-1500, Hall 8

## ePoster Session 1:

### **Stones, Imaging and Upper Tract Disorders 1**

Chairs: **Mathew Sorensen**, MD, Urology Clinic at UW Medical Center, Seattle, United States and **Sara Ramsey**, Raigmore Hospital, Inverness

**P1-1** **Is remote follow-up using Patient Reported Outcome Measure (PROM) feasible in patients with urolithiasis?: A prospective feasibility study using Urinary Stones and Intervention Quality of Life (USIQoL) measure**

Miss Ruth Jarvis<sup>1</sup>, Mr Phillip Pallman, Mr Hrishikesh Joshi

<sup>1</sup>University Hospital Of Wales, Cardiff, UK

**P1-2** **Is Serum Urate Clinically Useful as a Screening Test in Renal Stone Disease?**

Mr Robert Geraghty<sup>1</sup>, Mr John Fitzpatrick<sup>1</sup>, Mr Matthew Shaw<sup>1</sup>, Mr Alistair Rogers<sup>1</sup>, Professor Bhaskar Somani<sup>2</sup>, Dr Paul Cook<sup>2</sup>, Professor John Sayer<sup>2</sup>

<sup>1</sup>Freeman Hospital, Newcastle-upon-tyne, UK, <sup>2</sup>University Hospital Southampton, Southampton, UK

**P1-3** **Ideal Timing of Decompression of the Infected Obstructed Kidney: Is sooner always better?**

Dr Lori-Ann Vaz Vaz<sup>2</sup>

<sup>1</sup>Colchester General Hospital, Colchester, UK, <sup>2</sup>University of the West Indies, UWI, Mona, Jamaica

**P1-4** **“Silent Stones” can persist after initial presentation of ureteric colic with no hydronephrosis or symptoms**

Mr Eric Edison, Shiv Sarna, Dani Velinova, Siobhan Price, Emily Woodhead, Alberto Melchionna, Simon Choong, Sian Allen, Daron Smith, Vimoshan Arumuham

**P1-5** **Outcome of Treatment with Thiazide Diuretics for Prevention of Recurrent Renal Stones in Patients with Hypercalciuria**

Dr Jeetendra Rathod<sup>1</sup>, Ms Kimberley Chan<sup>1</sup>, Dr Tord HOGSAND<sup>1</sup>, Dr Kieran Sheimar<sup>1</sup>, Dr Shakir Zaman<sup>1</sup>, Dr Padmini Manghat<sup>1</sup>, Prof Seshadri Sriprasad<sup>1</sup>

<sup>1</sup>Darent Valley Hospital, Dartford, UK

**P1-6** **A cross-sectional study on the role of posterior acoustic shadow width in ultrasound in determining stone size in urolithiasis**

Dr Mohamed Javid Raja Iyub<sup>1</sup>, Dr Srikala Prasad T<sup>1</sup>, Dr S Sudhakaran<sup>1</sup>, Dr Senthil Kumar<sup>1</sup>, Dr G Ramesh<sup>1</sup>, Dr Ananda Kumar<sup>1</sup>, Dr Prabhu Elumalai<sup>1</sup>

<sup>1</sup>Chengalpattu Medical College, Chengalpattu, India

**P1-7** **Machine Learning to Predict Patients that are not Stone Free at Ureteroscopy**

Dr Ganesh Vigneswaran<sup>1,2</sup>, Dr Ren Teh<sup>1</sup>, Dr Amelia Pietropaolo<sup>3</sup>, Mr Francesco Ripa<sup>3</sup>, Dr Sachin Modi<sup>1</sup>, Professor Bhaskar Somani<sup>3</sup>

<sup>1</sup>Department of Interventional Radiology, University Hospital Southampton, Southampton, UK, <sup>2</sup>University of Southampton, Southampton, UK, <sup>3</sup>Department of Urology, University Hospital Southampton, Southampton, UK

**P1-8 Tailored antibiotic prophylaxis for day-case ureteroscopy: A strong case for microbiology participation in the stone MDT**

Dr Bronte Paice<sup>1</sup>, Mr Hari Ratan<sup>1</sup>, Dr Anna Wild<sup>1</sup>

<sup>1</sup>Nottingham City Hospital, Nottingham, UK

**P1-9 Less stent, more gain - A closed loop audit reducing the number of avoidable temporising JJ-stent insertion in ureteric colic patients with ureteric/PUJ stone - An endeavour to improve efficiency of the acute stone service**

Mr Subhabrata Mukherjee<sup>1</sup>, Mr Milad Hanna<sup>1</sup>, Mrs Mitra Kondjin-Smith<sup>1</sup>, Mr Hamid Abboudi<sup>1</sup>, Mr Tamer El-Husseiny<sup>1</sup>, Mr Ranan Dasgupta<sup>1</sup>

<sup>1</sup>Imperial College Healthcare NHS Trust, London, UK

**P1-10 The 'Renal Hit' Paradox to Kidney function recovery after an Acute Ureteral Stone Episode**

Miss Laura Waley<sup>1</sup>, Dr Megan Prosser, Dr Freya Fagan-Bird, Mr Alexander Corbett, Mr Hans Johnson, Mr Joe Philip

<sup>1</sup>Bristol Urological Institute, Southmead Hospital, Bristol, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Monday 19 June, 1400-1500 Hall 9

## ePoster Session 2

# Andrology, Genitourethral Reconstruction, Infertility & Male Genital Cancers

Chairs: **Amerdip Birring**, Russells Hall Hospital, Dudley and **Abi Kanthabalan**, Alexandra Hospital, Redditch

### P2-1 The seminal microbiome and its association with male fertility

Mr Shahriar Mowla<sup>1</sup>, Mr Tharu Tharakan<sup>2</sup>, Ms Linda Farahani<sup>3</sup>, Mr Goncalo Correia<sup>1</sup>, Ms Yun Lee<sup>1</sup>, Mr Suks Minhas<sup>2</sup>, Ms Jara BenNagi<sup>4</sup>, Mr Phillip Bennett<sup>1</sup>, Mr Channa Jayasena<sup>5</sup>, Mr David MacIntyre<sup>1</sup>

<sup>1</sup>IRDB, Imperial College London, London, UK, <sup>2</sup>Department of Urology, Charing Cross hospital, London, UK, <sup>3</sup>Department of Gynaecology, St. Mary's Hospital, London, UK, <sup>4</sup>Centre for Reproductive and Genetic Health (CRGH), London, UK, <sup>5</sup>Department of Andrology, Hammersmith Hospital, London, UK, <sup>6</sup>Department of Gynaecology, UCLH, London, UK, <sup>7</sup>Section of Investigative Medicine, Imperial College London, London, UK

### P2-2 The Efficacy of Clomiphene Citrate in the Management of Idiopathic Male Subfertility

Dr Nimo Ali<sup>1</sup>, Mr Mohammed Saber Khalaf Mahmoud<sup>1,2</sup>, Elizabeth Williamson<sup>1</sup>, Ms Philippa Sangster<sup>1</sup>

<sup>1</sup>University College London, London, UK, <sup>2</sup>Faculty of Medicine, Sohag University, Sohag, Egypt

### P2-3 Spiral Preputial Graft For Panurethral Strictures

Dr Shreyas Bhadranavar<sup>1</sup>, Dr Pankaj Joshi<sup>1</sup>, Dr Sanjay Kulkarni<sup>1</sup>, Dr Apurva Anand<sup>1</sup>, Dr Rathish Rajendra<sup>1</sup>, Dr Amey Talpallikar<sup>1</sup>, Dr Daniel Gomez<sup>1</sup>, Dr Cora Fogging<sup>1</sup>

<sup>1</sup>Kulkarni Urosurgery Institute Pvt Ltd, Pune, India

### P2-4 A Novel Surgical Technique to Create a Natural-Appearing Recessed Vaginal Introitus With Gender-Affirming Vulvoplasty ("Shallow-Depth Vaginoplasty")

Miss. Jenna Stelmar<sup>1</sup>, Miss. Samhita Mallavarapu<sup>1</sup>, Dr. Shannon Smith<sup>1</sup>, Dr. Nance Yuan<sup>1</sup>, Mr. Michael Zaliznyak<sup>2</sup>, Dr Sandeep Sandhu<sup>1</sup>, Dr. Maurice Garcia<sup>1</sup>

<sup>1</sup>Cedars-Sinai Medical Center, Los Angeles, United States, <sup>2</sup>St. Louis University School of Medicine, St. Louis, United States

### P2-5 Quality of life outcomes following penile prosthesis insertion post-priapism

Miss Katy Naylor<sup>1</sup>, Ms Aisling Looney, Ms Isabel Dighero, Ms Chloe Mount, Ms Fiona Holden, Mr Mark Johnson, Professor David Ralph, Ms Philippa Sangster

<sup>1</sup>University College Hospital London, London, UK

### P2-6 Withdrawn

### P2-7 Penoscrotal decompression should be considered for prolonged ischaemic priapism

Mr Matthew Megson<sup>1</sup>, Mr Shafi Wardak<sup>1</sup>, Professor David Ralph<sup>1</sup>, Mr Matthew Megson<sup>1</sup>

<sup>1</sup>University College London Hospitals, London, UK

**P2-8 Glans location, tumour thickness and LVI are independent predictors of metastatic risk in T1 penile squamous cell carcinoma**

Mr Adam Jones<sup>1</sup>, Mr Craig Jones<sup>1</sup>, Mr Adam Jones<sup>1</sup>, Dr Ashwin Sachdeva<sup>1</sup>, Mr Sean Rezvani<sup>1</sup>, Dr Pedro Oliveira<sup>1</sup>, Mr Maurice Lau<sup>1</sup>, Prof Vijay Sangar<sup>1</sup>, Mr Arie Parnham<sup>1</sup>

<sup>1</sup>The Christie NHS Foundation Trust, Manchester, UK

**P2-9 A 10 year retrospective study comparing outcomes of minimally invasive pelvic lymph node dissection for penile cancer vs open pelvic lymph node dissection in a tertiary care centre in England**

Miss Husay Janebdar<sup>1</sup>

<sup>1</sup>Norfolk And Norwich University Hospital, Norwich, UK

**P2-10 Identifying Metastatic Disease in Penile Cancer Patients Using Novel Hybrid MRI-PET Imaging**

Miss Michelle Christodoulidou<sup>1</sup>, Mr Varun Sahdev<sup>1</sup>, Mr Fabio Castiglione<sup>1</sup>, Mr Raj Nigam<sup>1</sup>, Dr Simon Wan<sup>2</sup>, Dr Jamshed Bomanji<sup>2</sup>, Mr Hussain Alnajjar<sup>1</sup>, Mr Manit Arya<sup>1</sup>, Professor Asif Muneer<sup>1,3</sup>

<sup>1</sup>Urology Department, University College London Hospitals, London, UK, <sup>2</sup>Nuclear Medicine Department, University College London Hospitals, London, UK, <sup>3</sup>NIHR Biomedical Research Centre, University College London Hospitals, London, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Monday 19 June, 1400-1500, Hall 10

## ePoster Session 3

# Female Urology and Bladder Dysfunction

Chairs: **Voula Granitsiotis**, Western General Hospital, Edinburgh and **Jaskarn Rai**, Leicester General Hospital

### **P3-1 Nocturnal Enuresis: is sacral neuromodulation a good treatment?**

Dr Jean O’Riordan<sup>1</sup>, Sr Julie Jenks<sup>1</sup>, Dr Konstantinos Kapriniotis<sup>1</sup>, Dr Alejandro Mercado-Campero<sup>1</sup>, Miss Helena Gresty<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Miss Tamsin Greenwell<sup>1</sup>, Mrs Mahreen Pakzad<sup>1</sup>  
<sup>1</sup>UCLH, London, UK

### **P3-2 Ketamine cystitis: presentation and management**

Miss Nikita Bhatt<sup>1</sup>, Ms Marita Isaac<sup>1</sup>, Dr Ravi Kare<sup>1</sup>, Dr Syed Alam<sup>1</sup>, Miss Charlotte Dunford<sup>1</sup>, Miss Ruth Doherty<sup>1</sup>  
<sup>1</sup>Norfolk And Norwich University Hospitals, Norwich, UK

### **P3-3 Urethral Diverticulum: Incidence and Management of Stress Urinary Incontinence**

Mr Wilson To<sup>1</sup>, Ms Jean O’Riordain<sup>1</sup>, Ms Helena Gresty<sup>1</sup>, Mr Richard Nobrega<sup>1</sup>, Mr Anthony Noah<sup>1</sup>, Mrs Mahreen Pakzad<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Ms Tamsin Greenwell<sup>1</sup>  
<sup>1</sup>University College London Hospital, Department of Urology, London, UK, LONDON, UK

### **P3-4 Topical and Oral Oestrogens for Recurrent Urinary Tract Infection (rUTI) - Evidence and recommendations from a systematic review of literature**

Mr Vaki Antoniou<sup>1</sup>, Professor Bhaskar Somani  
<sup>1</sup>University Hospital Southampton, Southampton, UK

### **P3-5 The efficacy of Intravesical iAluRil in the management of recurrent urinary tract infections, painful bladder syndrome and non-bacterial cystiti**

Mr Ekpeno Inyang<sup>1</sup>, Ms Jayne Morris-Laverick<sup>1</sup>, Ms Stephanie Benzemer<sup>1</sup>, Ms Mehwash Nadeem  
<sup>1</sup>South Tees Hospitals Nhs Foundation Trust, Middlesbrough, UK

### **P3-6 Vesico-uterine Fistulae: A case-series experience from a tertiary unit**

Dr Ioannis Loufopoulos<sup>1</sup>, Mr Alfred Cutner<sup>1</sup>, Mr Richard Nobrega<sup>1</sup>, Mr Anthony Noah<sup>1</sup>, Miss Helena Gresty<sup>1</sup>, Ms Tamsin Greenwell<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>  
<sup>1</sup>University College London Hospital, London, UK

### **P3-7 Equivalent efficacy of SNS PNE in patients with an underlying diagnosis of VD or DO, and in patients stratified by presence or absence of diagnosis of psychiatric condition**

Mr James Blackmur<sup>1</sup>, Miss Kaylah Simons-Bengston<sup>2</sup>, Miss Josephine Russell<sup>2</sup>, Mr Sami Hamid<sup>2</sup>, Miss Saddaf Hina<sup>2</sup>, Mr Ammar Alhasso<sup>2</sup>, Miss Paraskeve Granitsiotis<sup>2</sup>  
<sup>1</sup>University Of Edinburgh/NHS Lothian, Edinburgh, UK, <sup>2</sup>NHS Lothian, Edinburgh, UK

**P3-8 Outcomes of External Urethral Sphincter (EUS) Onabotulinum toxin type A (Botox) after failed Sacral Neuromodulation (SNM) therapy in women with voiding dysfunction (VD)/chronic non-obstructive urinary retention (CNOUR).**

Mr Konstantinos Kapriniotis<sup>1</sup>, Miss Amelia Snook<sup>2</sup>, Miss Maryam Imran<sup>2</sup>, Mr Alejandro Mercado-Campero<sup>3</sup>, Ms Elizabeth Day<sup>1</sup>, Ms Helena Gresty<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Ms Tamsin Greenwell<sup>1</sup>, Ms Mahreen Pakzad<sup>1,3</sup>

<sup>1</sup>University College London Hospital at Westmoreland Street, London, UK, <sup>2</sup>University College London Medical School, London, UK, <sup>3</sup>National Hospital For Neurology And Neurosurgery, London, UK

**P3-9 Change in urodynamic (UDS) parameters of women with dysfunctional voiding (DV) following long-term sacral neuromodulation (SNM)**

Mr Ross Stephens<sup>1</sup>, Mr Sachin Malde, Mr Arun Sahai, Dr Eskinder Solomon

<sup>1</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK

**P3-10 Should endoscopic laser removal of eroded urethral mesh/sling be offered to all patients with prior incontinence surgery: A systematic review of literature**

Dr Francesco Ripa<sup>1</sup>, Dr Mai Gamal Morsi<sup>1</sup>, Dr Amelia Pietropaolo<sup>1</sup>, Prof Bhaskar Somani<sup>1</sup>

<sup>1</sup>University Hospital Southampton NHS Foundation Trust, Southampton, UK



# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Monday 19 June, 1400-1500, Hall 11A

## ePoster Session 4

### Renal Cancer / Testis Cancer / Sarcoma

Chairs: **James Forster**, Bradford Royal Infirmary and **Faith McMeekin**, Cheltenham General Hospital

#### **P4-1 Use of renal tumour biopsy prior to nephrectomy - An analysis of the British Association of Urological surgeons nephrectomy outcome data from 2012-2019**

Dr Vinson Wai-shun Chan<sup>1,2,3</sup>, Mr Jon Cartledge<sup>4</sup>, Dr, Selina Bhattarai<sup>4</sup>, Prof. Tze Min Wah<sup>2,4</sup>,  
British Association of Urological Surgeons Nephrectomy Audit

<sup>1</sup>Royal Derby Hospital, Derby, UK, <sup>2</sup>University of Leeds, Leeds, UK, <sup>3</sup>University College London, London, UK,  
<sup>4</sup>Leeds Teaching Hospitals NHS Trust, Leeds, UK

#### **P4-2 Extended venous thromboembolism prophylaxis after minimal access retroperitoneal robot assisted partial or laparoscopic nephrectomy - is it necessary?**

Miss Louise Paramore<sup>1</sup>, Dr Sarah O'Neill<sup>1</sup>, Mr Mohammed Aldiwani<sup>1</sup>, Sister Joanne Oakley<sup>1</sup>, Mr Muddassar Hussain<sup>1</sup>, Mr Neil Barber<sup>1</sup>, Mr Manar Malki<sup>1</sup>

<sup>1</sup>Frimley Renal Cancer Centre, Frimley Park Hospital, Frimley, UK

#### **P4-3 Contemporary management of cT1a renal masses: results from the NEphron Spraying Treatment (NEST) for small renal masses cohort study**

Miss Joana Neves<sup>1,2</sup>, Miss Hannah Warren<sup>1</sup>, Dr Menelaos Pavlou<sup>3</sup>, Mr Joseph Santiapillai<sup>1,2</sup>,  
Mr Darryl Bernstein<sup>1,2</sup>, Mr Ravi Barod<sup>1,2</sup>, Mr Prasad Patki<sup>2</sup>, Professor Faiz Mumtaz<sup>1,2</sup>, Dr Miles Walkden<sup>2</sup>, Dr Soha El-Sheikh<sup>2</sup>, et al.

<sup>1</sup>Division of Surgery and Interventional Science, University College London, London, UK, <sup>2</sup>Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK, <sup>3</sup>Department of Statistical Science, University College London, London, UK

#### **P4-4 Oncological outcomes following pT3a partial nephrectomy - is the rollout of adjuvant immunotherapy in renal cell carcinoma generalisable?**

Mr Mohammed Aldiwani<sup>1</sup>, Miss Joanne Oakley<sup>1</sup>, Mr Manar Malki<sup>1</sup>, Mr Muddassar Hussain<sup>1</sup>, Mr Neil Barber<sup>1</sup>

<sup>1</sup>Frimley Renal Cancer Centre, Surrey, UK

#### **P4-5 Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases - An analysis of European multi-centre prospective EuRECA registry**

Dr Vinson Wai-shun Chan<sup>1,2,3</sup>, Dr Filzah Hanis Osman<sup>2</sup>, Dr David J Breen<sup>4</sup>, Dr Tommy Kjærgaard Nielsen<sup>5</sup>, Dr Julien Garnon<sup>6</sup>, Dr Des Alcorn<sup>7</sup>, Dr. Brunolf Lagerveld<sup>8</sup>, Dr Ole Graumann<sup>9</sup>, Mr Francis Xavier Keeley Jr<sup>10</sup>, Prof. Tze Min Wah<sup>1</sup>, et al.

<sup>1</sup>Royal Derby Hospital, Derby, UK, <sup>2</sup>University of Leeds, Leeds, UK, <sup>3</sup>University College London, London, UK, <sup>4</sup>Southampton University Hospitals, Southampton, UK, <sup>5</sup>Aarhus University Hospital, Aarhus, Denmark, <sup>6</sup>Nouvel Hôpital Civil, Paris, France, <sup>7</sup>Gartnavel General Hospital, Glasgow, UK, <sup>8</sup>OLVG, Amsterdam, Netherlands, <sup>9</sup>Odense University Hospital, Odense, Denmark, <sup>10</sup>North Bristol NHS Trust, Bristol, UK, <sup>11</sup>Leeds Teaching Hospitals NHS Trust, Leeds, UK

**P4-6 A comparison of perioperative outcomes between robotic-assisted partial nephrectomy in the solitary kidney and standard cases**

Miss Duaa Farugi, Mr Oliver Hald, Mr Usman Haroon, Dr Fairleigh Reeves, Yasmin Abu Ghanem, Mr Rajesh Nair, Mr Azhar Khan, Mr Timothy O'Brien, Archana Fernando, Mr Ben Challacombe  
<sup>1</sup>Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK

**P4-7 Functional Outcomes After Radical Nephrectomy Versus Nephron Sparing Surgery in Elderly Patients with T1a Renal Cell Carcinoma: A Multicentre Study**

Dr Thineskrishna Anbarasan<sup>1</sup>, Miss Flora Rogers<sup>2</sup>, Mr James Blackmur<sup>3</sup>, Miss Lucy Drummond<sup>4</sup>, Mr Ahmed Shehata<sup>5</sup>, Mr Edward Mains<sup>3</sup>, Mr Steve Leung<sup>3</sup>, Professor Alan McNeil<sup>3</sup>, Mr Simon Phipps<sup>3</sup>, Mr Alexander Laird<sup>3</sup>, et. al

<sup>1</sup>Churchill Hospital, Oxford, UK, <sup>2</sup>Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK, <sup>3</sup>Department of Urology, Western General Hospital, Edinburgh, UK, <sup>4</sup>Department of Urology, Victoria Hospital, Kirkcaldy, UK, <sup>5</sup>Department of Urology, Ninewells Hospital, Dundee, UK,

**P4-8 Exploring the feasibility of an ex-vivo high throughput screening platform in Kidney Cancer to improve treatment selection and novel drug discovery**

S Conroy<sup>1,2</sup>, G Wells<sup>1</sup>, H Gagg<sup>1</sup>, S Hansford<sup>1</sup>, J Rantala<sup>1</sup>, T Helleday<sup>1</sup>, M G Cumberbatch<sup>1,2</sup>, S Danson<sup>1,2</sup>, J WF Catto<sup>1,2</sup>

<sup>1</sup>Department of Oncology and Metabolism, University of Sheffield, UK, <sup>2</sup>Sheffield Teaching Hospitals NHS Foundation Trust UK

**P4-9 Association of Y chromosome genes with survival outcomes in men with renal cancer**

Ms Katie Valentine<sup>1</sup>, Ms Clare O'Connell<sup>1</sup>, Mr Paul Ryan<sup>1</sup>, Ms Laure Marignol<sup>2</sup>, Professor Thomas Lynch<sup>1</sup>, Mr Diarmuid Sugrue<sup>1</sup>

<sup>1</sup>St James Hospital, Dublin, Ireland, <sup>2</sup>Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland

**P4-10 Impact of Surgical Volume on Oncological Outcomes and Complications in Upper Tract Urothelial Cell Carcinoma: Results from a British Association of Urological Surgeons Audit**

Mr Saeed Dabestani<sup>1</sup>, Mr Ravi Barod<sup>2</sup>, Mr Rajesh Nair<sup>3</sup>, Mrs Yasmin Abu-Ghanem<sup>6</sup>, Mrs Sarah Fowler<sup>4</sup>, Mr Steve Bromage<sup>5</sup>

<sup>1</sup>Kristianstad Central Hospital, Dep of Urology, Region Skane, Lund University, Skane, Sweden, Malmö, Sweden, <sup>2</sup>Royal Free London, Urology Department, Specialist Centre for Kidney Cancer, London, UK, <sup>3</sup>Guy's and St Thomas', Urology Department, London, UK, <sup>4</sup>British Association of Urological Surgeons, London, UK, <sup>5</sup>Stepping Hill hospital, Urology Department, Stockport, UK, <sup>6</sup>Kings College Hospital, London, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Monday 19 June, 1630-1730, Hall 10

## ePoster Session 5 Management/Governance/Education/Quality Improvement

Chairs: **Rickaz Raheem**, Milton Keynes University Hospital and **Theodora Stasinou**, Salford Royal Hospital

### **P5-1 Evolving trends in route to diagnosis for urological cancers in England: a 12-year evaluation**

Miss Samantha Conroy<sup>1,2</sup>, Mr Marcus Cumberbatch<sup>1,2</sup>, Prof James Catto<sup>1,2</sup>

<sup>1</sup>Department of Oncology and Metabolism, University Of Sheffield, Sheffield, UK, <sup>2</sup>Sheffield Teaching Hospitals, Sheffield, UK

### **P5-2 Full stream ahead: utilising streamlining to improve efficiency in the Urology Multi-Disciplinary Team Meeting (MDTM)**

Miss Rachel Oliver<sup>1,2</sup>, Dr Melika Moghim<sup>2,3</sup>, Mr Shrey Palmar<sup>3</sup>, Mr John Hines<sup>2,4</sup>

<sup>1</sup>North Middlesex University Hospital, London, UK, <sup>2</sup>North Central London Cancer Alliance, London, UK, <sup>3</sup>University College London, London, UK, <sup>4</sup>University College London Hospital, London, UK

### **P5-3 PIT (Patient Integrated Teams) Urology MDT - a novel integrated approach between Primary and Secondary care to aid the elective recovery programme.**

Dr Ross Cunningham<sup>1</sup>, Mr Shiv Pandian, Dr James Harrison, Dr Sanjay Patel

<sup>1</sup>Evergreen Primary Care Centre, Enfield, UK

### **P5-4 Improving access to neuro-urology for patients undergoing neurorehabilitation**

Mr Adeoye Oluwakanyinsola Debo-Aina<sup>1</sup>, Dr Lenyalo King<sup>1</sup>, Dr Alifa Isaacs-Itua<sup>1</sup>, Ms Claire Taylor<sup>1,2</sup>, Mr Nicholas Faure-Walker<sup>1,3</sup>

<sup>1</sup>Kings College Hospital NHS Foundation Trust, London, UK, <sup>2</sup>Guy's and St Thomas NHS Foundation Trust, London, UK, <sup>3</sup>School of Immunology and microbial Science, Faculty of Life Sciences & Medicine, King's College London, London, UK

### **P5-5 Improving shared decision making in elective urological surgery using a digital consent platform: a prospective study**

Mr Martin John Connor<sup>1,2</sup>, Dr Daniel Hazelton<sup>1</sup>, Dr Nina Dela Cruz<sup>1</sup>, Miss Sarah Brown<sup>1</sup>, Mr Allaudin Issa<sup>1</sup>, Mr Nikhil Mayor<sup>1,2</sup>, Mr Jerry Tangle<sup>1</sup>, Ms Lona Vyas<sup>1</sup>, Mr Bijan Khoubehi<sup>1</sup>, Mr Nishant Bedi<sup>1</sup>, Mr Hama Attar<sup>1</sup>, Mr Michael Dinneen<sup>1</sup>

<sup>1</sup>Department of Urology, Chelsea and Westminster NHS Foundation Trust, London, UK, <sup>2</sup>Division of Surgery, Department of Surgery and Cancer, Imperial College London, UK

**P5-6 The Use of Clinical Teaching Associates (CTAs) in Teaching Male Intimate Examination to Medical Students: A Randomised Controlled Trial**

Mr Anthony Vijayanathan<sup>1</sup>, Ms Deborah Bruce<sup>2</sup>, Mr Chu Yiu<sup>3</sup>, Dr Findlay MacAskill<sup>1</sup>, Mr Jonathan Makanjuola<sup>4</sup>, Mr Arun Sahai<sup>2</sup>

<sup>1</sup>King's College London, London, UK, <sup>2</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK, <sup>3</sup>Queen Elizabeth Hospital, London, UK, <sup>4</sup>King's College Hospital Foundation Trust, London, UK

**P5-7 Use of Audio Recordings in the Consultation of Patients Seeking Genital Gender-Affirming Surgery: An Opportunity for Broader Application Throughout Urology, and Development of a Novel Smartphone App**

Dr. Shannon Smith<sup>1</sup>, Dr Sandeep Sandhu<sup>1</sup>, Miss. Jenna Stelmar<sup>1</sup>, Miss. Grace Lee<sup>1</sup>, Dr. Maurice Garcia<sup>1</sup>

<sup>1</sup>Cedars-Sinai Medical Center, Los Angeles, United States

**P5-8 High Intensity Theatre Lists in Urology: Implementing 'pit-stop' principles to increase theatre efficiency**

Mr Ahmed Khattak<sup>1</sup>, Dr Marc Furrer<sup>1</sup>, Ms Nisha Pindoria<sup>1</sup>, Mr Ata Jaffer<sup>1</sup>, Dr Kariem El-Boghdadly<sup>1</sup>, Dr Imran Ahmad<sup>1</sup>, Mr Ben Challacombe<sup>1</sup>, Mr Rick Popert<sup>1</sup>, Mr Jonathan Noel<sup>1</sup>

<sup>1</sup>Guy's and St Thomas' NHS Trust, London, UK

**P5-9 How Good is Your Male LUTS Service Really? Retrospective Review of Case Selection from over 1000 Patients Attending for HoLEP Surgery in a Single Centre.**

Mr Mohamed Hassan, Mr Anish Pushkaran, Mr M Vizreanu, Mr Richaz Raheem, Mr Angus Campbell, Mr Barnaby Barrass, Mr Mohamed Asad Saleemi, Mr Farooq Khan

<sup>1</sup>Luton & Dunstable NHS Foundation Trust, Luton, UK

**P5-10 BAUS 10-point plan for widening participation: Are principles of Equality, Diversity and Inclusion (EDI) framework being addressed - Evidence from annual BAUS meeting programmes**

Miss Virginia Massella<sup>1</sup>, Miss Jo Cresswell<sup>2</sup>, Miss Susan Willis<sup>3</sup>, Miss Olayinka Gbolahan<sup>4</sup>, Miss Mriganka Sinha<sup>5</sup>, Miss Amelia Pietropaolo<sup>1</sup>, Mr Nitin Shrotri<sup>6</sup>, Mr Joe Phillip<sup>7</sup>, Professor Ian Pearce<sup>8</sup>, Professor Bhaskar Somani<sup>1</sup>

<sup>1</sup>Southampton General Hospital, Southampton, UK, <sup>2</sup>South Tees Hospital, Middlesborough, UK, <sup>3</sup>Guy's and St Thomas Foundation Trust, London, UK, <sup>4</sup>Royal Free Academy of PMC, London, UK, <sup>5</sup>Cheltenham General Hospital, Cheltenham, UK, <sup>6</sup>Chaucer Hospital, Canterbury, UK, <sup>7</sup>Southmead Hospital Bristol, Bristol, UK, <sup>8</sup>Manchester Royal Infirmary, Manchester, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Monday 19 June, 1630-1730, Hall 11A

## ePoster Session 6

# Inequalities in Urological Healthcare Provision and Training

Chairs: **Tim Lane**, Lister Hospital, Stevenage and **Yinka Gbolahan**, Royal Free Hospital, London

### **P6-1 Pregnancy outcomes in UK urologists in training**

Ms Jessica Whitburn<sup>1,2</sup>, Mr Saiful Miah<sup>2</sup>, Dr Sarah Howles<sup>1,3</sup>

<sup>1</sup>Nuffield Department of Surgical Sciences, Oxford, UK, <sup>2</sup>Wycombe Hospital, High Wycombe, UK, <sup>3</sup>Churchill Hospital, Oxford, UK

### **P6-2 The Man Van – Community Based Targeted Case Finding For Prostate Cancer**

Mr Masood Moghul<sup>1</sup>, Miss Fionnuala Croft<sup>1</sup>, Miss Kaljit Kaur<sup>1</sup>, Miss Netty Kinsella<sup>1</sup>, Mr Declan Cahill<sup>1</sup>, Professor Nick James<sup>1</sup>

<sup>1</sup>Royal Marsden Hospital, London, UK, on behalf of the Guy's Post Pelvic Surgery Research Group

### **P6-3 Black patients have worse continence outcomes at 12 months following robotic-assisted radical prostatectomy**

Mr Findlay MacAskill<sup>1</sup>, Mr Arun Sahai<sup>1</sup>, Mr Majed Shabbir<sup>1</sup>, Mr Paul Cathcart<sup>1</sup>, Mr Jonathan Noel<sup>1</sup> on behalf of the Guy's Post Pelvic Surgery Research Group

<sup>1</sup>GSTT, London, UK

### **P6-4 Identifying challenges and reforms for difficulties faced and support needed by International Medical Graduates (IMGs) when they first move to UK: A survey of 173 IMG doctors**

Miss Jenni Lane<sup>1</sup>, Mr Nitin Shrotri<sup>2</sup>, Dr Sunil Daga<sup>3</sup>, Professor Bhaskar Somani<sup>1</sup>

<sup>1</sup>University Hospital Southampton, Southampton, UK, <sup>2</sup>East Kent Hospitals University NHS Foundation Trust, Canterbury, UK, <sup>3</sup>Leeds Teaching Hospitals NHS Trust, Leeds, UK

### **P6-5 Ethnic composition of the national urology workforce and BAUS leadership 2009-2020: A retrospective analysis**

Mr Kelvin Adasonla<sup>1</sup>, Mr Thomas Newman<sup>2</sup>, Mr Ricky Ellis<sup>3</sup>, Mr Matthew Parry<sup>4</sup>, Mr Nitin Shrotri<sup>5</sup>, Miss Joanne Cresswell<sup>6</sup>, Prof James Green<sup>1</sup>

<sup>1</sup>Whipps Cross University Hospital, London, UK, <sup>2</sup>Kings College Hospital, London, UK, <sup>3</sup>University Hospitals of Derby and Burton, Derby, UK, <sup>4</sup>Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK, <sup>5</sup>Chaucer Hospital, Canterbury, UK, <sup>6</sup>James Cook University Hospital, Middlesbrough, UK

### **P6-6 Ethnic disparities in uptake of prostate cancer clinical trials compared to clinical practice**

Mr Nikhil Mayor<sup>1</sup>, Professor Suks Minhas, Mr Alistair Grey<sup>1</sup>, Dr Lucy Simmons<sup>1</sup>, Professor Mark Emberton<sup>1</sup>, Miss Emma Cullen<sup>1</sup>, Mr Taimur Shah<sup>1</sup>, Ms Mariana Bertonecchi-Tanaka<sup>1</sup>, Professor Hashim Ahmed

<sup>1</sup>Imperial College Healthcare NHS Trust, London, UK

**P6-7 Gender representation and prevalence of manels at international urological surgery conferences**

Dr Kristie Hing Chi Leung<sup>1</sup>, Miss Maria Georgi<sup>2</sup>, Dr Aqua Asif<sup>2</sup>, Dr Monty Fricker<sup>3</sup>, Dr Sonam Patel<sup>4</sup>, Mr Arslan Khaliq Raja<sup>5</sup>, Dr Alice Gargan<sup>6</sup>, Dr Kate Gargan<sup>3</sup>, Dr Katherine Lee<sup>7</sup>, Dr Oliver E Burton<sup>8</sup>, et al

<sup>1</sup>University Hospitals Sussex NHS Foundation Trust, Brighton, UK, <sup>2</sup>University College London, London, UK, <sup>3</sup>Imperial College Healthcare NHS Trust, London, UK, <sup>4</sup>University Hospital Southampton NHS Foundation Trust, Southampton, UK, <sup>5</sup>University of Edinburgh, Edinburgh, UK, <sup>6</sup>St George's University Hospitals NHS Foundation Trust, London, UK, <sup>7</sup>Royal Berkshire NHS Foundation Trust, Reading, UK, <sup>8</sup>Newcastle Hospitals NHS Foundation Trust, Newcastle, UK

**P6-8 Do Urology Conferences demonstrate Gender Diversity within their Scientific programme? Evaluation of the gender of Podium Presenters (speakers) at BAUS22 and EAU22**

Dr Hannah Jeffery<sup>1</sup>, Miss Susan Willis<sup>2</sup>, Miss Sophie Rintoul-Hoad<sup>3</sup>

<sup>1</sup>Lister Hospital, Stevenage, UK, <sup>2</sup>Guy's and St Thomas' Hospitals, UK, <sup>3</sup>Epsom and St Helier University Hospitals, London, UK

BAUS SECTION OF  
ONCOLOGY MEETING

BRIDGEWATER HALL  
MANCHESTER  
13-14 NOVEMBER 2023



# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Tuesday 20 June, 1130-1230, Hall 10

## ePoster Session 7

### History of Urology

Chairs: **Iain Wharton**, University Hospital of Coventry & Warwickshire and **Robyn Webber**, Victoria Hospital, Kirkcaldy

#### **P7-1 The history so far: metallic ureteric stents**

Mr Lahiru Siriwardena<sup>1</sup>, Mr Christopher Berridge<sup>1</sup>, Mr Aran Nanthakumar<sup>1</sup>, Mr Raghuram Devarajan<sup>1</sup>, Mr Ayman Girgis<sup>1</sup>, Mr Priyadarshi Kumar<sup>1</sup>

<sup>1</sup>University Hospital Coventry and Warwickshire, Coventry, UK

#### **P7-2 Peter the Great and Urology in the Eighteenth Century**

Mr Jonathon Dawson<sup>1</sup>, Mr George Greenlees<sup>2</sup>

<sup>1</sup>Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK, <sup>2</sup>Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK

#### **P7-3 Bending the Truth: The Cardiff Coudé Catheter Con of 1957**

Mr John Hayes<sup>1</sup>

<sup>1</sup>Department of Urology, The James Cook University Hospital, Middlesbrough, UK

#### **P7-4 Alfred Zinner and how a rare genetic abnormality was described**

Dr Shail Shah<sup>1</sup>, Ms Theodora Stasinou<sup>1</sup>, Mr Vaibhav Modgil<sup>1</sup>, Professor Ian Pearce<sup>1</sup>

<sup>1</sup>Manchester University NHS Foundation Trust, Manchester, UK

#### **P7-5 The Man Behind the Sign: Douglas Prehn and his Contribution to the 'Scrotal Pain Dilemma'**

Miss Beth Flemington<sup>2</sup>, Miss Theodora Stasinou<sup>1</sup>, Mr Vaibhav Modgil<sup>1</sup>, Professor Ian Pearce<sup>1</sup>

<sup>1</sup>Manchester University NHS Foundation Trust, Manchester, UK, <sup>2</sup>University of Manchester, Manchester, UK

#### **P7-6 Napoleon Bonaparte: The Emperor's Penis**

Mr Benjamin Wharton<sup>1</sup>, Mr Iain Wharton<sup>2</sup>

<sup>1</sup>Corpus Christi College, University of Oxford, Oxford, UK, <sup>2</sup>University Hospital of Coventry & Warwickshire, Coventry, UK

#### **P7-7 Withdrawn**

#### **P7-8 Vikings and Urology: Past and Present**

Dr Sara Ramsey<sup>1</sup>, Mr Gordon McFarlane<sup>2</sup>

<sup>1</sup>Raigmore Hospital, Inverness, UK, <sup>2</sup>Gilbert Bain Hospital, Lerwick, UK

#### **P7-9 The Urological Contribution of Hôtel-Dieu, Paris**

Mr Benjamin Wharton<sup>1</sup>, Mr Iain Wharton<sup>2</sup>

<sup>1</sup>Corpus Christi College, University of Oxford, Oxford, UK, <sup>2</sup>University Hospital of Coventry & Warwickshire, Coventry, UK

#### **P7-10 Alexander Marcet and The First Bedside Chemical Diagnostics Kit**

Dr Kirandeep Saini<sup>1</sup>, Mr. Nikhil Mayor, Mr Martin Connor, Mr Michael Dineen<sup>1</sup>, Mr Nishant Bedi<sup>1</sup>

<sup>1</sup>Chelsea & Westminster Hospital, London, UK



# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Tuesday 20 June, 1400-1500, Hall 8

## ePoster Session 8 Prostate Cancer

Chairs: **Taimur Shah**, Imperial Prostate, London and **Meghana Kulkarni**, St George's NHS Foundation Trust, London

### **P8-1 A new approach to survivorship care following radical prostatectomy**

Mr Findlay MacAskill<sup>1</sup>, Ms Sammy Gharbieh<sup>1</sup>, Ms Amy Sandher<sup>1</sup>, Mr Tet Yap<sup>1</sup>, Miss Claire Taylor<sup>1</sup>, Mr Majed Shabbir<sup>1</sup>, Mr Arun Sahai<sup>1</sup> on behalf of the Guy's Post Pelvic Surgery Research Group  
<sup>1</sup>GSTT, London, UK

### **P8-2 Can we avoid systematic biopsies and do only targeted biopsies when there is a discernible lesion in MRI scan prostate with PI-RADS scores 4 or 5? A single high volume centre retrospective data analysis**

Mr Anish Pushkaran<sup>1</sup>, Mr Ray Hsu<sup>1</sup>, Mr Mohamed Hassan<sup>1</sup>, Mr Kadhim Hassan<sup>1</sup>, Mr Rickaz Raheem<sup>1</sup>, Dr Ahsen Razzaq<sup>1</sup>, Mr Farooq Khan<sup>1</sup>, Mr Aza Mohammed<sup>1</sup>, Mr Sanjeev Taneja<sup>1</sup>, Mr Barnaby Barrass<sup>1</sup>

<sup>1</sup>Luton & Dunstable NHS Foundation Trust, Luton, UK

### **P8-3 Assessing the potential of artificial intelligence for prostate MRI in a diverse multi-centre diagnostic population**

Dr Aarti Shah<sup>1</sup>, Prof Richard Hindley<sup>1</sup>, Prof Nikhil Vasdev<sup>2</sup>, Dr Paul Burn<sup>3</sup>, Mr Mark Hinton<sup>4</sup>, Dr Antony Rix<sup>4</sup>, Dr Nadia Moreira Da Silva<sup>4</sup>, Prof Evis Sala<sup>5</sup>

<sup>1</sup>Hampshire Hospitals NHS Foundation Trust, Winchester, UK, <sup>2</sup>East and North Herts NHS Trust, Stevenage, UK, <sup>3</sup>Somerset NHS Foundation Trust, Taunton, UK, <sup>4</sup>Lucida Medical Ltd, Cambridge, UK, <sup>5</sup>Catholic University Sacro Cuore and Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

### **P8-4 PSA density predicts clinically significant prostate cancer in a screening population: outcomes from the IPI-PROSTAGRAM study**

Mr Nikhil Mayor<sup>1</sup>, Mr David Eldred-Evans<sup>1</sup>, Mr Martin Connor<sup>1</sup>, Dr Paula Burak<sup>2</sup>, Dr Emily Day<sup>2</sup>, Dr Martin Evans<sup>1</sup>, Dr Francesca Fiorentino<sup>2</sup>, Dr Martin Gammon<sup>1</sup>, Dr Feargus Hosking-Jervis<sup>1</sup>, Professor Hashim Ahmed<sup>1</sup>, et al<sup>1</sup>

<sup>1</sup>Imperial Prostate, London, UK, <sup>2</sup>Imperial Clinical Trials Unit, London, UK

### **P8-5 Prospective implementation and early outcomes of a risk stratified prostate cancer active surveillance follow-up protocol -STRATified CANcer Surveillance (STRATCANS)**

Sister Vineetha Thankappanair<sup>2</sup>, Ms Alexandra Keates<sup>2</sup>, Dr Tristan Barret<sup>1</sup>, Professor Vincent Gnanapragasam<sup>1</sup>

<sup>1</sup>University of Cambridge, Cambridge, UK, <sup>2</sup>Cambridge University Hospitals NHS Trust, Cambridge, UK

### **P8-6 The impact of initiating ADT on PSMA PET/CT imaging**

Mr Mostafa Ragab<sup>1</sup>, Dr Michael Kay<sup>1</sup>, Mr Amit Mevcha<sup>1</sup>, Mr Joshua Phillips<sup>1</sup>, Mr Andrew Wedderburn<sup>1</sup>, Mr Kevin Turne<sup>1</sup>

<sup>1</sup>University Hospital Dorset, Bournemouth, UK

**P8-7 Self-removal of Catheter after Robot Assisted Radical Prostatectomy – Saving the Planet One Catheter at a Time**

Mr Wissam Abou Chedid<sup>1</sup>, Maria Innes<sup>1</sup>, Helen Casson<sup>1</sup>, Mr Dimitrios Moschonas<sup>1</sup>, Mr Matthew James Alexander Perry<sup>1</sup>, Mr Wissam Abou Chedid<sup>1</sup>

<sup>1</sup>Royal Surrey County Hospital, Guildford, UK

**P8-8 FRAX fracture risk and clinical fracture incidence in men with metastatic hormone sensitive prostate cancer (mHSPC): a HES-linked study in STAMPEDE trial patients**

Mr Craig Jones<sup>1</sup>, Laura Murphy, Macey L Murray, Louise C Brown, Janet Brown, Eugene McCloskey, Matthew R Sydes, Nicholas D James, Noel W Clarke, Ashwin Sachdeva

<sup>1</sup>Christie and Salford Royal NHS Hospitals, Manchester, UK

**P8-9 Identifying Prognostic Factors for Poorer Mental Wellbeing Outcomes in Prostate Cancer within the Prospective MIND-P Cohort Study: An Interim Analysis**

Mr Oliver Brunckhorst<sup>1</sup>, Mr Jaroslaw Liszka<sup>1</sup>, Dr Callum James<sup>1</sup>, Dr Jack Fanshawe<sup>2</sup>, Prof Robert Thomas<sup>3</sup>, Mr Shahid Khan<sup>4</sup>, Prof Matin Sheriff<sup>5</sup>, Prof Hashim Ahmed<sup>6</sup>, Prof Prokar Dasgupta<sup>1</sup>, Mr Kamran Ahmed<sup>1</sup>, et al,

<sup>1</sup>King's College London, London, UK, <sup>2</sup>Queen Elizabeth Hospital, London, UK, <sup>3</sup>Bedfordshire Hospitals NHS Foundation Trust, Bedford, UK, <sup>4</sup>East Surrey Hospital, Redhill, UK, <sup>5</sup>Medway NHS Foundation Trust, Gillingham, UK, <sup>6</sup>Imperial College London, London, UK

**P8-10 Targeted Prostate Health Checks, a novel system to identify those prostate cancer patients who failed to present during the pandemic.**

Professor Stephen Langley<sup>1</sup>, Dr Jeremy Goad<sup>3</sup>, Sister Michele Pietrasik<sup>1</sup>, Dr Alex Norman<sup>2</sup>, Dr Catherine Hodges<sup>2</sup>, Mr Lee Foster<sup>2</sup>, Mrs Stephanie Bell<sup>2</sup>, Ms Lara Brooks<sup>3</sup>, Dr Edward Bosonnet<sup>3</sup>, Dr Matthew Knight<sup>3</sup>

<sup>1</sup>Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK, <sup>2</sup>Surrey and Sussex Cancer Alliance, Guildford, UK, <sup>3</sup>Medefer Ltd, London, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Tuesday 20 June, 1400-1500, Hall 9

## ePoster Session 9

### **Stones / Imaging / Upper Tract Disorders 2**

Chairs: **Hrishikesh Joshi**, University Hospital Cardiff and **Danielle Whiting**, Royal Surrey Hospital

#### **P9-1 Moses laser lithotripsy vs Thulium fibre laser for flexible ureteroscopy(f-URS) for renal stones: Is there a clear winner? Outcomes from the FLEXOR study**

Miss Mriganka Mani Sinha<sup>1</sup>, Dr Vineet Gauhar<sup>2</sup>, Prof Bhaskar K Somani<sup>3</sup>, Group Tower Group<sup>2</sup>

<sup>1</sup>Cheltenham General Hospital, Cheltenham, UK, <sup>2</sup>Department of Urology, Ng Teng Fong General Hospital, Singapore, <sup>3</sup>University Hospital Southampton, Southampton, UK

#### **P9-2 Pediatric retrograde intra renal surgery (RIRS) with Thulium fibre laser (TFL) or High power Holmium laser: Which one to choose from - An experience in 126 cases**

Miss Mriganka Mani Sinha<sup>1</sup>, Dr EG Rojo<sup>1</sup>, Dr Vineet Gauhar<sup>2</sup>, Dr Oliver Traxer<sup>3</sup>, Dr L Ea Jean<sup>1</sup>, Dr Deepak Ragoori<sup>4</sup>, Dr Daniel Castellani<sup>5</sup>, Prof Bhaskar K Somani<sup>6</sup>

<sup>1</sup>Cheltenham General Hospital, Cheltenham, UK, <sup>2</sup>Ng Teng Fong General Hospital ( NTFGH), Singapore, <sup>3</sup>Department of Urology AP-HP, Sorbonne University, Tenon Hospital, Paris, France, <sup>4</sup>Asian Institute Of Nephrology & Urology, Hyderabad, India, <sup>5</sup>Urology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Università Politcnica delle Marche, Ancona, Italy, <sup>6</sup>University Hospital Southampton, Southampton, UK

#### **P9-3 Functional outcomes from stent or nephrostomy insertion in the Scottish Malignant Ureteric Obstruction Study**

Mr James Blackmur<sup>1</sup>, Dr Oliver Llewellyn<sup>2</sup>, Miss Rachel McLennan<sup>3</sup>, Miss Lynne Kerr<sup>4</sup>, Mr Ben Thomas<sup>5</sup>, Dr Neil Young<sup>6</sup>, Professor Paramananthan Mariappan<sup>5</sup>, Professor Alan McNeill<sup>5</sup>, Mr Seamus Teahan<sup>3</sup>, Mr Alexander Laird<sup>1</sup>, et al.

<sup>1</sup>Department of Urology, University Of Edinburgh/NHS Lothian, Edinburgh, UK, <sup>2</sup>Radiology Department, NHS Lothian, Edinburgh, UK, <sup>3</sup>Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, UK, <sup>4</sup>Department of Urology, NHS Ayrshire and Arran, Ayr, UK, <sup>5</sup>Department of Urology, NHS Lothian, Edinburgh, UK, <sup>6</sup>Department of Radiology, NHS Tayside, Dundee, UK

#### **P9-4 Renal aspirate culture during ureterorenoscopy - Is it worth it?**

Miss Naomi Drye<sup>1</sup>, Mr Samuel Shillito<sup>2</sup>, Mr Agapios Gkentzis ChM FRCS (Urol)<sup>3</sup>

<sup>1</sup>York Hospital, York, UK, <sup>2</sup>Stepping Hill, Stockport, UK, <sup>3</sup>Royal Bolton Hospital, Bolton, UK

#### **P9-5 Comparison of stent-related symptoms between conventional double-J stents and two novel metallic stents: a validated-questionnaire-based study.**

Ms Anastasia Kantartzis<sup>1,2</sup>, Mr Christopher Khoo<sup>2</sup>, Mr Hamid Abboudi<sup>2</sup>, Mr Tamer El-Husseiny<sup>2</sup>

<sup>1</sup>Lewisham And Greenwich Nhs Trust, London, UK, <sup>2</sup>Imperial College Healthcare NHS Trust, London, UK

#### **P9-6 Ureteroscopy in Patients with Urinary Diversion: Outcomes and Lessons Learned from two European Tertiary Referral Centres**

Mr Vaki Antoniou<sup>1</sup>, Mr Patrick Juliebø-Jones, Mr Christian Arvei Moen, Mr Peder Gjengstø, Mr Mathias Sørstrand Æsøy, Mr Christian Beisland, Mr Øyvind Ulvik, Professor Bhaskar Somani

<sup>1</sup>University Hospital Southampton, Southampton, UK

**P9-7 A multicenter propensity score matched pair study in 313 patients comparing percutaneous nephrolithotomy versus retrograde intra renal surgery for management of urolithiasis in calyceal diverticulum**

Miss Mriganka Mani Sinha<sup>1</sup>, Prof Bhaskar Kumar Somani<sup>2</sup>, Dr Daniele Castellani<sup>3</sup>, Dr Deepak Ragoori<sup>4</sup>, Dr Abhay Mahajan<sup>5</sup>, Dr Pankaj Nandkishore Maheshwari<sup>6</sup>, Dr Nariman Gadzhiev<sup>7</sup>, Dr Yiloren Tanidir<sup>8</sup>, Dr Bin Hamri Saeed<sup>9</sup>, Dr Olivier Traxer<sup>10</sup>, Dr Vineet Gauhar<sup>11</sup>

<sup>1</sup>Cheltenham General Hospital, Cheltenham, UK, <sup>2</sup>University Hospital Southampton, Southampton, UK, <sup>3</sup>Azienda ospedaliero-universitaria Ospedali riuniti di Ancona, Università Politecnica delle Marche, Ancona, Italy, <sup>4</sup>Asian Institute Of Nephrology & Urology, Hyderabad, India, <sup>5</sup>Mahatma Gandhi Medical College and Hospital, Aurangabad, India, <sup>6</sup>Fortis hospital Mulund, Mumbai, India, <sup>7</sup>Endourology department, Saint-Petersburg State Medical University, Russia, <sup>8</sup> Department of Urology, Marmara University, School of Medicine, Istanbul, Turkey, <sup>9</sup>Advanced Laser Endourology at king Abdulaziz National Guard Medical City, Saudi Arabia, <sup>10</sup>Department of Urology AP-HP, Sorbonne University, Tenon Hospital, Paris, France, <sup>11</sup>Ng Teng Fong General Hospital ( NTFGH), Singapore

**P9-8 Is Primary Treatment of the Stone Safe in the Presence of Urosepsis?**

Dr Andrew Mcintyre-robinson<sup>1</sup>, Dr Geena Loke<sup>1</sup>, Dr Carmella Catlow, Mr Jonathan Masters<sup>1</sup>

<sup>1</sup>Whangarei Hospital, Whangarei, New Zealand

**P9-9 Covid Killed Kidneys: a comparison of the management of benign non-functioning kidneys before and during the COVID era.**

Dr Chirag Rao<sup>1</sup>, Mr Zhi-Yang Low<sup>2</sup>, Ms Siobhan Price<sup>2</sup>, Ms Dani Velinova<sup>2</sup>, Mr Vimoshan Arumuham<sup>2</sup>, Ms Sian Allen<sup>2</sup>, Mr R. Daron Smith<sup>2</sup>

<sup>1</sup>Epsom And St Helier University Hospitals NHS Trust, London, UK, <sup>2</sup>Institute of Urology, University College London Hospitals NHS Foundation Trust, London, UK

**P9-10 Endoscopic Management of Upper Tract Urothelial Carcinoma at a Tertiary Centre Over An 11-Year Period-A Retrospective Single Cohort Analysis**

Mr Paul Gravestock<sup>1</sup>, Mr Bhavan Prasad Rai<sup>1</sup>, Mr Alistair Rogers<sup>1</sup>, Mr Matthew Shaw<sup>1</sup>, Mr David Rix<sup>1</sup>, Mr Rajan Veeratterapillay<sup>1</sup>

<sup>1</sup>Freeman Hospital, Newcastle Upon Tyne, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Tuesday 14 June, 1400-1500, Hall 10

## ePoster Session 10

### General Urology 1

Chairs: **Su-Min Lee**, Southmead Hospital, Bristol and **Anna Wright**, Bradford Royal Infirmary

#### **P10-1 Aquablation Therapy® vs Transurethral Resection of the Prostate: 5-year Outcomes of the WATER Randomized Clinical Trial for Medium-sized Prostates**

Mr Richard Hindley<sup>1</sup>, Dr Kussil Oumedjbeur, Dr Ahmed Ibrahim, Dr Imad Matta, Dr David-Dan Nguyen, Dr Adel Areski, Dr Iman Sadri, Dr David Bouhadana, Dr Tawfik Elsherbini, Prof Peter Gilling, Mr Neil Barber, Dr Mihir Desai, Dr Alexis E Te, Dr Claus G Roehrborn, Dr Kevin C Zorn  
<sup>1</sup>Hampshire Hospitals FT, Basingstoke, UK, <sup>2</sup>University of Winchester, Winchester, UK

#### **P10-2 Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150mL): FINAL 5-year Results**

Mr Neil Barber<sup>1</sup>, Dr Naeem Bhojani, Dr Mitch Humphreys  
<sup>1</sup>Frimley Health, Camberley, UK

#### **P10-3 Undertreatment affects Prostatic Urethral Lift (PUL) durability in pooled analysis of 330+ subjects**

Dr Neil Barber<sup>1</sup>, Dr Claus Roehrborn, Dr Steven Gange, Dr Mark Rochester, Dr Peter Chin  
<sup>1</sup>Frimley Park Hospital, Camberley, UK

#### **P10-4 Prostatic Urethral Lift (PUL) provides consistent patient experience outcomes for men with lateral and median lobe obstruction**

Dr Neil Barber<sup>1</sup>, Dr Gregg Eure, Dr Karl-Dietrich Sievert, Dr Christian Gratzke, Dr Daniel Rukstalis  
<sup>1</sup>Frimley Park Hospital, Camberley, UK

#### **P10-5 Success Predictors and Long-term Durability in Acute Urinary Retention (AUR) Patients Treated with the Prostatic Urethral Lift (PUL)**

Dr Mark Rochester<sup>1</sup>, Dr. Oliver Kayes, Dr. Neil Barber, Dr. Rajesh Kavia, Dr. Toby Page, Dr. Nikesh Thiruchelvam, Dr. Gregg Eure  
<sup>1</sup>Norfolk And Norwich University Hospital, Colney, UK

#### **P10-6 Efficacy of modified mini bladder neck incision with prostatic urethral lift in men with LUTS secondary to high tight bladder neck and BPE: Single Urology Institution's Experience**

Dr Rami Abuseedou<sup>1</sup>, Mr Keng NG, Mr Neil Barber  
<sup>1</sup>Frimley Park Hospital, Surrey, UK, <sup>2</sup>Frimley Health, Surrey, UK

#### **P10-7 Is Power Everything in HoLEP Surgery? Efficiency of a Low-Power Holmium Laser at Enucleating Large Prostates**

Mr Mohamed Hassan<sup>1</sup>, Mr Anish Pushkaran<sup>1</sup>, Mr Rickaz Raheem<sup>1</sup>, Mr Angus Campbell<sup>1</sup>, Mr Mohammed Saleemi<sup>1</sup>, Mr Barnaby Barrass<sup>1</sup>, Mr Ian Nunney<sup>2</sup>, Mr Farooq Khan<sup>1</sup>  
<sup>1</sup>Luton & Dunstable NHS Foundation Trust, Luton, UK, <sup>2</sup>Norwich Medical School, Norwich, UK

#### **P10-8 Defining the Learning Curve in HoLEP Surgery from a Contemporary Series of**

## 1000 Cases

Mr Anish Pushkaran<sup>1</sup>, Mr Mohammed Hassan<sup>1</sup>, Mr Richaz Raheem<sup>1</sup>, Mr Angus Campbell<sup>1</sup>, Mr Mohamed Asad Saleemi<sup>1</sup>, Mr Barnaby J R Barrass<sup>1</sup>, Mr Ian Nunney<sup>2</sup>, Mr Farooq Khan<sup>1</sup>

<sup>1</sup>Luton & Dunstable NHS Foundation Trust, Luton, UK, <sup>2</sup>Norwich Medical School, Norwich, UK

### **P10-9 Transperineal Laser Ablation (TPLA) of the prostate. The first UK patients treated.**

Mr Chris Ogden, MR Abul Kashim Mohammed Anisul Haque, Ms Deepa Leelamany

<sup>1</sup>UCL and Princess Grace Hospitals, London, UK

### **P10-10 Rezum thermotherapy for large prostate volumes (>/= 80 cc): 2-year clinical outcomes**

Dr Abdulla Uthman<sup>1</sup>, Dr Martin J Connor<sup>2</sup>, Dr Charlie Khoo<sup>2</sup>, Dr Amar Rai<sup>2</sup>, Dr Edward J Bass<sup>2</sup>, Dr Sanjiv Agarwal<sup>2</sup>, Dr Ranan Dasgupta<sup>2</sup>, Dr Mathias Winkler<sup>2</sup>, Dr Hamid Abboudi<sup>2</sup>, Dr Tamer El-Husseiny<sup>2</sup>, Professor Hashim U Ahmed<sup>2</sup>

<sup>1</sup>Cwm Taf Morgannwg University Health Board, Cardiff, UK, <sup>2</sup>Imperial College Health Care NHS Trust, London, UK

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Tuesday 20 June, 1630-1730, Hall 10

## ePoster Session 11

### General Urology 2

Chairs: **Kiki Mistry**, Frimley Park Hospital, Surrey and **Kenneth Hiew**, Belfast City Hospital

**P11-1 Clinical audit of pre-biopsy multi-parametric MRI (mpMRI) for patients with suspicion of prostate cancer (PCa): Correlation of PIRADS score with clinically significant prostate cancer (csPCa) stratified by PSA density (PSAD) ubsequent diagnosis of clinically significant prostate cancer**

Dr Haripriya Eadala<sup>1</sup>, Dr Mohammed Hassan<sup>1</sup>, Mr Kevin Wardlaw<sup>1</sup>, Dr Hae in Ra<sup>1</sup>, Dr Anjali Nandakumar<sup>1</sup>, Dr Senthil Ragupathy<sup>1</sup>, Mr David Douglas<sup>1</sup>, Ms Justine Royle<sup>1</sup>, Mr Thomas Lam<sup>1</sup>  
<sup>1</sup>NHS Grampian, UK

**P11-2 Ultrasound for the diagnosis of testicular torsion: a systematic review and meta-analysis of diagnostic accuracy**

Mr Cameron Alexander<sup>1,11</sup>, Mr Alexander Light<sup>2,11</sup>, Dr Vinson Chan<sup>3,11</sup>, Dr Aqua Asif<sup>4,11</sup>, Mr Keiran Clement<sup>5,11</sup>, Dr Yuhong Yuan<sup>6</sup>, Professor Yemisi Takwoingi<sup>7</sup>, Mr Sinan Khadouri<sup>8,11</sup>, Ms Hannah Warren<sup>9,11</sup>, Ms Eleanor Zimmermann<sup>10,11</sup>, et al,

<sup>1</sup>Colchester General Hospital, Colchester, UK, <sup>2</sup>Imperial College, London, London, UK, <sup>3</sup>University of Leeds, Leeds, UK, <sup>4</sup>University College London, London, UK, <sup>5</sup>NHS Greater Glasgow and Clyde, Greater Glasgow, UK, <sup>6</sup>McMaster University, Canada, <sup>7</sup>University of Birmingham, Birmingham, UK, <sup>8</sup>NHS Fife, Fife, UK, <sup>9</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK, <sup>10</sup>Torbay and Southern Devon Health and Care NHS Trust, UK, <sup>11</sup>British Urology Researchers in Surgical Training, BURST, UK

**P11-3 Complications in patients with Xanthogranulomatous Pyelonephritis(XGP) undergoing nephrectomy, a global multicentre analysis of 400 patients**

Dr Vineet Gauhar<sup>2</sup>, Miss Mriganka Mani Sinha<sup>1</sup>, DR Daniele Castellani<sup>3</sup>, Dr Deepak Ragoori<sup>4</sup>, Dr Santosh Kumar<sup>5</sup>, Dr Abhay Mahajan<sup>6</sup>, Dr Pankaj Nandkishore Maheshwari<sup>7</sup>, Dr Arvind P Ganpule<sup>8</sup>, Dr José Iván Robles Torres<sup>9</sup>, Prof Bhaskar K Somani<sup>10</sup>

<sup>1</sup>Cheltenham General Hospital, Cheltenham, UK, <sup>2</sup>Department of Urology, Ng Teng Fong General Hospital, Singapore, Singapore, <sup>3</sup> Azienda ospedaliero-universitaria Ospedali riuniti di Ancona, Università Politecnica delle Marche, Ancona, Italy, <sup>4</sup> Asian Institute Of Nephrology & Urology, behind More Mega mart, Irram Manzil Colony, Hyderabad, India, <sup>5</sup>Christian medical college, Vellore, India, <sup>6</sup>Mahatma Gandhi Medical College and Hospital, Aurangabad, India, <sup>7</sup>Fortis Hospital Mulund, Mumbai, India, <sup>8</sup>Muljibhai Patel Urological Hospital Nadiad, Nadiad, India, <sup>9</sup>Hospital Universitario "Dr. José Eleuterio González", Mexico, <sup>10</sup>University Hospital Southampton, Southampton, UK

**P11-4 Catheter-Related Bladder Discomfort Questionnaire: Development and validation of a novel comprehensive questionnaire to evaluate the symptoms in urethral catheterisation**

Dr Mohamed Javid Raja Iyub<sup>1</sup>, Dr Srikala Prasad T<sup>1</sup>, Dr S Sudhakaran<sup>1</sup>, Dr Senthil Kumar<sup>1</sup>, Dr G Ramesh<sup>1</sup>, Dr Ananda Kumar<sup>1</sup>, Dr Prabhu Elumalai<sup>1</sup>

<sup>1</sup>Chengalpattu Medical College, Chengalpattu, India

**P11-5 Does Uromune® reduce UTI related hospital admissions for patients with recurrent UTI?**

Mr Xiang Wei Jonathan Lee<sup>1</sup>, Ms Jennifer Jones<sup>1</sup>, Ms Holly Bekarma<sup>1</sup>

<sup>1</sup>University Hospital Ayr, Ayr, UK

**P11-6 Treatment outcomes for the patients with recurrent urinary tract infections using a multidisciplinary approach in a complex UTI clinic - A 20 month's experience**

Mr Ekpeno Inyang<sup>1</sup>, Ms Jayne Morris-Laverick<sup>1</sup>, Ms Stephenie Benzemer<sup>1</sup>, Dr Victoria McCune<sup>1</sup>, Dr Igor Kulbeka<sup>1</sup>, Ms Mehwash Nadeem<sup>1</sup>

<sup>1</sup>South Tees Hospitals Nhs Foundation Trust, Middlesbrough, UK

**P11-7 Are Intravesical Aminoglycosides the New Gold Standard in the Management of Refractory Urinary Tract Infection: A Systematic Review of Literature**

Dr Andrea Ong<sup>1</sup>, Miss Amelia Pietropaolo, Mr George Brown, Professor Bhaskar K. Somani

<sup>1</sup>Portsmouth Hospitals University NHS Trust, Portsmouth, UK

**P11-8 Trends in day-case surgery and technology adoption for bladder outflow obstruction in England - analysis of 118,966 cases using Hospital Episode Statistics**

Mr Joseph John<sup>1,2</sup>, Mr Kieran O'Flynn<sup>2,3</sup>, Professor Sir Tim W. R. Briggs<sup>2,4</sup>, Mr John S. McGrath<sup>1,2</sup>, Mr William K. Gray<sup>2</sup>

<sup>1</sup>Royal Devon and Exeter Hospital, Exeter, UK, <sup>2</sup>Getting It Right First Time (GIRFT), London, UK, <sup>3</sup>Salford Royal NHS Foundation Trust, Salford, UK, <sup>4</sup>Royal National Orthopaedic Hospital, Stanmore, London, UK

**P11-9 Nurse-Led Post-operative Male LUTS Clinics - a potential new paradigm or not?**

Mr Matthew Schembri<sup>1</sup>, Dr George Gibbs<sup>1</sup>, Mr Sanjiv Agarwal<sup>1</sup>, Mr Tamer El-Husseiny<sup>1</sup>, Mr Ranan Dasgupta<sup>1</sup>, Prof Hashim Ahmed<sup>1</sup>, Mr Hamid Abboudi<sup>1</sup>

<sup>1</sup>Imperial College Healthcare NHS Trust, London, UK

**P11-10 The aetiology and presenting symptoms of men with prostatic reflux**

Mr Ross Stephens<sup>1</sup>, Mr Sachin Malde, Miss Claire Taylor, Mr Arun Sahai, Dr Eskinder Solomon

<sup>1</sup>Guy's And St Thomas' NHS Foundation Trust, London, UK





# There are two sides of every story

An alternative first-line treatment option for durable BPH symptom relief

## YOUR EXPERTISE



## HIS CHOICE

**Rezūm™**  
Water Vapour Therapy



Clinical study results demonstrate Rezūm™ Water Vapour Therapy is a safe and effective BPH treatment that significantly relieves symptoms and preserves sexual function out to 5 years.<sup>1</sup>

<sup>1</sup>McVary KT, Roehrborn C. Five year results of the prospective, randomized controlled trial of water vapor thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Late-Breaking Abstract. J Urol. 2020 Apr;203(4):e1021.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Information not intended for use and distribution in France. All trademarks are the property of their respective owners.



# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

ANNUAL  
MEETING  
19-21 June



Wednesday 21 June, 1130-1300, Hall 10

## ePoster Session 12

### TUF-BAUS Best of the Regions

Chairs: **Mark Lynch**, Croydon University Hospital, Surrey, **Imran Ahmad**, Queen Elizabeth University Hospital, Glasgow and **Caroline Moore**, University College Hospital, London

#### **P12-1 Is the need to treat acute ureteric stones within 48 hours necessary for Shockwave Lithotripsy?**

Mr Jacob Wilson<sup>1</sup>, Mr Sam Compton<sup>2</sup>, Miss Abigail Irish<sup>2</sup>, Miss Jodie Prynn<sup>2</sup>, Miss Glynis Sanderson<sup>2</sup>, Mr Jonathan Manley<sup>2</sup>, Mr James Dunn<sup>2</sup>, Mr Andrew Dickinson<sup>2</sup>

<sup>1</sup>Cheltenham General Hospital, Cheltenham, UK, <sup>2</sup>Plymouth Hospitals NHS Foundation Trust, Plymouth, UK

#### **P12-2 The impact of initiating Androgen Deprivation Therapy on PSMA PET/CT imaging**

Mr Mostafa Ragab<sup>1</sup>, Dr Michael Kay<sup>1</sup>, Mr Joshua Phillips<sup>1</sup>, Mr Amit Mevcha<sup>1</sup>, Mr Andrew Wedderburn<sup>1</sup>, Mr Kevin Turner<sup>1</sup>

<sup>1</sup>University Hospital Dorset NHS Foundation Trust, Bournemouth, UK

#### **P12-3 An acute scrotal pain pathway incorporating the TWIST score and ultrasound has decreased the time to scrotal exploration and the negative exploration rate, without any missed testicular torsion**

Mr Samuel Folkard<sup>1</sup>, Mr Chim Chipeta<sup>1</sup>, Mr Ed Hart<sup>1</sup>, Dr Sarah Lim<sup>1</sup>, Dr Chigoziem Ogbolu<sup>1</sup>, Dr Amaury Trockels<sup>1</sup>, Dr Erica Mulholland<sup>1</sup>, Dr Samaher Al Binali<sup>1</sup>, Dr Sharon Darkwa<sup>1</sup>, Mr Max Kemp<sup>2</sup>, Mr Ian Rudd<sup>1</sup>, Mr Ali Henderson<sup>1</sup>

<sup>1</sup>Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK, <sup>2</sup>Kent and Medway Medical School, Canterbury, UK

#### **P12-4 The design and validation of a low-cost trans perineal (TP) prostate biopsy simulator for training: improving trainees' confidence and cognitive targeting skills**

Miss Kelly Ong<sup>1</sup>, Mr David Dryhurst<sup>1</sup>, Mr Philip Bald, Mr Rahul Lunawat<sup>1</sup>, Mr Saif Ahmed<sup>2</sup>, Miss Gauri Thapa<sup>2</sup>, Miss Alice Tirnoveanu<sup>2</sup>, Mr Richard Webb<sup>2</sup>, Mr Eqram Rahman<sup>2</sup>, Professor Sri Sriprasad<sup>2</sup>

<sup>1</sup>Princess Royal University Hospital, Bromley, UK, <sup>2</sup>Canterbury Christ Church University

#### **P12-5 Management of small testicular masses: outcomes from a single-centre specialist multidisciplinary team**

Mr Jamie Lindsay, Mr Shafi Wardak<sup>2</sup>, Mr Karl H. Pang<sup>3</sup>, Mr Fabio Castiglione<sup>3</sup>, Dr Miles Walkden<sup>5</sup>, Dr Dan Heffernan Ho<sup>5</sup>, Dr Alex Kirkham<sup>5</sup>, Mr Paul Hadway<sup>2</sup>, Mr Raj Nigam<sup>3</sup>, Mr Rowland Rees<sup>3</sup>, Dr Constantine Alifrangis<sup>8</sup>, Mr Hussain M. Alnajjar<sup>3</sup>, Mr Asif Muneer<sup>9</sup>

<sup>1</sup>Whipps Cross University Hospital, Barts Health NHS Foundation Trust, London, UK, <sup>2</sup>Department of Urology, Royal Berkshire NHS Foundation Trust, Reading and Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>3</sup>Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>4</sup>Department of Urology, King's College Hospital NHS Foundation Trust and Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>5</sup>Department of Radiology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>6</sup>Department of Urology, Royal Surrey NHS Foundation Trust, Guildford and Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>7</sup>Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton and Male Genital Cancer Centre, Institute of Andrology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>8</sup>Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>9</sup>Male Genital Cancer Centre, Institute of Andrology, University

College London Hospitals NHS Foundation Trust, London, UK and NIHR Biomedical Research Centre, University College London, London, UK and Division of Surgery and Interventional Science, University College London, London, UK

**P12-6 One-stop prostate clinic (OSPC) in a DGH: Does it deliver?**

Mr Mohamed Mustafa<sup>1</sup>, Dr Marc Lyons<sup>1</sup>, Mr Peter Senada<sup>1</sup>, Mr Lokesh Suraparaju<sup>1</sup>, Mr David MAnson-Bahr<sup>1</sup>, Dr Vinod Shenoy<sup>1</sup>

<sup>1</sup>James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK

**P12-7 Is remote follow up using a Patient Reported Outcome Measure (PROM) feasible in urolithiasis? A prospective feasibility study using Urinary stones & Intervention Quality of Life (USIQoL) measure**

Miss Ruth Jarvis<sup>1</sup>, Mr Phillip Pallmann, Mr Hrishikesh Joshi

<sup>1</sup>University Hospital Of Wales, Cardiff, UK

**P12-8 Shockwave Lithotripsy (SWL) During the COVID-19 Global Pandemic in the Stented and Anticoagulated Patient Cohort**

Dr Katherine Chin<sup>1</sup>, Mr Arjuna Brodie<sup>1</sup>, Mr Mohamed Elajnaf<sup>1</sup>, Mr Jerry Raju<sup>1</sup>, Professor Masood A. Khan<sup>1</sup>

<sup>1</sup>Urology Department, Leicester General Hospital, Leicester, UK

**P12-9 Ketamine Urology: Clinical Experience in a High Prevalence Centre**

Mr George Sturgess<sup>1</sup>, Mr Ian Beckley<sup>1</sup>, Mr Robin Shepherd<sup>1</sup>, Ms Alison Downey<sup>1</sup>

<sup>1</sup>Pinderfields Hospital, Mid Yorkshire Hospitals NHS Foundation Trust, Wakefield, UK

**P12-10 Setting up a regional local anaesthetic ureteric stent change service; suitability, safety and satisfaction.**

Mr Sidney Parker<sup>1</sup>, Mr Kamran Haq<sup>2</sup>, Dr Ricardo Fernandes<sup>1</sup>, Mr Jonathan Broughton<sup>3</sup>, Miss Lauren Moore<sup>2</sup>, Dr Clare White<sup>2</sup>, Dr Natalie Bowes<sup>2</sup>, Mr Ashok Sakthivel<sup>3</sup>, Mr John Fitzpatrick<sup>2</sup>, Mr Alistair Rogers<sup>2</sup>, Mr Kanagasabai Sahadevan<sup>1</sup>

<sup>1</sup>Sunderland Royal Hospital, Sunderland, UK, <sup>2</sup>Freeman Hospital, Newcastle, UK, <sup>3</sup>James Cook University Hospital, Middlesbrough, UK

**P12-11 Is Active Surveillance a Safe Option when Prostate Biopsies have Reported Low-Grade Disease?**

Dr Ruairidh Taggart<sup>1</sup>, Mr Imran Ahmad<sup>2</sup>

<sup>1</sup>Glasgow Royal Infirmary, Glasgow, UK, <sup>2</sup>Queen Elizabeth University Hospital, Glasgow, UK

**P12-12 Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?**

Mr Matthew Trail<sup>1</sup>, Mr Muhammad Sajid Waheed Rahman<sup>2</sup>, Mr William J Broadhurst<sup>2</sup>, Mr James P Blackmur<sup>1,3</sup>, Mr Abhishek Sharma<sup>1</sup>, Mr Etienne Chew<sup>2</sup>, Dr Marie O'Donnell<sup>4</sup>, Dr Julian Y Keanie<sup>5</sup>, Dr John Brush<sup>5</sup>, Dr John Taylor<sup>5</sup>, Mr Simon Phipps<sup>1</sup>, Mr Ben Thomas<sup>1</sup>, Mr Edward AA Mains<sup>1</sup>, Professor S Alan McNeill<sup>1,2</sup>, Mr Steve Leung<sup>1</sup>, Mr Mark L Cutress<sup>1</sup>, Mr Alexander Laird<sup>1,3</sup>

<sup>1</sup>Department of Urology, Western General Hospital, Edinburgh, UK, <sup>2</sup>College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK, <sup>3</sup>Centre for Genomic & Experimental Medicine, Institute Genetics and Cancer, The University of Edinburgh, Edinburgh, UK, <sup>4</sup>Department of Histopathology, Western General Hospital, Edinburgh, UK, <sup>5</sup>Department of Radiology, Western General Hospital, Edinburgh, UK

**P12-13 MRCS part B Preparation Courses: Improving access in Northern Ireland**

Ms Susan Cull<sup>1</sup>, Miss Rosemary O'Donoghue<sup>2</sup>

<sup>1</sup>Craigavon Area Hospital, Portadown, UK, <sup>2</sup>Royal Victoria Hospital, Belfast, UK

**P12-14 A Prospective Multicentre Audit Evaluating the Incidence of Iatrogenic Urethral Catheterisation Injuries**

Ms Leah Hayes<sup>1</sup>, Ms Stefanie Croghan, Ms Aisling Nic an Riogh, Ms Aideen Madden, Mr Shane Considine, Mr Mark Rochester, W Finch, A Carrie, W Mahhmalji, W Elhadi, H Thursby, I Pearce, V Modgil, H Noweir, C Cunnane, Subhasis Giri, Mr Niall Davis, J Mulvihill, M Walsh, Mr Hugh Flood

<sup>1</sup>Beaumont Hospital, Dublin, Ireland

# EPOSTER SESSIONS

6 minutes for each ePoster Presentation

4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 21 June, 1400-1500, Hall 10

## ePoster Session 13

### Bladder Cancer: Muscle & Non-Muscle Invasive

Chairs: **Flora Rodger**, Queen Elizabeth University Hospital and **Edward Calleja**, Eastbourne District General Hospital

**P13-1 Global variation in early recurrence after TURBT surgery in the RESECT study (NCT05154084): There is significant inter-site variation that is independent of differences in tumour factors.**

Mr Kevin Gallagher<sup>1,9</sup>, Miss Nikita Bhatt<sup>2,9</sup>, Dr. Fortis Gaba<sup>3,9</sup>, Dr. Alexander Light<sup>4,9</sup>, Dr. Aqua Asif<sup>5,9</sup>, Dr. Thines Anbarasan<sup>6,9</sup>, Mr. Vinson Chan<sup>7,9</sup>, Dr. Alexander Ng<sup>5,9</sup>, Professor Paramanathan Mariappan<sup>8</sup>, Mr. Veeru Kasivisvanathan<sup>5,9</sup>, RESECT Global Study Group<sup>9</sup>

<sup>1</sup>Department of Urology, Western General Hospital Edinburgh, Edinburgh, UK, <sup>2</sup>Department of Urology, Norfolk and Norwich University Hospital, Norwich, UK, <sup>3</sup>Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, United States of America, <sup>4</sup>Department of Surgery and Cancer, Imperial College London, London, UK, <sup>5</sup>Division of Surgery and Interventional Science, University College London, London, UK, <sup>6</sup>Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, <sup>7</sup>University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK, <sup>8</sup>Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK, <sup>9</sup>British Association of Urology Researchers in Surgical Training, London, UK

**P13-2 A Protocol for Placement of 24K Gold Fiducial Markers in the Bladder to Optimize Targeting and Decrease Collateral Radiation with Bladder Preserving Multi-Modal Therapy, and Strategies to Optimize Inter-Disciplinary Collaboration**

Dr. Maurice Garcia<sup>1</sup>

<sup>1</sup>Cedars-Sinai Medical Center, Los Angeles, United States

**P13-3 External Validation of the IDENTIFY Risk Calculator for patients with haematuria referred with suspected urinary tract cancer**

Mr Sinan Khadhour<sup>1</sup>, Dr Luca Orecchia<sup>2</sup>, Mr Ravi Banthia<sup>3</sup>, Dr Pietro Piazza<sup>4</sup>, Dr David Mak<sup>5</sup>, Dr Nikos Pyrigidis<sup>6</sup>, Dr Prabhat Narayan<sup>7</sup>, Dr Faisal Nawaz<sup>8</sup>, Dr Thines Anbarasan<sup>9</sup>, Mr Veeru Kasivisvanathan<sup>10</sup>

<sup>1</sup>Nhs Fife, Kirkcaldy, UK, <sup>2</sup>Policlinico Tor Vergata, Rome, Italy, <sup>3</sup>University Hospital Coventry, Warwickshire, UK, <sup>4</sup>RCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, <sup>5</sup>Royal Wolverhampton Hospitals, Wolverhampton, UK, <sup>6</sup>Martha-Maria Hospital, Nuremberg, Germany, <sup>7</sup>Royal Berkshire Hospital, Reading, UK, <sup>8</sup>Royal Derby Hospital, Derby, UK, <sup>9</sup>Oxford University Hospitals, Oxford, UK, <sup>10</sup>University College London, London, UK

**P13-4 Perception of a non-invasive urinary biomarker test for the detection of bladder cancer among patients referred to a Rapid Access Haematuria Clinic with suspected urological malignancy**

Mr Nicholas Bullock<sup>1,2,4</sup>, Mr Mohamed Mubarak<sup>2</sup>, Dr Ceri Morris<sup>3</sup>, Ms Collette Clements<sup>4</sup>, Ms Clare Geere<sup>4</sup>, Ms Elizabeth Bois<sup>4</sup>, Mr Jonathan Featherstone<sup>2</sup>, Professor Ian Weeks<sup>5</sup>, Mr Krishna Narahari<sup>2,4</sup>, Professor Howard Kynaston<sup>1,2,4</sup>

<sup>1</sup>Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK, <sup>2</sup>Department of Urology, Cardiff and Vale University Health Board, Cardiff, UK, <sup>3</sup>Clinical Innovation Cardiff, Cardiff University School of Medicine, Cardiff, UK, <sup>4</sup>Urology Research Delivery Team, Cardiff and Vale University Health Board, Cardiff, UK, <sup>5</sup>College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK

**P13-5 Cutaneous ureterostomy – Vintage or Vantage Urinary Diversion?**

Mr Andrew Atayi<sup>1</sup>, Mrs Nina Patrick, Mr Nigel Parr, Mr Thiagarajan Nambi Rajan  
<sup>1</sup>Arrowe Park Hospital, Wirral, UK

**P13-6 Phase IV Translational Research by outcome audit confirms relevance of and informs changes to national Quality Performance Indicators (QPIs) for NMIBC.**

Professor Paramanathan Mariappan<sup>1,2</sup>, Mr Allan Johnston<sup>3</sup>, Mr Matthew Trail<sup>4</sup>, Mr Sami Hamid<sup>4</sup>, Mr Barend A Dreyer<sup>5</sup>, Mr Sara Ramsey<sup>6</sup>, Dr Alasdair Boden<sup>7</sup>, Mr Gianluca Maresca<sup>8</sup>, Mr Rami Hasan<sup>1,9</sup>, Mr Graham Hollins<sup>9</sup>, Mrs Claire Sharpe<sup>10</sup>, Mr Benjamin G Thomas<sup>11,12</sup>, Ms Luisa Padovani<sup>1</sup>, Ms Roberta Garau<sup>1</sup>, Dr Julia Guerrero Enriquez<sup>2</sup>, Ms Helen Simpson<sup>5</sup>, Mr Jaimin Bhatt<sup>3</sup>, Mr Imran Ahmad<sup>3</sup>, Mr Altaf H Chaudhry<sup>10</sup>, Mr Rehan S Khan<sup>7</sup>, Mr Konstantinos Dimitropoulos<sup>8</sup>, Dr Catriona Graham<sup>13</sup>, Mr David Hendry<sup>3</sup>

<sup>1</sup>Edinburgh Bladder Cancer Surgery (EBCS), Department of Urology, Western General Hospital, Edinburgh, UK, <sup>2</sup>University of Edinburgh, Edinburgh, UK, <sup>3</sup>Department of Urology, Queen Elizabeth University Hospital, Glasgow, UK, <sup>4</sup>Department of Urology, Ninewells Hospital, Dundee, UK, <sup>5</sup>Department of Urology, Victoria Hospital, Kirkcaldy, UK, <sup>6</sup>Department of Urology, Raigmore Hospital, Inverness, UK, <sup>7</sup>Department of Urology, University Hospital Monklands, Airdrie, UK, <sup>8</sup>Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK, <sup>9</sup>Department of Urology, University Hospital Ayr, Ayr, UK, <sup>10</sup>Department of Urology, Dumfries and Galloway Royal Infirmary, Dumfries, UK, <sup>11</sup>Department of Urology, Western General Hospital, Edinburgh, UK, <sup>12</sup>Department of Urology, Borders General Hospital, Melrose, UK, <sup>13</sup>Edinburgh Clinical Research Facility, University of Edinburgh, Western General Hospital, Edinburgh, UK.

**P13-7 Outpatient en-bloc resection of new and recurrent bladder tumours at local anaesthetic flexible cystoscopy**

Mr John Pascoe, Dr Lucy Lee-Smith, Ms Vanessa Wilcox, Mr Salvatore Natale, Mr Richard Percy, Mr Andrew Dickinson, Mr Paul Hunter-Campbell, Mr Oliver Fuge  
<sup>1</sup>University Hospitals Plymouth, Devon, UK

**P13-8 Predicting bladder cancer disease progression risk using tumour and urinary immune profiling.**

Miss Madhavi Natarajan<sup>1</sup>, Mr Tyler Wooldridge<sup>2</sup>, Dr Nicola Annels<sup>2</sup>, Dr Ben Haagsma<sup>1</sup>, Mr Matthew Perry<sup>1</sup>, Professor Hardev Pandha<sup>2</sup>

<sup>1</sup>Royal Surrey Hospital, Guildford, UK, <sup>2</sup>University of Surrey, Guildford, UK

**P13-9 Objective measurement of physical recovery using wearable devices in open vs intracorporeal robotic cystectomy: analysis of the secondary outcomes of the iROC randomized trial.**

Mr Pramit Khetrapal<sup>1</sup>, Prof James Catto, Prof Muhammad Shamim Khan, Mr Imran Ahmad, Mr Philip Charlesworth, Mr Sanjeev Kotwal, Mr John McGrath, Prof Nikhil Vasdev, Mr Vishwanath Hanchanale, Prof John Kelly, N.A., iROC collaborators

<sup>1</sup>Barts Health, London, UK

**13-10 Prediction of stage, grade and bladder recurrence patterns in Upper Tract Urothelial Cancer : Our experience using a machine learning approach**

Mr Kamran Haq<sup>1</sup>, Mr Robert Geraghty<sup>1</sup>, Mr Karthick Rajan<sup>1</sup>, Mr Harneet Khanuja<sup>2</sup>, Mr Nithesh Naik<sup>2</sup>, Mr Rajan Veerratterapillay<sup>1</sup>, Mr David Rix<sup>1</sup>, Mr Bhavan Prasad Rai<sup>1</sup>

<sup>1</sup>Freeman Hospital, Newcastle, UK, <sup>2</sup>Manipal Institute of Technology, Bangalore, India



**TUF is delighted to be part of BAUS 2023**

**Come and see us at our sessions, and our stand in the Exhibition Hall,  
to learn more about how we can support you in your career**

**Monday 19 June  
3.00pm, Hall 1**

**TUF Guest Lecture  
"Survival of the Fittest"  
given by Sir Tom Hughes-Hallett**

**Tuesday 20 June, 7.00am,  
ICC , Centenary Square**

**BSoT Fun Run for TUF**

**Wednesday 21 June,  
8.00am, Hall 11a**

**Research in Focus: Bringing the  
urological community together  
to accelerate progress**

**Wednesday 21 June,  
11.30am, Hall 10**

**TUF - BAUS Best of the Regions**

**Monday 19 - Wednesday 21  
Exhibition Hall, Stand 602**

**Come and meet members of the  
TUF Team on Stand 602**

**We are proud to work with researchers, nurses, consultants,  
trainees, surgeons, industry, decision makers, patients  
and their families to improve the nation's urology care**

**Find out more at [theurologyfoundation.org](http://theurologyfoundation.org)**

## Regions

- South West
- South Central
- South East
- London
- East of England
- Wales
- West Midlands
- East Midlands
- North West
- Yorks and Humber
- North East
- Scotland West
- Scotland East
- Northern Ireland
- Republic of Ireland



**Poster No**   **Poster Title**

**Unit**

## SOUTH WEST

1	<b>Review of clinical outcomes of robot-assisted laparoscopic radical cystectomy: learning curve at single centre</b>	Cheltenham General Hospital
2	<b>Snapshot audit examining serum calcium and urate testing and dietary advice on discharge in acute renal colic presentations.</b>	North Devon District Hospital
3	<b>Nurse-led direct-to-test testicular two-week wait pathway: a novel approach to reduce demand on face-to-face consultations</b>	Royal Cornwall Hospital, Truro
4	<b>The drive for local anaesthetic circumcisions in the outpatient setting.</b>	Royal United Hospital, Bath
5	<b>Emergency Urology Simulation for the Multidisciplinary Team</b>	Southmead Hospital, Bristol
6	<b>Evaluation of the complication rate following transperineal prostate biopsies</b>	The Great Western Hospital, Swindon

## SOUTH CENTRAL

7	<b>Factors affecting Patient Satisfaction in LA TP Prostate Biopsies</b>	Basingstoke and North Hampshire Hospital
8	<b>Lessons learnt from the experience of implementing an ERAS nephrectomy pathway</b>	Churchill Hospital, Oxford



<i>Poster No</i>	<i>Poster Title</i>	<i>Unit</i>
9	Robotic nephroureterectomy as the gold-standard for upper urinary tract urothelial carcinoma (UTUC): a retrospective consecutive case series at a high volume robotic centre	Queen Alexandra Hospital, Portsmouth
10	Transurethral Laser Ablation (TULA) at Salisbury District Hospital. Initial Experience, Safety and Service Outcomes in Comparison to Transurethral Resection of Bladder Tumour (TURBT)/Rigid Cystoscopy and Biopsy	Salisbury District Hospital
11	A regional multidisciplinary management pathway for functioning and non-functioning adrenal lesions at the University Hospital Southampton NHSFT (UHS)	Southampton General Hospital
12	<b>*Straightening the curve*</b> : Safety and Efficacy of the minimally invasive Verapamil Intralesional Injection in Peyronie disease	Wexham Park Hospital, Slough

## KENT, SURREY, SUSSEX

13	Day Case TURP and TURBT Surgery: A District General Hospital Experience	Darent Valley Hospital, Kent
14	Optimizing Bone Health in Men with Metastatic Prostate Cancer	East Surrey Hospital, Redhill
15	Core Trainee led dedicated Urology Ambulatory Clinic: A means to reduce strain on acute urological services.	Eastbourne District General Hospital
16	Evolution of the Prostate Biopsy	Frimley Park Hospital
17	Surgeons' Factor on Recurrence and Progression in Non-muscle invasive Bladder cancer on Primary Transurethral resection of Bladder tumour followed by Adjuvant BCG instillations	Kent and Canterbury Hospital
18	Working towards an improved Length of Stay (LOS) for TURBT as per GIRFT recommendations	Medway Maritime Hospital, Gillingham
19	An Audit on the Safety and Efficiency of Cystoscopic Surveillance During Intravesical BCG Therapy	Princess Royal Hospital, Haywards Heath
20	Striving towards the highest quality care for patients undergoing robotic-assisted radical prostatectomy	Royal Surrey County Hospital, Guildford
21	3 years on: Valuable learning through continued use of a virtual platform for multidisciplinary team meetings, initiated during COVID-19	St Peter's Hospital, Chertsey
22	Outcomes of Ureterorenoscopy (URS) in a district general hospital - post Covid period	St Richard's Hospital, Chichester

## LONDON

23	For patients re-referred after discharge off the two-week rule pathway for prostate cancer, when should we perform a repeat MRI?	Epsom General Hospital, Surrey
24	Intravesical antibiotics for recurrent and chronic UTI; addressing the stalemate	Guy's & Thomas's Hospital

<i>Poster No</i>	<i>Poster Title</i>	<i>Unit</i>
25	Preoperative assessment and Optimization of Surgical patients: an audit to preserve safe and effective methodology in the COVID era and 5Cs Flowchart (Comorbidity, Consent, Covid, Clinical protocols, Change).	Kingston Hospital, London
26	Primary ureteroscopy in the emergency setting: Our experience from a District General Hospital.	Princess Royal University Hospital, Orpington
27	Sampling the mid-zone in systematic transperineal prostate biopsies - does this increase the cancer detection rate?	Queen Elizabeth Hospital, Woolwich
28	Management of Genital Lymphoedema in a dedicated, multi-disciplinary clinic	St George's Hospital, London
29	Reducing intraoperative laser time with Thulium versus Holmium for ureterorenoscopic laser lithotripsy	Chelsea & Westminster Hospital, London
30	Potential impact of the change in PSA referral thresholds on patient referral and cancer diagnosis	Hillingdon Hospital, Uxbridge
31	MUTUAL AID - Helping our neighbours	Homerton University Hospital, London
32	A comparison of the STONE and Modified STONE Score in predicting ureterolithiasis on CT Kidneys Ureters and Bladder in UK Emergency Department Patients	Northwick Park Hospital
33	A 5-year single centre experience and outcomes of robotic-assisted laparoscopic pyeloplasty	The Royal London Hospital
34	The Virtual Classroom for Surgical Skills Training at University College London Hospital (UCLH)	University College Hospital, London

## EAST OF ENGLAND

35	HoLEP for acute and non-neurogenic chronic urinary retention: How effective is it? Results from a single surgeon cohort	Addenbrooke's Hospital, Cambridge
36	HoLEP as a day case: Experience at Bedford Hospital	Bedford Hospital
37	Running a Weekly Urology Emergency List and the Management of "Hot" Ureteric Stones	Broomfield Hospital, Chelmsford
38	The impact of Covid-19 pandemic on the Urology services at Luton & Dunstable university hospital	Luton & Dunstable University Hospital
39	Optimising and Improving Access to a GIRFT Regional Lithotripsy Service	Norfolk And Norwich University Hospital
40	Cystoscopic application of PuraStat® in the treatment of radiation induced haemorrhagic cystitis	The Queen Elizabeth Hospital, King's Lynn
41	From Insertion to Documentation: An audit of Urinary Catheterisation Processes and Catheter Plans following Discharge from Hospital	West Suffolk Hospital

## WALES

42	Can we delay Radical Orchiectomy? Outcomes of 55 cases with four years follow-up.	Glan Clwyd Hospital, Rhyl
43	Incidence of recurrence in patients who had maintenance BCG therapy for high grade NIMBC- an audit done in Glangwili General Hospital	Glangwili General Hospital, Carmarthen

<i>Poster No</i>	<i>Poster Title</i>	<i>Unit</i>
44	Single-Use Flexible Cystoscopy (SUFC) Service Enhances Patient Flow and Accessibility and is cost-effective.	Morrison Hospital, Swansea
45	Barriers to day case Transurethral resection of bladder tumor (TURBT)-Royal Glamorgan Experience?	Royal Glamorgan Hospital
46	Holistic patient care and continuous QI with an established nurse-led rUTI clinic at the heart	Royal Gwent Hospital
47	Local Anaesthetic Transperineal Prostate Biopsy (LA TP Bx): A District General Hospital Experience	Wrexham Maelor Hospital

## WEST MIDLANDS

48	Long road to Tredit	Royal Shrewsbury Hospital
49	Single-use and multiple-use LAMP biopsy guides -Comparison in clinical outcomes, usability, ergonomics, eco-friendliness and economics	Sandwell District General Hospital, West Bromwich
50	A single centre experience of the effect of robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy on 90-day morbidity and mortality	University Hospital, Coventry
51	Introducing a Local Anaesthetic Transperineal Prostate Biopsy Service at a District General Hospital: Outcomes of Initial Experience.	Warwick Hospital

## EAST MIDLANDS

52	QIP : 2WW Hematuria Clinic Chesterfield Royal Hospital	Chesterfield Royal Hospital
53	Pouch calculi as a complication of a continent cutaneous urinary diversion: a management plan from a large case series	Leicester General Hospital
54	Concordance between biparametric MRI and radical prostatectomy specimen in the detection of clinically significant prostate cancer and staging	Northampton General Hospital
55	The implementation of a Urology Assessment Unit at Nottingham City Hospital	Nottingham City Hospital
56	An analysis of Microsurgical Testicular Sperm Extraction (mTESE) outcomes in a tertiary referral centre	Royal Derby Hospital

## NORTH WEST

57	The introduction of EPIC electronic patient record; does it improve care?	North Manchester General Hospital
58	The Prostate one stop clinic at East Lancashire Hospitals NHS Trust	Royal Blackburn Hospital
59	The Emergency 'grab-bag': an essential in every Urology Unit.	Royal Bolton Hospital

<i>Poster No</i>	<i>Poster Title</i>	<i>Unit</i>
60	<b>Percutaneous CT guided renal tumour cryotherapy for small renal masses: a review of complication and survival outcomes over a 9 year period.</b>	Wythenshawe Hospital, Manchester

## YORKS & HUMBER

61	<b>Green Light Laser vaporization of the prostate: Our experience in a District General Hospital.</b>	Doncaster Royal Infirmary
62	<b>Greenlight Laser Prostatectomy: Day Case Surgery in Elderly Patients with Voiding Difficulties</b>	Royal Hallamshire Hospital, Sheffield
63	<b>A single centre 12-year retrospective review of cystinuria patients managed in dedicated metabolic stone clinic</b>	St James's University Hospital, Leeds
64	<b>A review of day case rates of transurethral resection of bladder tumour (TURBT) from a single unit in the post-Covid recovery era.</b>	York Hospital

## NORTH EAST

65	<b>Post CCT Fellowships at the Freeman Hospital: Newcastle Upon Tyne</b>	Freeman Hospital, Newcastle
66	<b>Percutaneous Renal Cryoablation: a 300 Case Series From Sunderland Royal Hospital</b>	Sunderland Royal Hospital
67	<b>Creating a hybrid SHO level Rota using SHOs and SCPs in a tertiary Urology unit</b>	The James Cook University Hospital, Middlesbrough

## WEST SCOTLAND

68	<b>A QI project evaluating the transfusion rates in patients undergoing elective urology procedures and the need for routine pre-operative Group and Save</b>	Glasgow Royal Infirmary
69	<b>Centralisation of upper tract cancer services in Greater Glasgow and Clyde</b>	Royal Alexandra Hospital, Paisley
70	<b>A Safe AYR of Hands: DGH Urology in Ayrshire and Arran</b>	University Hospital, Ayr

## EAST SCOTLAND

71	<b>Population-based Review of the ovErall Survival outcomEs in Radical Vs partial nEphrectomy (PRESERVE) - a Pilot Study</b>	Aberdeen Royal Infirmary
72	<b>Its five o'clock somewhere: Managing Urological emergencies out of hours in a geographically remote district general hospital</b>	Raigmore Hospital, Inverness
73	<b>Development and validation of the Scottish MUO Score to predict short overall survival and augment decision-making in patients with Malignant Ureteric Obstruction</b>	Western General Hospital, Edinburgh

*Poster No*    *Poster Title*

*Unit*

## NORTHERN IRELAND

74	<b>Bladder Botox in Belfast - A retrospective data analysis on intravesical Botox use over a seven year period</b>	Belfast City Hospital
75	<b>Developing Single Site ESWL Centre for Northern Ireland: Increasing the Availability of ESWL in Keeping GIRFT Report</b>	Craigavon Area Hospital, Portadown
76	<b>Enhancing Theatre Utilisation in the Day Case Setting: A single centre review of service development</b>	The Ulster Hospital, Belfast

## REPUBLIC OF IRELAND

77	<b>Comparing the Outcomes of Open, Laparoscopic &amp; Robotic Partial Nephrectomy: A Network Meta-Analysis</b>	St Vincent's Hospital
----	--	-----------------------

# THE BAUS ANNUAL MEETING 2023

**The BJUI Blandy Prize Presentation**

**Integrated Care Boards - complicated plumbing  
or the route to improved flow through systems?**

**BJU International Guest Lecture**

Dr. Nigel Acheson  
Regional Medical Director,  
South Region,  
NHS England



**Keep up-to-date with BJUI Journals and E-learning**

**BJUI**

**BJUI**  
Knowledge

**BJUI**  
Compass

## By the Honorary Secretary Elect

Welcome to BAUS 2023. As we recover from the pandemic and the NHS goes through a turbulent time with post covid recovery programmes and problems with pension, tax and pay; we look forward to the conference where we have included topics that interest and concern the urology communities and arms us with up-to-date knowledge and skills for our day-to-day practice, varied that maybe.



The conference continues in the same format as the successful 2022 meeting with an earlier start on Sunday and then opportunities to once again network, socially interact and update on scientific progress over the last year. BAUS sections chairs, course directors and the events team lead by Harry Heald, have done a tremendous job in bringing the teaching courses and the skills sessions to you.

#BAUS23 offers a hybrid approach for the Courses, with more face-to-face teaching and skills courses. The successful format of the skills courses from last year has been re-energised to again offer opportunities to get simulation training and helpful pointers and discussions with expert international faculty.

The transperineal prostate biopsy course faculty will be led by Rajan Veeratterapillay and Matthew Shaw along with consultant radiologists and specialist nurses, taking us through the nuances of TP biopsy and prostate MRI.

Male LUTS surgery is at the fore front of the recovery programme. Ananda Dhanasekharan and colleagues' simulation course (Basic & Advanced) on Ambulatory treatment options for Benign Prostate Enlargement course has simulation learning for Urolift, Rezum, iTind and green light laser vapourisation looks to be a favourite for the attendees.

Introduction to Robotics lead by Vishwanath Hanchanale & Bhavan Rai continues to be well subscribed providing a framework, tips & tricks for Robotic Urological Surgery. This is going to be an indispensable and useful course for beginners and surgical practitioners alike.

For the younger generation looking to Urology as a career, Jennifer Nowers & Megan Thomas (Trainees) continue to run the Urology NTN Simulated Interview for the CT/Fellows/junior SAS doctors looking into entering the Higher urology training programme. This course has a 1:1 opportunity for mock interviews, six different stations, reflecting the NTN interviews. Popular teaching courses are returning for the first time in four years, such as the Good urodynamics practice with Chris Harding leading this iconic course and the return of the Paediatric urology course with Peter Cuckow. We have the Endourology section revamping the Updates in Stone management with Hari Ratan and Bhaskar Somani promising to bring a stellar panel.

The Journal of Clinical Urology team lead by Bhaskar Somani and Colleagues will tease the nuances of 'How to Write a paper' sharing their wealth of experience. This course will also have experts advising writing grant applications; a 'must' course for the budding academics and clinical researchers.

The virtual teaching courses continue with all Sections contributing for 2023, bringing a wide range of courses for all levels of training and Consultant/Senior SAS grades across all sub-specialties. Andrology sub-section offer courses on penile cancer (Arie Parnham & Ayo Kalejaiye), Male factor Infertility (Asif Muneer) and Andrology Emergencies (Richard Percy & Ayo Kalejaiye). A Masterclass in Bladder cancer is presented by Dominic Hodgson. Sheilagh Reid and Mahreen Pakzad's Neuro-urology for the general urologist course developed last year continues. Courses on Research Methodology course and Genomics in Urology (Vincent Gnanapragasam) will help us understand the nuances of Research and genomics. We also have courses on navigating the CESR route by Mehwash Nadeem & Ajay Pahuja; and the course Thriving as a Consultant led by Sunjay Jain, which should help navigate the early pitfalls of independent urology practice.

I am looking forward to these opportunities for us to learn and reflect, and deeply grateful to the faculty on behalf of BAUS, for delivering high quality courses.

Finally, I would like to take this opportunity to thank Ian Pierce for his support, guidance and friendship over the last two years; and more so for his zeal to widen the pool of speakers and better representation.

Best wishes,

**Joe Philip**

Honorary Secretary Elect





Advanced  
Accelerator  
Applications

A Novartis Company

This session is for healthcare professionals  
from Great Britain only

# Advanced Accelerator Applications symposium at the BAUS Annual Scientific Meeting 2023

**WHEN:** TUESDAY, 20<sup>TH</sup> JUNE 2023 | 17:30–18:00

**WHERE:** Hall 1, International Convention Centre,  
Broad Street, Birmingham B1 2EA

**Please  
join us**

for an interactive  
30-minute panel  
discussion with  
our expert  
multidisciplinary  
faculty:

**CHAIR**



**MR WILLIAM CROSS**  
Consultant Urologist  
Leeds Teaching Hospitals  
NHS Trust

**PANELLISTS**



**PROFESSOR AMIT BAHL**  
Consultant Clinical Oncologist  
University Hospitals Bristol  
and Weston NHS Trust



**DR AMY ECCLES**  
Consultant Radionuclide Radiologist  
Imperial College Healthcare  
NHS Trust

**Adverse Event Reporting:**

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/>. Adverse events should also be reported to Novartis via [uk.patientsafety@novartis.com](mailto:uk.patientsafety@novartis.com) or online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report). If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com)

This promotional meeting is organised and funded by Advanced Accelerator Applications, a Novartis company.  
Advanced Accelerator Applications products will be discussed at this meeting.  
Prescribing information and adverse event reporting details will be available at the meeting for all products discussed.

# BAUS ACADEMY

## COURSE LIST: ON-SITE COURSES

ANNUAL  
MEETING  
19-21 June



No.	Course Title	Course Director(s)	Cost	No. of Spaces	Location	Time
<b>MONDAY 19 JUNE</b>						
1	Teaching Course: <b>Paediatric Urology</b>	Peter Cuckow	£40 BAUS Member £75 Non-Member	60	Hall 11B	1100-1300
2	Skills Course: <b>Ambulatory Treatment Options for Bladder Outflow Obstruction (Advanced)</b>	Ananda Kumar Dhanasekaran	£50 BAUS Member £90 Non-Member	20	Hall 6	1100-1300
3	Skills Course: <b>Ambulatory Treatment Options for Bladder Outflow Obstruction (Basic)</b>	Ananda Kumar Dhanasekaran	£50 BAUS Member £90 Non-Member	20	Hall 6	1400-1530
4	Skills Course: <b>Ambulatory Treatment Options for Bladder Outflow Obstruction (Basic)</b>	Ananda Kumar Dhanasekaran	£50 BAUS Member £90 Non-Member	20	Hall 6	1630-1800
5	Teaching Course: <b>JCU: How to Write a Paper and Successful Grant Application</b>	Bhaskar Somani	£40 BAUS Member £75 Non-Member	60	Hall 11B	1630-1800

### TUESDAY 20 JUNE

6	Skills Course: <b>LA Transperineal Biopsy of Prostate &amp; MP-MRI Prostate Interpretation for Urologists</b>	Rajan Veeratterapillay & Matthew Shaw	£50 BAUS Member £90 Non-Member	20	Hall 6	1100-1230
7	Skills Course: <b>LA Transperineal Biopsy of Prostate &amp; MP-MRI Prostate Interpretation for Urologists</b>	Rajan Veeratterapillay & Matthew Shaw	£50 BAUS Member £90 Non-Member	20	Hall 6	1400-1630

<i>No.</i>	<i>Course Title</i>	<i>Course Director(s)</i>	<i>Cost</i>	<i>No. of Spaces</i>	<i>Location</i>	<i>Time</i>
<b>WEDNESDAY 21 JUNE</b>						
8	Teaching Course: <b>Simulated Course for Urology NTN Interviews</b>	Jennifer Nowers & Megan Thomas	£25 BAUS Member £35 Non-Member	12	Hall 4	0800-0930
9	Skills Course: <b>Introduction to Robotics</b>	Vishwanath Hanchanale & Bhavan Rai	£50 BAUS Member £90 Non-Member	20	Hall 6	1130-1300
10	Teaching Course: <b>Good Urodynamics Practice</b>	Chris Harding	£40 BAUS Member £75 Non-Member	60	Hall 11B	1130-1300
11	Skills Course: <b>Introduction to Robotics</b>	Vishwanath Hanchanale & Bhavan Rai	£50 BAUS Member £90 Non-Member	20	Hall 6	1400-1600
12	Teaching Course: <b>Updates in Stone Management</b>	Bhaskar Somani & Hari Ratan	£40 BAUS Member £75 Non-Member	60	Hall 11B	1400-1600

# BAUS ACADEMY

## COURSE LIST: VIRTUAL COURSES

ANNUAL  
MEETING  
19-21 June



No.	Course Title	Course Director(s)	Cost	Location
13	Teaching Course: <b>Neurourology for the General Urologist</b>	Sheilagh Reid & Mahreen Pakzad	FREE	BAUS 2023 Platform
14	Teaching Course: <b>CESR (Navigating the CESR Route)</b>	Mehwash Nadeem & Ajay Pahuja	FREE	BAUS 2023 Platform
15	Teaching Course: <b>Research Methodology</b>	Vincent J Gnanapragasam	FREE	BAUS 2023 Platform
16	Teaching Course: <b>Male Factor Infertility</b>	Asif Muneer & Rowland Rees	FREE	BAUS 2023 Platform
17	Teaching Course: <b>Penile Cancer</b>	Arie Parnham & Ayo Kalejaiye	FREE	BAUS 2023 Platform
18	Teaching Course: <b>Andrological Emergencies</b>	Richard Percy & Ayo Kalejaiye	FREE	BAUS 2023 Platform
19	Teaching Course: <b>Bladder Cancer Masterclass</b>	Dominic Hodgson & Arthur McPhee	FREE	BAUS 2023 Platform
20	Teaching Course: <b>Thriving as a Consultant</b>	Sunjay Jain	FREE	BAUS 2023 Platform
21	Teaching Course: <b>Genomics for Urologists</b>	Vincent J Gnanapragasam & John McGrath	FREE	BAUS 2023 Platform



FRCS (UROL) REVISION  
COURSE SEPTEMBER  
2023

25-29 SEPTEMBER 2023  
COLLEGE COURT, LEICESTER

## Course 1: Paediatric Urology

Monday 19 June 2023

Hall 11B

1100-1300

60 Places

Cost: £40 BAUS Member & £75 Non-Member

Course Director: **Peter Cuckow**, The Portland Hospital for Women and Children, London

### Outline and Objectives

The aim of this course is to reinforce and support the practice of paediatric urology outside a specialist unit. We are grateful that we can continue to provide a focus on children within the BAUS meeting and an opportunity for established Consultants and interested trainees to meet. There will also be didactic mini lectures on key topics, each led by a paediatric urologist and illustrated by appropriate clinical scenarios. We do hope, as usual, to provide a 2-hour interactive feast that will leave delegates better equipped – be it for forthcoming exams or their next paediatric clinic.

### Faculty

**May Bisharat**, Consultant Paediatric Urologist, Addenbrookes Trust, Cambridge

**Emma Parkinson**, Consultant Paediatric Urologist, Birmingham Women's and Children's Hospital NHS Foundation Trust

**Navroop Johal**, Consultant Paediatric Urologist, Great Ormond Street Hospital for Children NHS Trust, London

**Kevin Cao**, SPR in Paediatric Surgery, Addenbrookes Trust, Cambridge

## Courses 2, 3 & 4: Skills Course: Ambulatory Treatment Options for Bladder Outflow Obstruction

Monday 19 June 2023	1100-1300	Hall 6
Monday 19 June 2023	1400-1530	Hall 6
Monday 19 June 2023	1630-1800	Hall 6
20 Places Per Course	Cost: £50 BAUS Member & £90 Non-Member	

Course Director: **Ananda Kumar Dhanasekaran**, Sandwell & West Birmingham Hospitals NHS Trust

### Aim

This course will provide hands-on training on ambulatory treatment options for BPE like UroLift, Rezum, iTind, Aquablation and Green Light vaporization for BPE.

### Outline and Objectives

1. To introduce the newer treatment options for the benign prostatic enlargement to the participants
2. Hands-on simulation-based training on the principles, procedure and trouble shooting
3. Discuss the existing evidence and guidelines on the newer treatment modalities
4. Empower the participants to choose the best treatment option for their patients
5. Facilitate the participants to start the ambulatory treatment pathway in their practice

This course is aimed as a single source to learn and practice the newer ambulatory treatment options for benign prostatic enlargement. Because of rapidly changing evidence and guidelines, this course will enable participants to get up-to-date details. This course will empower the participants to take up the newer modalities in their practice resulting in better patient outcomes. This will be in line with National GRIFT protocols.

### Faculty

One-Stop LUTS Clinic	<b>Vinnie During</b> , New Cross Hospital, Wolverhampton <b>Tamer El-Husseiny</b> , Charing Cross Hospital, London <b>Leena Anthony</b> , Imperial College Healthcare NHS Trust
UroLift	<b>Nick Bryan</b> , Huddersfield Royal Infirmary <b>Mark Rochester</b> , Norfolk And Norwich University Hospital
Rezum	<b>Kasra Saeb-Parsy</b> , Addenbrooke's Hospital, Cambridge
iTind	<b>Gordon Muir</b> , King's College Hospital, London <b>Keng NG</b> , HCA The Princess Grace Hospital, London
Green Light Vaporization	<b>Sanjay Rajpal</b> , Airedale General Hospital <b>Feras Al-Jafaari</b> , NHS Fife
Aquablation	<b>Neil Barber</b> , Frimley Park Hospital

## Course 5: Teaching Course: JCU: How to Write a Paper and Successful Grant Application

Monday 19 June 2023

Hall 11B

1630-1800

60 Places

Cost: £40 BAUS Member & £75 Non-Member

Course Director: **Bhaskar Somani**, Southampton General Hospital and Editor, JCU

### Outline and Objectives

This course will cover scientific writing, manuscript preparation, pitfalls, submission, and revision of manuscripts. It will also focus on grant and funding applications, structure, planning and engaging with the funders.

This course is intended for trainees to consultants wishing to write papers or grants and improve their skills and chances of making these a success.

### Faculty

**Hashim Ahmed**, Charing Cross Hospital, London

**Caroline Moore**, University College Hospital, London



## Courses 6 & 7: Skills Course: LA Transperineal Biopsy of Prostate & MP-MRI Prostate Interpretation for Urologists

Tuesday 20 June 2023

Hall 6

1100-1230

Tuesday 20 June 2023

Hall 6

1400-1630

20 Places Per Course

Cost: £50 BAUS Member & £90 Non-Member

Course Directors: **Rajan Veeratterapillay**, Freeman Hospital, Newcastle and **Matthew Shaw**, Freeman Hospital, Newcastle

### Aims and Objectives

- To discuss the technique for local anaesthetic prostate biopsies (LATP)
- To discuss the setup and equipment required for LATP
- To perform LATP on a simulated model
- To describe the role of MRI in prostate cancer diagnostics
- To identify MRI prostate abnormalities to guide prostate biopsy

### Faculty

**Andy McNeill**, Consultant Radiologist, Freeman Hospital, Newcastle

**Ishaana Munjal**, Consultant Radiologist, Freeman Hospital, Newcastle

**Jonah Rusere**, Urology Clinical Nurse Specialist, Guy's and St Thomas' Hospital, London

**Tariq Dosani**, Freeman Hospital, Newcastle

**Edgar Paez**, Freeman Hospital, Newcastle

**Rahul Gujadhur**, Freeman Hospital, Newcastle

**Campbell Tait**, Freeman Hospital, Newcastle

**Stefanos Bolomytis**, Southmead Hospital, Bristol

## Course 8: Teaching Course: Simulated Course for Urology NTN Interviews

Wednesday 21 June 2023

Hall 4

0800-0930

12 Places

Cost: £25 BAUS Member & £35 Non-Member

Course Directors: **Jennifer Nowers**, West Midlands NTN Trainee, New Cross Hospital, Wolverhampton and **Megan Thomas**, ST Lead for 'Students for Urology', Wales NTN Trainee, Royal Gwent Hospital, Newport

### Outline and Objectives

The aim of this face-to-face course is to provide a first-hand experience on how to perform in the interview process to be successful in getting an NTN.

### Target Participants

Aimed at Core Surgical Trainees (CST) and Trust Grade Doctors interested in applying for the Urology NTN in 2024 and 2025. The aim of this course is to provide an opportunity for the participants to have their portfolios reviewed by the faculty on a 1 to 1 basis to strengthen their application. Other stations will provide a simulated setting for practice of clinical scenarios and communication skills as well as provide tips & tricks to enhance their chance of having a successful interview.

### Programme

Introduction talk on how the course will run with tea, coffee and pastries provided. Talk from a successful trainee on preparation, including tips and tricks for the application process.

6 stations with 1:1 faculty: participant ratio.

There will be 12 candidates for the session with 12 faculty members. Each candidate will be on a circuit of 6 stations, 1 minute to read each scenario, and 9 minutes of questions and answers.

Each candidate will need to bring their portfolio to the session. Please keep portfolios focused to the most recent self-assessment scoring system available on the urology national recruitment website.

1. Portfolio station
2. Outpatient station
3. Emergency Station
4. Practical Skills Station
5. Communication Station
6. MCQ Station

We will be doing a speed dating style feedback session for all candidates to get immediate verbal feedback on their performance at the end of their circuit.

### Outcome

We hope this course will be a fairly accurate representation of the interview process, with common themes and scenarios. Invaluable individual advice and feedback regarding performance and portfolios will be provided to each candidate.

### Faculty

The faculty are all current NTN's who have been successful in the national selection process and motivated to help the trainees to focus on their skills to be successful at the interview. They are ideally placed to review, discuss, and share their experiences with the participants

**Anil Krishan**, West Midlands NTN Trainee

**Christina Fontaine**, Southwest NTN Trainee

**Jacob Wilson**, Southwest NTN Trainee

**Mariele Trimboli**, Wales NTN Trainee

**Raghav Varma**, West Midlands NTN Trainee

**Mike NG**, Southwest NTN Trainee

**Francesca Lewis**, Southwest NTN Trainee

**Sarah Prattley**, Wales NTN Trainee

## Courses 9 & 11: Skills Course: Introduction to Robotics

Wednesday 21 June 2023	Hall 6	1130-1300
Wednesday 21 June 2023	Hall 6	1400-1600
20 Places Per Course	Cost: £50 BAUS Member & £90 Non-Member	

Course Directors: **Vishwanath Hanchanale**, Royal Liverpool University Hospital and **Bhavan Rai**, Freeman Hospital, Newcastle,

### Outline

This course will provide a good understanding of robotic technology and enable the delegates with basic robotic skills (Urology) with an emphasis on robotic urological procedures.

#### Aims and Objectives

- To become familiar with the ergonomics of Robotic Surgical System
- To learn the components and Setup of the Surgical Robot (Console, Patient Cart and Vision Cart)
- To learn Robotic Instruments Used for Different Robotic Abdominal Procedures
- To learn Robot Docking and Undocking
- To understand the concepts on patient position, surgical team and robotic surgical approaches
- To learn basic concepts in robotic urological procedures (i.e. Robotic Prostatectomy, Robotic Partial Nephrectomy, Cystectomy...)

### Overview

Delegates will be split into two groups, with first group having practical skills session and the second learn the basic concepts in robotics with emphasis on robotic urological procedures.

**Group 1:** 2 trainees at each station (12-15 minutes with each station)

- Station A: Robotic skills with the simulator
- Station B: Patient positioning, docking, undocking,
- Station C: Approach, instruments, energy sources

**Group 2:** Learning Concept of Robotic Urology with emphasis on robotic urological procedures

### Faculty

**Mohantha Dooldeniya**, Mid Yorks NHS Trust, Wakefield

**Robin Weston**, Liverpool University Hospitals NHS Foundation Trust

**Philip Charlesworth**, Royal Berkshire Hospital, Reading

**Arjun Nambiar**, Freeman Hospital, Newcastle

**Muddassar Hussain**, Frimley Park Hospital

**Justine Royle**, Aberdeen Royal Infirmary and JCST Chair, SAC in Urology

**Gokul Kandaswamy**, Morrision Hospital, Swansea

**Sherly Jose**, Surgical Care Practitioner, Liverpool University Hospitals NHS Foundation Trust

**Amy Bradburn**, Surgical Care Practitioner, Newcastle University Hospitals NHS Foundation Trust

**Brian Chaplin**, The James Cook University Hospital, Middlesbrough

## Course 10: Teaching Course: Good Urodynamic Practice

Wednesday 21 June 2023

Hall 11B

1130-1300

60 Places

Cost: £40 BAUS Member & £75 Non-Member

Course Directors: **Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne and **Laura Thomas**, Clinical Scientist, Bristol Urological Institute, Bristol

### Aims and Objectives

This course aims to provide focused teaching to enable urologists to improve their skills in the topic area of urodynamic testing. There will be an emphasis on clinical aspects of urodynamics including interpretation of traces, quality control and troubleshooting. All the speakers are involved in similar courses, which are run successfully in the United Kingdom and Internationally. The aim is to teach and emphasize good urodynamic practice using accepted international standards. At the end of the workshop delegates should feel more confident in their practice of urodynamics, specifically interpretation of traces which is a required skill for the FRCS (Urol) viva examination.

### Outline

#### Introduction

**Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne

#### Physics of Urodynamics in a nutshell

**Andrew Gammie MA CEng MIEE CSci MIPEM**, Clinical Engineer, Bristol Urological Institute, Bristol

#### Update on Good Urodynamics Practice

**Emily Collinshaw**, Clinical Scientist, Freeman Hospital, Newcastle-upon-Tyne

#### Running a video urodynamic test and troubleshooting

**Laura Thomas**, Clinical Scientist, Bristol Urological Institute, Bristol

#### Interpretation of Results and Traces using clinical scenarios

**Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne

#### Conclusion

**Chris Harding**, Freeman Hospital, Newcastle-Upon-Tyne

### Faculty

**Andrew Gammie MA CEng MIEE CSci MIPEM**, Clinical Engineer, Bristol Urological Institute, Bristol

**Emily Collinshaw**, Clinical Scientist, Freeman Hospital, Newcastle-upon-Tyne

**Laura Thomas**, Clinical Scientist, Bristol Urological Institute, Bristol

## Course 12: Teaching Course: Updates in Stone Management

Wednesday 21 June 2023

Hall 11B

1400-1600

60 Places

Cost: £40 BAUS Member & £75 Non-Member

Course Directors: **Bhaskar Somani**, Southampton General Hospital and Editor-in-chief JCU and **Hari Ratan**, Nottingham University Hospitals

### Outline and Objectives

This course will provide an update for management of stone disease taking into account the latest developments in ESWL, Ureteroscopy, PCNL, Metabolic and Conservative management. We will also cover the latest technological concepts, nuances and evidence base to support it.

We will then have a few cases or video-based presentations from the faculty with discussion and audience participation. It will cover some practical aspects and 'tips and tricks' to help with decision making at all stages of patient journey.

### Faculty

**Sian Allen**, University College Hospital, London

**Kim Davenport**, Cheltenham General Hospital

**Jake Patterson**, Royal Hallamshire Hospital, Sheffield

## Emergency announcement

If it becomes necessary to evacuate the building, the following message will be broadcast:  
*“Ladies and Gentlemen, may I have your attention please. We must ask you to leave the building by the nearest exit as quickly as possible. Do not use the lifts and do not stop to collect personal belongings”*

## First Aid Emergencies

In cases of medical emergency call Security Control (0121 200 2000 option 1) giving the exact location of the casualty and details of injuries sustained. Security Control will then arrange for all necessary assistance. Alternatively, please contact the nearest Host.

## Fire Procedures

An intelligent fire alarm system and audible sounders protect the ICC and Symphony Hall. There are portable fire extinguishers, fire hoses and a sprinkler system throughout.

In the event of discovering a fire in your vicinity:


- 1) Raise the alarm by breaking the glass in the fire alarm call point.
- 2) Inform the Security Control Room on an internal telephone by dialling 3333 or inform the nearest Host giving location and nature of the fire.
- 3) Turn off all electrical equipment in your area, where safe and practicable to do so.
- 4) Follow Hosts’ instructions.
- 5) Make your way to the nearest fire exit; do NOT use lifts or escalators.
- 6) Do NOT go back to collect personal belongings.
- 7) Report to the assembly point on Civic Centre Estate and await instructions.
- 8) Please notify a Security Officer if you believe a member of your team is missing.
- 9) Only return to the building when instructed by a fire officer.

## Security

Please remember to be vigilant throughout your event to ensure the safety of your property. If items cannot be watched then it is important that they are properly secured.

## Evacuation Area

Located at Civic Centre Estate





ICC • 19-21 June 2023



[www.baus.org.uk](http://www.baus.org.uk)  
[@BAUSurology](https://twitter.com/BAUSurology)